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Endoperoxides as Antimalarials and the Application of Singlet Oxygen to the Synthesis o f Key 
Synthetic Intermediates en Route to Synthetic 1,2,4-Trioxanes and the Synthesis and Biological 
Activity of Minor Groove Binding-Artemisinin Conjugates 
Artemisinin, is a naturally occurring sesquiterpene lactone with potent antimalarial activity imparted 
by a 1,2,4-trioxane pharmacophore. Artemisinin based combination therapies are currently considered 
the most effective treatment in advanced cases of malaria. Synthetic 1,2,4-trioxanes retain the 
pharmacophore of artemisinin and have demonstrated excellent antimalarial activity. Previous 
research has produced spirocyclic 1,2,4-trioxanes via dye-sensitised photooxygenation of allylic 
alcohols (ene reaction) to obtain P-hydroperoxy alcohols. The P-hydroperoxy alcohols then undergo 
condensation with a variety of cyclic ketones to generate the target 1,2,4-trioxane heterocycle.
We have developed a route to enantiomerically enriched 1,2,4-trioxanes via the diastereoselective ene 
reaction of enantiomers of chiral allylic alcohols. The use of phosphite ozonide adducts as a chemical 
source of singlet oxygen has also been explored as an alternative to traditional photochemical 
conditions.
Initially, we prepared a chiral m-allylic alcohol (93% ee) via asymmetric transfer hydrogenation of a 
propargyl ketone, f/ireo-selective photooxygenation to the P-hydroperoxy alcohol progressed in 
moderate yield (40-43% yield) and subsequent condensation with 2-adamantanone, provided 
opposing enantiomerically enriched, spirocyclic 1,2,4-trioxanes.
This was then adapted to a more facile route, whereby enantioenriched allylic alcohols were accessed 
via the enantioselective addition of dialkyl zinc reagents to an a,p-unsaturated aldehyde, catalysed by 
(+)- or (-)-exo-(morpholino)isobomeol (MIB). The resulting chiral disubstituted allylic alcohols (90­
98% ee) were subjected to diastereoselective photooxygenation to give (S,S)- and (R,R)-threo P- 
hydroperoxy alcohols in excellent yields (86-100% yield). Peroxyacetalisation of the P-hydroperoxy 
alcohols with various cyclic ketones provided a series of optically active 1,2,4-trioxanes.
In addition to their well-known antimalarial activity, artemisinin and derivatives possess potent 
activity against cancer cells with DNA cleavage being implicated as a potential mode of cytotoxic 
action. Netropsin and distamycin are naturally occurring antibiotics, consisting of a chain of amide- 
linked A-methyl pyrrole units, demonstrating high affinity for the minor groove of DNA. Oligopyrrole 
derivatives of netropsin and distamycin have been exploited as DNA delivery agents, where coupling 
to cytotoxic moieties have provided hybrids with enhanced cytotoxic activity.
Herein, we have prepared novel artemisinin-oligopyrrole conjugates using amide coupling chemistry. 
Modification of artemisinin at the C-10 position provided a C-10 phenoxy carboxylic acid linker 
which underwent successful peptide coupling with a dipyrrole carboxamide chain to yield the desired 
conjugate. The chemistry was then extended to incorporate 3-carbon and 5-carbon spacers between 
artemisinin and the minor groove binding portion.
DNA binding studies of our conjugates with a synthetic dodecamer indicate a reduction in DNA 
binding affinity when compared to netropsin. However, work is ongoing to further evaluate the 
thermodynamic effect the conjugates have on double-strand DNA. The synthetic procedures 
developed in this project will pave the way for the synthesis of analogues with higher affinity for 
DNA than our current derivatives, defining the relationship between the binding affinity and cytotoxic 
properties of this novel class of DNA directed drug.
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1.0 Introduction - Endoperoxides as Antimalarials and the Application of 
Singlet Oxygen to the Synthesis of Key Synthetic Intermediates en Route to 
Synthetic 1,2,4-Trioxanes
1.1 Artemisinin and Malaria
M alaria is a disease responsible for millions of deaths every year and it is becoming 
an increasing problem as many parasite strains are developing resistance to 
established treatments such as the 4-aminoquinolines including chloroquine. 
Artemisinin, and its first generation derivatives, have emerged as a mainstay in the 
treatment of advanced cases of malaria. Their efficacy against chloroquine resistant 
malarial strains is attributed to an alternative mechanism of action, involving several 
different parasite targets.
1.1.1 The Discovery o f Artemisinin
Artemisinin 1 is a natural product isolated from the plant Artemisia annua. Infusions 
o f Artemisia annua were widely used as a remedy for fever in ancient China, being 
first recorded in The Handbook fo r  Emergency Treatments by Ge Hang written 
340AD.1 In 1967, the Chinese government launched a program to find new malaria 
treatments including research into plants used traditionally in medicine. Artemisinin 
was successfully isolated and identified as the active component. The semi-synthetic 
derivatives sodium artesunate 2, artemether 3 and arteether 4 have allowed for simple 
administration of the drug and have since been used clinically (Figure 1.2).
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Figure 1.1 Artemisinin
1.1.2 Implications fo r  the Clinical Administration o f Artemisinin 
The overall yield o f artemisinin from the extraction process is poor being 0.01-0.80% 
of its dry weight and this has limited its commercialisation.2 The poor solubility of 
artemisinin in oil and water has also previously posed a problem. The drug could be 
administered orally but this was impossible in advanced and comatose cases. The 
design and synthesis of first generation artemisinin derivatives sodium artesuneate3 2 
(water soluble) and artemether 3, arteether 4 (lipid soluble)4 allow for parenteral and 
intrarectal routes.
2 3 4
Figure 1.2 First generation artemisinin derivatives artesunate 2, artemether 3 and
arteether 4.
An important consideration in the utility of these compounds is their short half lives. 
The aforementioned ether derivatives are metabolised by cytochrome P450 mediated
2
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dealkylation, to the clinically effective metabolite dihydroartemisinin (DHA). 
Likewise artesunate undergoes hydrolysis to DHA within 10 minutes of 
administering. DHA is metabolised by glucuronidation at the C-10 position and 
excretion.5 As a result o f this swift metabolism, artemisinin based treatments reduce 
parasite burden below detectable levels but without eliminating all the parasites.6 
This ultimately creates a risk of recrudescence: to circumvent these risks and 
m aintain the high efficacy o f artemisinin, the W orld Health Organisation (WHO) has 
advised administration of artemisinins in combination with other antimalarial agents
» 7(e.g. lumefantrine, amodiaquine, mefloquine, sulfadoxine-pyrimethamine).
1.1.3 The Mechanism o f Action o f Artemisinin
1.1.3.1 The Malaria Parasite Life Cycle
A fter a person is initially bitten by the infected Anopheles mosquito vector, the 
parasites of genus Plasmodium, first accumulate in liver hepatocytes. They then 
invade the host erythrocytes, digesting host haemoglobin and replicating in an 
asexual manner. The erythrocyte will then burst releasing merozoites into the blood 
stream  which infect more erythrocytes and continue replicating. A small proportion 
o f merozoites will differentiate into male and female gametocytes which lie dormant 
in the host until taken up by the next mosquito to bite the infected person. The 
gametocytes will then reproduce sexually in the digestive tract of the mosquito to 
produce sporozoites which, residing in the mosquito saliva, wait for inoculation into 
the next host.
The mechanism by which artemisinin exerts its antimalarial activity has been the 
subject o f extensive research and debate. The drug displays preferential accumulation
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in parasite infected erythrocytes8 and demonstrates a high efficacy against the 
erythrocytic stages o f Plasmodium with activity against asexual stages and early 
gam etocytes.6 The endoperoxide bridge o f artemisinin has been confirmed as crucial 
to its pharmacological mechanism, as removal results in loss of antimalarial activity.9
1.1.3.2 The Endoperoxide Bridge is Cleaved Forming Toxic Species 
It is understood that the endoperoxide is activated by ferrous iron to form species 
capable o f attacking biomacromolecules of the malaria parasite. This active species 
and the intermediates formed during its production have split artemisinin research 
into two main concepts: homolytic cleavage of the endoperoxide to form carbon 
centred radicals (CCRs) and heterolytic cleavage to form a hydroperoxide and 
reactive oxygen species (ROSs). These concepts shall be expanded upon in the 
following section and are summarised in Figures 1.3 and 1.4.
1.1.3.2.1 Homolytic Cleavage
Examination of the Fe(II) facilitated degradation of artemisinin led to the isolation of 
two major products: a THF acetate 7 and deoxoartemisinin 10 (Figure 1.3). The 
following homolytic mechanism was proposed accordingly.10' 12
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01
ring contracted 
THF acetate
Fe(!ll)Os
4-hydroxy
deoxoartemisinin
11
1,5-H shift Fe (M )CW  H 0
secondary carbon
centred radical
Figure 1.3 Homolytic cleavage o f the endoperoxide bridge and the resulting harmful
species.
Iron (II) acts as a catalyst where the initial step is the transfer of a single electron to 
the 0 - 0  a* orbital cleaving the 0 - 0  bond and forming an oxy radical and an OFe3+ 
complex, 5 and 8 . This scission of the fused ring structure allows for two paths. In 
the first, scission of the C3-C4 bond generates a primary carbon centred radical on 
C4, 6 . Loss and regeneration of Fe(II) leaves two radical centres which combine to 
produce the furan acetate metabolite 7. In the second, the production o f the free oxy 
radical attracts H-atom migration and results in a 1,5-hydrogen shift to give 9. Loss
5
o f the ‘OFe3+ complex allows for unsaturation of the C3-C4 bond and subsequent 
deoxoartemisinin formation, 10 and 11.
Posner13 sought to give further support to the hypothesis that the 1,5-hydrogen 
transfer is a crucial step in heme-promoted activation o f artemisinin. Structurally 
m odified 1,2,4-trioxanes, that would prevent such a 1,5-shift, were synthesised and 
displayed very poor activity in vitro. A number o f these intermediates have also been 
confirmed by radical trapping experiments.14' 17
However the interaction of these radical species with some of the proposed parasitic 
targets has never been directly observed. W u et al. also highlights fundamental 
problem s with proposing carbon centred radicals as causing fatal damage to parasite 
macromolecules: 1) carbon centred radicals should theoretically be eliminated by 
endogenous parasite radical-scavenging systems, 2) The structure of artemisinin 
means that intramolecular quenching o f the formed primary and secondary radical 
centres would be a much more plausible path than any intermolecular attack, and 3) 
If  artemisinin were able to attack via intermolecular radical attack; why is it more 
potent than simple organic peroxides that can potentially generate stoichiometric 
radical levels?18 W u proposes that artemisinin could form  artemisinin-heme adducts 
or cysteine based S-Fe-artemisinin chelates that would allow for more plausible
intramolecular attack and potentially produce irreversible binding to enzyme active
* if sites.
1.1.3.2.2 Heterolytic Cleavage
The formation of deoxoartemisinin as a by-product of iron(II) mediated cleavage has 
also been implicated in a heterolytic mechanism (Figure 1.4).
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deoxoartemisinin
4-hydroxy
deoxoartemisinin
Figure 1.4 Heterolytic cleavage o f the endoperoxide bridge and the resulting
harmful species.
In the proposed path for heterolytic ring opening, artemisinin acts as a masked 
hydroperoxide, which is opened by Fe(II) behaving as a Lewis acid, to give 13. 
Capture of the peroxide anion 13 by a nucleophile, such as H2O, forms the 
hydroperoxide 14 which can then undergo reduction by Fe(II) (Fenton chemistry) to 
form  hydroxyl radicals and a number of reactive oxygen species. Alternatively, loss
7
o f the C3 hydroxyl group gives a saturated C3-C4 bond which can be oxidised to an 
epoxide 15.
In 1996 Haynes confirmed Fe(II) and not Fe(IH) as the peroxide activating species, 
presented evidence for a iron-artemisinin adduct and proposed that artemisinin 
interacts with hemin via a free hydroperoxide.20,21 Further evidence for 
hydroperoxide formation was the observation that in the presence o f artemisinin 
tertiary amines formed 7V-oxides. This transformation is reminiscent of N-oxide 
formation by peracids and hydroperoxides in the presence o f a Lewis acid or protic 
acids. Additional support for a hydroperoxide intermediate is the non-endoperoxide 
oxygen o f the trioxane ring. Hydroperoxide formation is proposed to be aided by this 
structural feature through stabilisation o f the carbocation by resonance forms: lack 
thereof resulting in a reduction in potency.
1.1.3.3 Artemisinin is Implicated in Attacking a Number o f Parasite Targets 
It has been hypothesised that artemisinin may cause oxidative stress at non-specific 
lipid targets via the formation of reactive oxygen species22 and may enhance the 
redox activity of heme.23 The proposed mechanism (Figure 1.5) begins with cleavage 
o f the peroxide bridge by lipid solubilised heme24 to produce carbon centred radicals 
on artemisinin. These radicals facilitate the formation of a hydroperoxide moiety on 
the lipid bilayer. Fenton type chemistry results in cleavage o f the hydroperoxide and 
the release o f reactive oxygen species (hydroxyl radicals and superoxide anions). 
M ore recently these reactive oxygen species have been linked to the damage o f the 
parasite food vacuole, vacuolar rupture and parasite autodigestion.25
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Reactive oxygen species allylic C-radical
Figure 1.5 Proposed mechanism fo r  artemisinin mediated lipid peroxidation.
M uch evidence has gathered indicating that artemisinin and its analogues may exert 
their antimalarial effect via a similar mechanism to that of the quinoline class of 
antimalarial i.e. by the formation of heme adducts to block hemozoin formation. 
M eshnick and co-workers identified that artemisinin can form adducts with heme and 
that during this process the peroxide bridge is cleaved, thereby activating 
artem isinin.26,27 Robert, M eunier and co-workers characterised the heme-artemisinin 
adduct 16, indicating that all four meso positions of heme were alkylated by the
28 31prim ary carbon centred radicals of activated artemisinin (Figure 1.6). '
Biological testing of various artemisinin derivatives has also shown a positive 
correlation between levels of heme alkylation and in vitro antimalarial activity 
adding support for this proposed mechanism of action. ’
9
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Figure 1.6 Alkylation o f heme by artemisinin. Only alkylation at the ¡1-position is
shown.
Pandey et al. have demonstrated that artemisinin has the capacity to inhibit parasitic 
enzymes responsible for the digestion o f haemoglobin (aspartic acid proteases and 
cysteine proteases) and a histidine rich protein (PfHRP II) shown to catalyse the 
polymerisation of heme.34
The structural similarity of artemisinin to thapsigargin 17 (Figure 1.7), a known 
sarcoplasmic/endoplasmic reticulum Ca2+-ATPase (SERCA) inhibitor, has 
highlighted the SERCA of P. falciparum  (P/ATP6) as potential parasiticidal 
target.35,36 The inhibition of P/A T P6 by artemisinin was confirmed by the 
antagonistic relationship displayed by artemisinin and thapsigargin. The 
endoperoxide bridge also appears to play a role in enzyme inhibition as 
desoxyartemisinin (lacking the endoperoxide bridge) had no inhibitory effect on 
P /A T P6 and the iron-chelator, desferrioxamine, quenched inhibition o f P/A T P6 by 
artemisinin indicating cleavage of the peroxide bridge by Fe(II) is vital.
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Figure 1.7  Thapsigargin, a known SERCA inhibitor.
However, arguments against this mode of activity are that the opposing enantiomers 
o f trioxanes, structurally similar to artemisinin, have equal activity. This indicates 
that the mechanism o f artemisinin does not in fact depend on stereospecific 
interactions with a protein. These studies will be discussed in more depth in Section 
1.4.38’39
It has also been proposed that artemisinin may target NADH dehydrogenase enzymes 
o f parasite mitochondria, thereby breaking down the mitochondrial electron transport 
chain, causing depolarisation of mitochondrial membrane potential and disruption of
. • ■ 40parasite respiration.
It is unlikely that artemisinin acts at one, single biological target. This is supported 
by the wealth o f evidence proposing a number o f reactive intermediates and 
demonstrating that artemisinin has the potential to affect a wide variety o f parasite 
structures and systems. Add to this the limited resistance to artemisinin observed, 
and it suggests a multi-targeted attack of the m alaria parasite, the exact nature of 
which is yet to be confirmed.
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1.2 Photooxygenation as a Route to 1,2,4-Trioxanes
As elucidated by Jefford,41 the 1,2,4-trioxane m oiety found on artemisinin has 
proved essential for antiparasitic activity. In an effort to provide more economic and 
readily available analogues of artemisinin, research has focused on the synthesis of 
sim plified analogues incorporating the 1,2,4-trioxane pharmacophore (Figure 
1.8).38,42’43 A key step in the synthesis o f 1,2,4-trioxanes is the introduction of the 
peroxide functionality. Singlet oxygen, generated via photooxygenation, is a popular 
reagent allowing the introduction of oxygen in a controlled manner. In the following 
sections we will discuss the origins of singlet oxygen as a synthetically useful species 
and the remarkable regio- and stereoselectivity many of its reactions display. W e will 
then continue in Section 1.4 with an examination o f the previous routes, employing 
singlet oxygen, used to realise the 1,2,4-trioxane target.
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Figure 1.8 1,2,4-Trioxane artemisinin analogues displaying antimalarial activity 
comparable to that o f the parent compound.
1.2.1 Elucidation o f the Singlet Oxygen Intermediate ( ^ 2)
Research into photooxidation processes dates back to the late 19th century when 
biologists discovered that a combination of dyes, oxygen and light were toxic to 
organisms such as paramecia and photochemical reactions involving oxygen resulted
12
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in oxygenation of biological m aterial.44 In 1928 Mulliken proposed molecular orbital 
descriptions o f triplet ground state (3Xg‘), excited singlet delta ('A g) and excited 
singlet sigma (1Eg+) oxygen (Figure 1.9).45’46
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Figure 1.9 Ground, first and second excited states o f molecular oxygen.
W ork by Kautsky in the 1930s developed the theory that dye-sensitised 
photooxygenation reactions proceed via a singlet oxygen intermediate by 
demonstrating the diffusible nature of the reactive species, presumed to be ' 2 g+47 
However, during the 1930s, and through to the mid-60s, there was considerable 
doubt that such a singlet oxygen intermediate was involved in the mechanism of 
photooxidation reactions. A large body of evidence amassed contrary to the 
intermediacy of singlet oxygen, arguing that energy transfer (37 kcal/mol) from a dye 
molecule to molecular oxygen required to form 'E g+ was not viable. In fact a 
sensitiser-oxygen complex was proposed by many as the reactive species.48 Kautsky 
responded to this by indicating that formation o f 1 Ag (22 kcal/mol above ground state 
O2) was a viable energy transfer from dyes (emitting at 820 nm ).49 However, this 
response from Kautsky was largely ignored in the subsequent literature produced by 
his peers.
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Not until 1963 was the idea o f singlet oxygen as a vital intermediate revived. 
Observations o f solutions of NaOCl and H20 2 detected a red chemiluminescence 
attributed to the emission pairs of *02 m olecules.50"52 Pathways where }0 2 decays to 
triplet ground state 0 2 and hv [1268nm (22kcal/mol)] were reported.53"55 Foote and 
W exler further confirmed !0 2 to be the reactive intermediate in dye-sensitised 
photooxygenation.56 Comparison of the H20 2/N a0C l reaction conditions, known to 
generate singlet oxygen, and dye-sensitised photooxygenation conditions 
demonstrated that 2 ,5-dimethylfuran underwent transformation to 2 ,5-dimethyl-2- 
hydroperoxy-5-methoxy dihydrofuran in both cases: thereby linking the mechanistic 
pathways and intermediates (Figure 1.10).
1.0 - Introduction
Endoperoxides as Antimalarials and the Application of Singlet Oxygen to the Synthesis of
Key Synthetic Intermediates en Route to Synthetic 1,2,4-Trioxanes
a or b 9 
MeOH
OH
Figure 1.10 Identical reaction pathway o f a) the H202/Na0Cl system and b) dye-
sensitised photooxygenation.
Arguments for an excited sensitiser-oxygen complex were finally quashed when it 
was shown that a) rates o f photooxidation were independent o f the sensitiser used, b) 
sensitisers exert no steric influence, and c) radical scavengers do not influence the 
reaction.57’58
7.2.2 The Synthetic use o f Singlet Oxygen
In the following section we will discuss the nature of singlet oxygen in a qualitative 
fashion, however a discussion of the quantum mechanical aspects o f this subject can 
be found in a review by Kearns.59
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Synthetically useful singlet oxygen is the first excited state ( ' Ag) of molecular oxygen 
at 22 kcal mol' 1 above the triplet ground state (3S g ). The second excited singlet state 
(1Eg+), at 37 kcal mol' 1 above the ground state, is not synthetically active as a result 
o f its transient existence in solution (1 0 12 seconds). This transience and instability is 
due to the rapid spin allowed transition from  the second excited state, 1Eg+, to the 
first excited singlet state, *Ag. Correspondingly, the synthetic use o f the first excited 
state is derived from its metastability in solution ( 10'3- 10'6 seconds) as a result o f the 
spin disallowed transition to the ground state (Figure 1.11).
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Figure 1.11 Spin-disallowed transition from  the singlet excited to the triplet ground 
state imparts stability to singlet oxygen.
The triplet oxygen ground state is paramagnetic rendering capable o f free radical 
reactions and processes. Conversely, singlet oxygen is diamagnetic denoting its 
restriction to two electron reactions in a similar manner to ethylene.
1.2.3 The Generation o f Singlet Oxygen via Photooxygenation 
There are a number of chemical sources o f singlet oxygen reported in the literature, 
including the hydrogen peroxide/sodium hypochlorite system,60 disproportionation of 
H2O2 by mineral compounds,61’62 thermolysis o f phosphite ozonide adducts,63 base-
15
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catalysed disproportionation o f peracids64 and from the thermolysis of naphthalenic 
endoperoxides.65’66
The m ost efficient method however, is the dye-sensitised photochemical excitation of 
ground state molecular oxygen. Commonly used dyes are aromatic compounds, Rose 
Bengal, methylene blue and tetraphenylporphine (TTP) (Figure 1.12).
Endoperoxides as Antimalarials and the Application of Singlet Oxygen to the Synthesis of
Key Synthetic Intermediates en Route to Synthetic 1,2,4-Trioxanes
Figure 1.12 Commonly used sensitiser dyes.
Dye-sensitised photooxygenation is initiated by the excitation of a triplet ground 
state dye-molecule, by visible light, to the excited singlet state. Once the sensitiser is 
excited, three reaction paths are in fact available and are classified into 3 types: of 
note are Types I and II (Figure 1.13). Type I refers to an interaction between the 
excited dye-stuff and the substrate (H-atom extraction or electron transfer) to form 
radical species which react with ground state triplet oxygen to form the 
photooxygenation product. This pathway is often unfavourable as it facilitates 
degradation of the sensitiser dye.
16
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Type II involves energy-transfer oxygenation where singlet oxygen is the reagent. 
Rapid intersystem crossing of the singlet state sensitiser molecule results in the 
formation of the excited triplet state o f the dye, which can then undergo triplet-triplet 
energy transfer to molecular oxygen (triplet ground state). This energy transfer forms 
excited singlet oxygen and returns the sensitiser to its ground state. Singlet oxygen 
can then go on to react with the substrates present.
Sensitiser
Substrate
Type I
Substrate*
30 2
Photooxidised Product
Figure 1.13 Flow diagram to illustrate the pathways o f photooxygenation.
Prevalence of one of these pathways can be controlled by manipulation of the 
experimental conditions. The concentration of oxygen and substrate, temperature, 
lifetime of singlet oxygen in the chosen solvent and the selected dye, can all affect 
which process is followed.67 Type II photooxygenation, in particular, has been used 
for numerous synthetic applications as singlet oxygen is highly reactive and at the
17
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same time a selective reagent showing remarkable chemo-, regio- and 
stereoselectivity patterns.
1.2.4 Mechanistic Pathways o f Singlet Oxygen
The m ost important examples o f reactions that are facilitated by Type II 
photooxygenation are a) the ene-reaction with an olefin resulting in allylic 
hydroperoxides 18, b) [4+2]-cycloaddition with a 1,3-diene yielding 1,4- 
endoperoxides 19 and c) [2+2]-cycloaddition with an electron rich olefin, or olefin 
lacking P-hydrogen atoms, to give 1,2-dioxetanes 20 (Figure 1.14). The oxidation of 
heteroatoms (e.g. sulphide to sulfoxide) is also a prominent side reaction.
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The exact mechanistic intermediates formed during these reactions have been a 
subject of debate since their discovery. Proposed mechanisms include concerted 
cycloadditions as well as stepwise processes via zwitterionic 21, biradical 22 or 
perepoxide 23 intermediates or via an exciplex complex 24 (Figure 1.15).
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21 22 23 24
Figure 1.15 Proposed intermediates o f olefin photooxygenation.
The precise pathways of the formally termed [4+2]- and [2+2]-cycloaddition 
reactions have been extensively discussed in reviews by Frimer68 and Clennan67 and 
shall be summarised shortly. For our purposes, we will then proceed to discuss in 
depth the mechanistic features and stereoselectivity of the Schenk-ene reaction.
1.2.4.1 Proposed Mechanisms o f the l02 [4+2]-Cycloaddition Reaction 
The [4+2]-cycloaddition pathway is very versatile, occurring readily with acyclic, 
cyclic and aromatic 1,3-dienes, and can accommodate various substituents, latent 
functional groups and heteroatoms. A concerted pathway has often been favoured 
due to the structural similarity o f the reactants, to those involved in the Diels Alder 
reaction. The often observed c/s-stereoselectivity69 of this reaction and its apparent 
insensitivity to solvent also indicated a concerted process.70,71 Evidence contrary to a 
Diels Alder type mechanism is the fact that singlet oxygen [4+2]-cycloadditions have 
an activation barrier very close to zero.72 Aubrey also later highlighted the sensitivity 
o f reaction rate to solvent conditions through performing the [4+2]-cycloadition in 28 
different solvents.73 This has prompted support for a reversible exiplex complex 
(characterised by low activation barriers) with subsequent collapse to the 1,4- 
endoperoxide.74'75
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1.2.4.2 Proposed Mechanisms o f the 70 2 [2+2]-Cycloaddition Reaction 
The reaction path to 1,2-dioxetanes has been shown to have a higher activation 
energy to that of the formation o f endoperoxides and hydroperoxides and appears 
only to occur when other paths are unavailable. An exception to this is the reaction of 
electron rich olefins which undergo [2+2]-cycloaddition even when allylic hydrogens 
are accessible, though the ene-product is formed competitively. Again, the 
stereochemical properties demonstrated by this pathway suggest a concerted 
mechanism. However, arguments for a polar intermediate, either an open zwitterionic 
or a closed perepoxide intermediate, have gathered weight in the form of observed 
solvent effects.71 An example is the yield o f dioxetane 27 from treatment of 25 with 
singlet oxygen, which was found to increase from 3 to 50% as the polarity o f the
76solvent was increased (Figure 1.16).
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Figure 1.16 Effect o f solvent polarity on product distribution. Numbers refer to
percentage yield.
W ilson proposes a zwitterionic perepoxide intermediate having observed that the rate 
o f reaction of enol ester 28 was insensitive to solvent change while the products 
formed are dramatically affected. 28 was found to undergo acyl shift to 29 in 
acetone, whereas conditions in methanol facilitated formation o f 1,2-dioxetane 30
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(Figure 1.17). This supports the hypothesis that an intermediate to the formation of 
1,2-dioxetanes requires intermolecular H-bonding (satisfied by M eOH) i.e. a dipolar 
intermediate.77
Figure 1.17 Use o f a H-bonding solvent, such as MeOH, favours 1,2-dioxetane
formation.
1.2.4.3 Proposed Mechanisms o f the 7 02 Schenk-Ene Reaction 
Early observations indicated a concerted mechanism analogous with that of a 
reactive enophile which undergoes the formal “ene” reaction with an olefin. These 
observations included: a) a ds-relationship between the newly formed C-O bond and 
the breaking allylic C-H bond78, b) the inability o f cis- and trans-olefins to isomerise 
during the reaction indicating no free rotation around an intermediary single bond79 
and c) examples of the powerful stereoselectivity indicated that the mechanism could 
not proceed via an initial H-abstraction leading to an allylic free radical.58 However, 
elucidation of the d i-effec t (discussed in more detail below) demonstrated that the 
ene-reaction was not in fact subject to steric constraints that would be observed if  a
on
concerted process were involved.“”
Ab initio calculations have modelled a biradical intermediate as a major reaction 
pathway81, however, these suggestions contradict the high stereoselectivity 
demonstrated by the ene-reaction.82 Early suggestions presented by Jefford83 stated 
that the intermediate must be dipolar as the one-point attachment of the incoming 
singlet oxygen, before H-abstraction, causes an imbalance o f charge. However, later
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literature only discusses a zwitterionic intermediate in the context o f 1,2-dioxetanes, 
where the zwitterionic intermediate en route to the 1,2-dioxetane is intercepted by the 
solvent (e.g. methanol) to give the hydroperoxide. ’ ’
The majority of evidence supports the perepoxide intermediate as the pathway to the 
hydroperoxide product. The perepoxide intermediate was tentatively proposed by 
Sharp86 and Kearns.87,88 in the late 1960s. Semi-empirical methods highlighted the 
perepoxide on the CNDO/2 potential energy surface, and termed it a “quasi­
intermediate” . Frontier orbital theory describes singlet oxygen as having a very low 
energy LUMO, making it a strong electron acceptor, and presenting the olefin as 
providing the HOMO.
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Figure 1.18 Perepoxide interactions from  the olefin HOMO to singlet oxygen
LUMO.
The HOMO/LUMO interaction is most effective when the reactive nuclei are 
arranged with the two nucleophilic centres o f the e'-donor (olefin), and one 
electrophilic atom of the e‘-acceptor (!0 2), forming a triangle with the remaining 
atom of the acceptor tailing out of the trigonal plane giving perepoxide 31 (Figure 
1 .18 ).89 91
During the H-abstraction mechanistic step, singlet oxygen demonstrates preferences 
for certain allylic hydrogen atoms. These preferences have been studied by primary
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isotope effects82,92"95 demonstrated by tetramethylethylene-d6 and show the 
following: a) substituents with a m -relationship are in competition during H- 
abstraction which is consistent with a step-wise mechanism94, b) singlet oxygen 
displays suprafacial selectivity which is most closely accommodated by the 
perepoxide intermediate model (the tailing O-atom can only interact with one face of 
the olefin to abstract a H-atom)96 and c) in the case of trimethylethylene-rf6, singlet 
oxygen abstracts H-atoms from the m ost substituted face in what is termed the “cis- 
effect” (explained by the tailing O-atom of the perepoxide requiring stabilisation 
from  adjacent methyl groups).97'99 The cis-effect will be further discussed in Section
1.3 concerning the stereoselectivity of the ene-reaction.
Further support for perepoxides are the reaction of various trapping agents (e.g. 
sulfoxides, diphenyl sulphide, sulfenate/sulfinate esters and phosphites) with singlet 
oxygen to form the oxidised trapping agent and an epoxide of the olefin.100,101 
It can be summarised that it is the differentiating of the intermediate that controls 
product distribution in these pathways: a) perepoxides giving hydroperoxides, b) 
exiplex complexes giving endoperoxides and c) polar intermediates giving 1,2,- 
dioxetanes. The factors driving the choice of intermediate are often substrate 
structure and solvent conditions. However, as often is the case, overlap o f these 
pathways highlight exceptions that make definition of these highly transient species 
very difficult.
1.3 Regio- and Stereoselectivity o f the Schenk-Ene Reaction
Thorough reviews of the factors influencing the selectivity o f the Schenk-ene 
reaction with regard to a variety o f substrates have been provided by Stratakis102 and
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Clennan103. For our purposes we shall focus on simple di- and trisubstituted alkenes 
including enol ethers and particularly allylic alcohols.
1.3.1 Methoxy Groups cis-Direct H-Abstraction
Early studies identified the polarity of the olefinic rc-bond as driving regiocontrol 
and, in the case of enol ethers (Figure 1.19), the HOM O/LUM O interactions between 
attacking terminal oxygen atom and the methoxy group as exerting stereocontrol.90 A 
classic experiment demonstrating the regio- and stereocontrol exerted by the 
presence o f a methoxy group and the resulting m -effec t was performed by Rousseau 
in 1977.97 The singlet oxygen was found to have such a strong preference for the 
position cis to the methoxy group that it overcomes the highly awkward formation of 
the a-cyclopropylidene (Figure 1.19).
1.0 - Introduction
Endoperoxides as Antimalarials and the Application of Singlet Oxygen to the Synthesis of
Key Synthetic Intermediates en Route to Synthetic 1,2,4-Trioxanes
Figure 1.19 Singlet oxygen displays a preference fo r  H-abstraction cis to the
methoxy group.
Similarly, a methoxy group on a substituted styrene directs incoming '0 2 attack cis, 
giving 1,4-addition, if  the phenyl is cis to methoxy 32, or the ene reaction if  the 
m ethyl is cis to methoxy 33. If no substituent was positioned cis to methoxy then 1,4- 
attack takes place but at a much slower rate 34 (Figure 1.20)/°
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Figure 1.20 Singlet oxygen displays a preference fo r  H-abstraction cis to the
methoxy group.
As previously mentioned this preference for H-abstraction, suprafacial to a methoxy 
group, can be explained by the perepoxide model where the tailing oxygen atom is 
directed by interactions with the methoxy group to remove an allylic hydrogen from 
the cis-position.
1.3.2 H-Abstraction Occurs on the Most Congested Side o f the Olefin
This observation o f suprafacial H-abstraction was extended to the photooxygenation
on
o f  trisubstituted alkenes as displayed by Orfanopoulos (Figure 1.21).””
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Figure 1.21 Singlet oxygen displays preference fo r  H-abstraction from  the most
congested side o f the olefin.
A  preference for syn-ene addition to 1-methyl cycloalkenes was also demonstrated 
by singlet oxygen, which complies with a perepoxide intermediate where the trailing 
cationic O-atom is stabilised by allylic hydrogen atoms lying above the plane of the 
double bond (Figure 1.22).104
Figure 1.22 Singlet oxygen demonstrates a preference to syn-addition to 1-methyl
cycloalkenes.
This stabilisation effect is supported by Stephenson105 who postulates a secondary 
orbital interaction between the terminal oxygen LUMO and the allylic hydrogen 
contribution to the HOMO, stabilises the transition state leading to syn-addition.
An elegant hypothesis for the varied reactivity of, and preference for, specific allylic 
hydrogen atoms, was presented by Houk106 with respect to acyclic alkenes. Houk 
agrees that allylic hydrogen atoms m ust be perpendicular to the olefin in order to 
facilitate syn-selectivity but postulates that rather than the stabilisation of a
26
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perepoxide intermediate, the selectivity is derived from conformational barriers of 
alkyl substituents adopting the optimum perpendicular conformation. Houk also 
postulates that in a concerted transition state the bond to the allylic hydrogen which 
is being abstracted must also be perpendicular to the olefinic plane. It is therefore 
suggested that the differences in reactivity (% H-abstraction) of different substituents 
correlates to the differences in energy required to rotate to a perpendicular 
conformation.
1.3.3 An Anti cis-Effect has been Observed where t-Bu is Allylic 
For trisubstituted alkenes, where an allylic position possesses a i-Bu substituent 
(Figure 1.23), an anti ds-effect has been observed.102 For these substrates, the less 
substituted side of the double bond is more reactive.
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Figure 1.23 Numbers indicate percentage allylic hydrogen abstraction. Substituents 
bearing a t-Bu group do not direct a cis-ejfect.
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Figure 1.24 The perepoxide model shows that H-abstraction from  the most 
congested side o f the olefin does not provide any additional stabilisation for the
terminal O-atom.
During the formation of the intermediate, the terminal oxygen finds no improved 
stabilisation on the more congested side as there is now equal distribution of allylic 
H-atoms on both sides o f the olefin. Additionally, formation o f a perepoxide 
intermediate on the more substituted side of the olefin is not favourable because of 
steric repulsion between the oxygen and the two alkyl groups (Figure 1.24).
1.3.4 Allylic Alcohols have a Directing Effect on Singlet Oxygen 
In 1992, Adam and co-workers specifically looked at the directing effect of allylic 
alcohols and reported very high regio- and stereocontrol in one o f the most 
diastereoselective examples of the ene reaction.107,108 The reaction introduces a new 
stereogenic centre with a peroxy functionality adjacent to the hydroxyl group in a 
threo configured relationship (Figure 1.25). It was also observed that the substituents 
at R 1 and R2 had a negligible effect on the excellent 97: 3 diastereomeric ratio.
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diastereomeric ratio = 93% 7%
Figure 1.25 Photooxygenation o f ally lie alcohols displays high diastereoselectivity
in favour o f the threo-conformation.
Interestingly the diastereofacial selectivity of allylic alcohols behaves in an opposite 
respect to the “classical” c/i-effect discussed above. The classical ci'i-effect dictates 
that the tailing oxygen atom is stabilised by d i-a lly lic  hydrogen atoms positioned 
perpendicular to the plane of the olefin. If the classic d i-e ffec t were operating one 
would not predict a threo-relationship (between hydroxyl and peroxy groups). The 
i/zr<?o-conformation would not be viable as simultaneous positioning o f the allylic 
hydrogen perpendicular to the olefinic bond would leave the remaining Me group 
orientated to maximise 1,3-allylic strain and a highly unstable intermediate 35 
demonstrated in Figure 1.26. The classically predicted e^i/iro-relationship (between 
hydroxyl and peroxy groups) would result in a conformation with minimised 1,3- 
allylic strain and a stable viable intermediate 36 (Figure 1.26).
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Figure 1.26 Newman projection o f the perepoxide intermediates i f  the classic cis-
effect were operating.
However, in the case of allylic alcohols the opposite threo-result is observed, thus 
indicating that it is not in fact an allylic hydrogen stabilising the tailing oxygen but 
the hydroxyl group. If we look at Figure 1.27, we see that a conformation where the 
hydroxyl group is positioned perpendicular, 1,3-allylic strain can also be minimised 
as the methyl group is directed away from the adjacent ds-alkyl group. It can be 
summarised that the selectivity is a combination of 1,3-allylic train disallowing the 
perpendicular positioning o f a H-atom and the availability of a hydroxyl group to 
assum e a perpendicular alignment to stabilise the tailing O-atom, producing a threo- 
relationship the between hydroxyl and peroxy groups.
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Figure 1.27 Newman projection o f a novel cis-effect where the tailing oxygen atom
is stabilised by the -OH group.
The hydroxyl group is essential for selectivity as demonstrated by solvent effects and 
functionalisation o f the hydroxyl group. W hen the reaction was carried out in 
solvents that interact with the OH group via hydrogen bonding, e.g. MeOH and 
M eCN, a drop in diastereoselectivity was observed. Allylic ethers, 41 and 42, still 
demonstrated significant stereoselectivity however an allylic acetate 40 inverted the 
selectivity to favour erythro following the classic cis-effect (Figure 1.28).
X=
(37)
(38) H
(39)
CCI4
MeOH
MeCN
(40) Ac CCI4
(41) SiMe3 CCI4
(42) Me CCI4
39
80
72
61
20
28
Figure 1.28 Solvent polarity and functionalisation o f the hydroxyl group affect
stereoselectivity.
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This trend is explained by the fact that the nucleophilic allylic oxygen functions are 
the initial interaction with incoming '0 2  thereby directing the attack threo in 
examples 37 to 39, 41 and 42. The acetate group, being less nucleophilic, does not 
interact as strongly with 'Ch thereby allowing the reaction to be governed by the d i ­
effect 40.
In an analogous reaction, involving the photooxygenation of allylic amines, it was 
also observed that the free amine and its ammonium chloride proceeds with threo- 
selectivity. Similarly, for acylated amines erythro-selectivity was observed and the 
larger the nitrogen containing group, the higher the preference for an erythro- 
relationship.109
However, the position and direction of the hydroxyl group is ultimately decided by
the orientation of the adjacent alkyl substituent, dictated by 1,3-allylic strain. The
importance o f 1,3-allylic strain in stereoselection was highlighted by comparison of
cis and trans allylic alcohols 43, 44 and 45 (Figure 1.29).
Diastereomeric ratio 
threo erythro
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45
OH
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34
Figure 1.29 Allylic alcohols, where 1,3-allylic strain can operate, demonstrate
threo-selectivity.
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Absence o f a methyl group cis to the hydroxyl bearing substituent, i.e. 44 and 45, and 
therefore lacking 1,3-allylic government, demonstrate a loss stereoselectivity. 
Presence o f a gem-methyl group, as in 45, introducing 1,2-allylic strain, has only a 
small diastereoselective effect.
Adam  supports these hypotheses by comparison with examples of m-CPBA and 
vanadium  catalysed epoxidations. It is established that the selectivity demonstrated 
by these oxidations, mirroring that of the ene reaction, is a result o f the combined 
effects of hydroxyl coordination and allylic strain. 'n7’,n8
1.4 Synthesis of Antimalarial 1,2,4-Trioxanes
In 1983 Jefford reported on both the capture of 1,2-dioxetanes and 1,4-endoperoxides 
by acetaldehyde to form 1,2,4-trioxanes.84’110 The formation and utility of these 
critical intermediates, as a route to 1,2,4-trioxanes, sparked a body o f research 
com m itted to the synthesis of simplified artemisinin analogues. The two-fold purpose 
o f these derivatives was firstly to provide novel, economically viable antimalarial 
agents, and secondly, as models in an effort to elucidate the mechanistic action of 
artemisinin. This work will be summarised in the following sections, divided into 
photooxygenation routes employing either [4+2]-cycloaddition, [2+2]-cycloaddition 
or the Schenk-ene reaction.
1.4.1 [4+2]-Cycloaddition as a Route to 1,2,4-Trioxanes
As mentioned above, the first reported use o f photooxygenation (via [4+2]- 
cycloaddition pathways) to form a 1,4-endoperoxide, and its subsequent use in the
33
synthesis o f 1,2,4-trioxanes, was by Jefford and co-workers (Figure 1.30).110 Use of 
the 1,4-dimethoxynaphthalene starting material 46, including the diene moiety, 
ensured that upon photooxygenation, the reaction would proceed via a [4+2]- 
cycloaddition pathway to provide the desired 1,4-endoperoxide 47. To afford the
1,2 ,4-trioxane, an excess of acetaldehyde and catalytic amounts of the acidic 
amberlyst-15 resin were added to a solution of the 1,4-endoperoxide.
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Figure 1.30 Synthesis o f a 1,2,4-trioxane via [4+2]-cycloaddition and a 1,4-
endoperoxide intermediate.
The condensation step was also shown to give similar results in the presence of 
trifluoroacetic acid and even aq. H2SO4. Acidic conditions allowed for the opening of 
the endoperoxide bridge, to give the hydroperoxide 48, and its subsequent attack on 
the aldehyde to initiate cyclisation to the trioxane ring 49. 49 was formed as a pair of 
epimers at the 3-position and with an exclusively c/s-fused ring structure.111 
[4+2]-Cycloaddition was used to synthesise a racemic mixture o f cis-fused 
cyclopenteno-1,2,4-trioxanes which were then separated by chiral chromatography to 
afford enantiomerically pure trioxanes.38 These enantiomers were then tested for
34
antimalarial activity to ascertain if  the stereochemistry had any effect on activity. The 
synthetic 1,2,4-trioxanes displayed excellent activity, particularly the p-fluorinated 
derivative 50. 50 showed oral activity better than that o f the parent compound 
artemisinin and has been presented as a potentially clinically viable agent under the 
name o f Fenozan B07.
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F
Figure 1.31 Potent 1,2,4-trioxane antimalarial, Fenozan.
However, there was no significant difference in activity of either the enantiopure or 
racemic compounds. This was linked to the hypothesis of activation by heme as it is 
also achiral. A proposed mechanism of action for these 1,2,4-trioxanes (Figure 1.32) 
is an initial coordination of the 1,2-peroxy group with the Fe(II) centre o f heme 51 
and subsequent cleavage of the peroxide bond via single electron transfer (SET) to 
form  a spirocyclic acetal radical 52. The newly formed negatively charged oxygen is 
now free to bond covalently to Fe(II) 53. Radical mediated opening o f the 
cyclopentyl ring forms an ester derivative with a primary carbon centred radical 54, 
previously implicated in heme alkylation.28'31 Opening of the cyclopentyl ring and 
the resulting ester formation is given credence by molecular modelling studies in
38which it is demonstrated to be a strongly exothermic process.
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Figure 1.32 A proposed mechanism o f action o f synthetic spirocyclic 1,2,4-
trioxanes.38
1.4.2 [2+2]-Cycloaddition as a Route to 1,2,4-Trioxanes
Jefford et al. ensured a [2+2]-cycloaddition reaction path by dye-sensitised
84photooxygenation of the vinyl ether, 2-norbomeol methyl ether 55.
Figure 1.33 Synthesis o f a 1,2,4-trioxane via [2+2]-cycloaddition and a 1,2-
dioxetane intermediate.
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Photooxygenation of 55 in acetaldehyde as the solvent, gave the exo- 1,2,4-trioxane 
product as a mixture o f two isomers at the 5-position 57 as well as the dioxetane 
cleavage product 58 (Figure 1.33). 2-(M ethoxymethylene)adamantane was also 
treated under the same conditions to give isomer 59, and 2-adamantanone.
This chemistry was extended to the synthesis o f a series of artemisinin derivatives 
designed to lack one o f the four ring functionalities found on the parent compound 
60 (Figure 1.34).41
Figure 1.34 Inter- and Intramolecular [2+2]-cycloaddition is employed in the 
synthesis o f  a variety o f artemisinin 60 derivatives.
The ring systems essential for antimalarial potency were elucidated by comparison of 
the antimalarial activity of analogues 62, 63, 65 and 66. The derivative designed to 
lack the 1,2-dioxepane ring d, was synthesised from a dihydropyran derivative 61. 
Photooxygenation to give the ejco-l,2-dioxetane was followed by enlargement of the 
ring by acetone or cyclopentanone to afford 62 and 63 respectively. Products 62 and 
63 had the precise chirality o f artemisinin; however the trioxane 62 adopted a chair 
conformation unlike the boat conformation found on the parent compound. The
37
spirocyclic derivative 63 was proposed to have a conformational bias towards the 
boat structure.
An intramolecular variant o f the condensation step was used to produce the second 
derivative lacking the 5-lactone ring b. Photooxygenation of vinyl ether 64 and 
subsequent intramolecular condensation gave the desired product 65 and by-product 
66. The spirocyclic compound 63 demonstrated the best antimalarial activity, 
attributed to the 1,2,4-trioxane being in a boat form, brought about by conformational 
compression o f the spirocyclic group. 66 was also tested but displayed poor activity 
confirming that the trioxane is vital: a cyclic peroxide being insufficient for activity. 
Posner used 1,2-dioxetanes to access the exact 1,2-dioxepane, 1,2,4-trioxane fused 
ring system found on artemisinin, in the synthesis of analogues 67a, 67b and 67c 
(Figure 1.35), which showed antimalarial activity comparable to artemisinin.112' 114
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Figure 1.35 Artemisinin analogues 67a112, 67b113, and 67c114 with antimalarial 
activity comparable to that o f the parent compound.
This synthetic route, starting from cyclohexanone and pyrrolidine, was modified to
facilitate an enantioselective synthesis.39,42 The key step was the synthesis of the
nitrile 70, where an enamine reacting with a Michael acceptor in the presence of
M gC h proceeds with excellent enantiomeric excess. (5)-(-)-Pyrrolidine methanol 68
38
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provides the chiral starting material. The nitrile group of 71 allows for 
functionalisation of the C-3 position on the target 74. Introduction of a Z-configured 
enol ether 71 allows for [2+2]-cycloaddition and subsequent intramolecular 
cyclisation to give 74.
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a) cyclohexanone, TsOH; b) TMSCI, DIPEA; c) acrylonitrile, MgCI2; d) Ph3P+CH20MeBr-, LDA; 
e) 4-F-PhLi; f) Methylene Blue, -78°C, 02, hv; g) TBDMSOTf, Et3N.
Figure 1.36 Asymmetric synthesis o f an antimalarial 1,2,4-trioxane via [2+2]-
cycloaddition.
The stereochemistry o f the vinyl ether and the diastereospecific nature of the [2+2]- 
cycloaddition results in si-facial attack by singlet oxygen. Lewis acid catalysed 
dioxane opening and condensation to the trioxane is also stereoselective. The 
opposing enantiomer was easily synthesised using readily available (/?)-(+)- 
pyrrolidine methanol as the starting material. Both enantiomers were obtained with 
85% ee.
39
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The eventual purpose o f these enantiomerically pure artemisinin derivatives was to 
investigate the antimalarial activity of the opposing enantiomers. A difference in 
activity would have implications for the mechanism of action o f artemisinin, i.e. a 
detrimental interaction with a specific protein target (e.g. P/ATP6) rather than 
random ised attack of parasite macromolecules. However, the trioxane enantiomers 
showed the same level o f in vitro antiparasitic activity arguing against specific 
interactions with a chiral protein or enzyme and supporting the achiral heme- 
activation hypothesis.
1.4.3 The Schenk-ene Reaction as a Route to 1,2,4-Trioxanes
In 1990, Singh and co-workers were first to use the synthesis o f hydroperoxy 
alcohols in the context of 1,2,4-trioxanes as antimalarial agents.115 The hydroperoxy 
alcohol intermediate 76 was stable enough to be handled at room temperature, and 
underwent condensation with cyclohexanone to afford the spirocyclic 1,2,4-trioxane 
77 (Figure 1.37).
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Figure 1.37 Synthesis o f 1,2,4-trioxanes via hydroperoxy alcohols.
1,2,4-Trioxane analogues have since been synthesised with aryl115 and naphthyl116,117
groups at the y-position and withstood reductive amination conditions to furnish
• • 118amino functionalised derivatives.
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Griesbeck and co-workers discussed in more depth the diastereoselectivity o f the 
Schenk-ene reaction and its implications as a route to 1,2,4-trioxanes. In order to 
characterise the major and m inor isomers, the chiral allylic alcohol 78 underwent 
photooxygenation in methanol to give a 73:27 mixture of the threo- and erythro- 
hydroperoxy alcohol, 79 and 80 respectively (Figure 1.38).
Endoperoxides as Antimalarials and the Application of Singlet Oxygen to the Synthesis of
Key Synthetic Intermediates en Route to Synthetic 1,2,4-Trioxanes
fhreo-configured
79
OH
HOO,
eryf/iro-configured
80
BF,
Figure 1.38 NMR study o f the coupling constants fo r  cis- and trans-1,2,4-trioxanes.
Condensation with cyclopentanone gave a transí cis m ixture o f the 1,2,4-trioxane, 
81/82 respectively. M easurement of the coupling constants unambiguously showed 
that the major diastereoisomer 81 has trans-configuration (1 = 9.5 Hz) residual from 
the t/ireo-hydroperoxyalcohol. Correspondingly, the m inor diastereoisomer 82 
displayed ds-configuration (7=  5.4 Hz) due to the erythro-starting material.
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Griesbeck later reported on a number of spiroanellated 1,2,4-trioxanes, synthesised 
by the same route, with excellent antimalarial activities.120 The spirocyclic products 
were derived from cyclic ketones and from antimalarial evaluation a clear structure 
activity relationship emerged:
monocyclic<spirocyclopentyl<spirocyclohexyl<spirocycloadamantyl.
The spirocycloadamantyl derivative 83 (Figure 1.39) demonstrated activity against P. 
falciparum  in the range of artemisinin.
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Figure 1.39 Most potent antimalarial spirocyclic 1,2,4-trioxane in the series.
83 was characterised by X-ray crystallography studies, which showed that the central 
trioxane adopts a near perfect cyclohexane chair conformation with substituents at C- 
5 and C-6 in an equatorial position.
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1.5 Summary
1) Artemisinin has emerged as a mainstay in the treatment o f advanced cases of 
malaria, its mechanism of action initiated by the cleavage o f the 
endoperoxide bridge. Proposed parasite targets include: a) causing oxidative 
stress at lipid targets, b) alkylation of heme, c) inhibition of parasitic enzymes 
(e.g. cysteine proteases, NADH dehydrogenase, ATPase).
2) Synthetic 1,2,4-trioxanes incorporate the endoperoxide pharmacophore and 
have exhibited excellent antimalarial activity.
3) A popular route to 1,2,4-trioxanes is the use o f singlet oxygen to generate the 
peroxide functionality and subsequent condensation with an aldehyde or 
ketone.
4) Excited state singlet oxygen is most commonly generated from ground state 
triplet oxygen via dye-sensitised photooxygenation. The sensitiser is excited 
by a photon of light and intersystem crossing allows for energy transfer to 
molecular oxygen and excitation to the singlet state.
5) Singlet oxygen reacts through 3 major pathways: a) [4+2]-cycloaddition to 
give 1,4-endoperoxides, b) [2+2]-cycloaddition to give 1,2-dioxetanes, c) 
ene-reaction to give hydroperoxides.
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6) Singlet oxygen reacts in a highly regio- and stereospecific manner. One o f the 
most diastereoselective examples is the photooxygenation o f allylic alcohols 
demonstrating high f/ireo-selectivity in non-protic solvents.
7) Acid catalysed treatment o f 1,4-endoperoxides, 1,2-dioxetanes and 
hydroperoxy alcohols with cyclic ketones furnishes cis-fused and spirocyclic
1,2,4-trioxanes, where diastereoselectivity is conferred to the 1,2,4-trioxane 
target.
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2.0 Results and Discussion - Endoperoxides as Antimalarials and the 
Application of Singlet Oxygen to the Synthesis of Key Synthetic Intermediates 
en Route to Synthetic 1,2,4-Trioxanes
Previously, Singh1 and Griesbeck2 have synthesised racemic trioxanes similar to 
trioxanes 89a-f and reported excellent in vitro antimalarial activities against the K1 
strain o f P.falciparum. Given the promising profile of some o f these endoperoxides 
we were interested in developing a general enantioselective route to 1,2,4-trioxanes 
in this class.
The hydroxy-directed regio- and diastereoselective photooxygenation o f chiral allylic 
alcohols, to yield allylic hydroperoxides, was first discovered by Adam et al? The 
synthesis o f 1,2,4-trioxanes via dye-sensitised photooxygenation of achiral allylic 
alcohols to obtain hydroperoxy alcohols and the subsequent acid catalysed 
peroxyacetalisation with cyclic ketones has been used by Chandan Singh to access
1,2,4-trioxanes similar to 89a-f.1,4-7 The stereoselectivity of both reaction steps has 
been elucidated further by Griesbeck who has synthesised racemic threo-p- 
hydroperoxy alcohols that were in turn used to synthesise diastereomerically pure 
racemic chiral 1,2,4-trioxanes.2,8 To our knowledge no one has ever reported the 
synthesis of enantiomerically enriched chiral 1,2,4-trioxanes. This chapter describes 
the development of a facile route to enantiomerically enriched 1,2,4-trioxanes via 
chiral allylic alcohols. W e have also evaluated phosphite ozonide adducts, a chemical 
source of singlet oxygen, as an alternative to traditional dye-sensitised photochemical 
m ethods of oxygenation. Preliminary in vitro antimalarial activity of a series of 
individual conformers o f enantiomerically enriched 1,2,4-trioxanes is also reported.
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2.1 Threo-Selective Photooxygenation o f Allylic Alcohols and the Synthesis of 
Racemic 1,2,4-Trioxanes
2.1.1 Threo-Selective Photooxygenation o f Allylic Alcohols
2.1.1.1 Threo-Selective Photooxygenation o f Mesityl Allylic Alcohol 78
To confirm  the diastereomeric ratio and r/ireo-selectivity reported by Griesbeck et 
al.2, we performed photooxygenation o f racemic allylic alcohol 78 which was 
obtained via LiAlH4 reduction of mesityl oxide 84.
Using tetraphenylporphine (TPP) as a sensitiser dye, photooxygenation of 78 was 
carried out in dichloromethane by irradiating with a single 400W tungsten lamp for 4 
hours (Scheme 2.1).
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Schem e 2.1 Reagents and conditions: i) U A IH 4, EtC>2, 0 °C, 30 mins: ii) O2, TTP, 
CH 2CI2, hv, 0 °C, 4 hr.
The reaction showed excellent diastereoselectivity (d.r., threo:erythro = 90:10), 
which was calculated using *H NM R spectroscopy on the crude reaction mixture. A 
doublet at 8 4.17 (JHa-Hp = 8.3 Hz) corresponds to the major threo-isomer 79 and the 
doublet at 8 4.31 (JHa-Hp = 4.6 Hz) indicates the presence of the eo^ro -con figu red  
isom er 80. The crude reaction mixture was visualised on t.l.c. with p-anisaldehyde 
and showed the two diastereoisomers as two close spots staining purple, typical of
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the peroxide moiety. The major threo-product was easily purified from the m inor by 
column chromatography in 46% yield. Repeating the photooxygenation of 78 with an 
additional tungsten lamp resulted in the threo-isomer being isolated in 54% yield. 
After four hours o f reaction time, there still remained some unreacted starting 
material. W hen the reaction time was increased to 16 hours, no increase in yield was 
observed. M onitoring by t.l.c. showed an impurity forming at the base o f the plate 
after 4 hours of reaction and the intensity of this spot increased as the reaction 
progressed. Interestingly, the aeration o f the solution with a stream o f pure oxygen 
was not imperative, as it was observed that using a stream of compressed air in its 
place had no detrimental effect on the yield.
The volatility of the solvent and starting material also posed a problem, as the heat 
produced by the lamp and the air passing through the reaction caused it to evaporate, 
presumably before conversion occurred. To avoid the evaporation o f the solvent a 
system to cool the flask was also needed. It was found that the most effective and 
easy to maintain, was to have a stream of water flowing around the outside of the 
flask.
2.1.1.2 Photooxygenation Conditions on Solid Support Media 
Griesbeck9 and co-workers also outlined a procedure for photooxygenation in a 
solvent-free system using a polystyrene solid support. In this set-up the sensitiser and 
substrate were pre-loaded onto the support media sequentially. The dry m ixture was 
then irradiated for 4 hours. The product, and any remaining starting material, was 
then washed from the polystyrene support using methanol, leaving the sensitiser 
behind, still loaded onto the polystyrene. This was a great advantage as removal of
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the TPP from the product by chromatography was a lengthy process. Moreover, 
solvent levels did not need to be constantly topped up. The desired threo-isomer was 
obtained in 47% yield.
However, *H NM R spectroscopy showed that the reaction performed on the solid 
support showed reduced diastereoselectivity (d.r., threo:erythro = 70:30) in contrast 
to the 90:10 selectivity obtained using the dichloromethane solvent system. Due to 
the reduced selectivity and a moderate yield of 47% under solid support conditions, 
all the succeeding photooxygenation reactions were carried out in dichloromethane. 
The loading and removal o f the substrate and TPP from the solid support media did 
allow us to readdress the problem o f purification by column chromatography. 
Purification of the reaction mixture by column chromatography using a 
EtOAc/Hexane solvent system led to the contamination o f the desired product with 
TPP. As TPP is soluble in CH2CI2 whereas the oxygenated substrates are insoluble, 
all TPP was successfully removed from the column first by flushing with CH2CI2. 
Thereafter the original EtOAc/Hexane eluent system could be applied to successfully 
purify the hydroperoxy alcohol.
2.1.1.3 Threo-Selective Photooxygenation o f Benzylic Allylic Alcohol 87 
In an effort to make the photooxygenation step more efficient, we used a less volatile 
substrate with a higher molecular weight. A  Grignard reaction was chosen as a 
suitable route to the racemic allylic alcohol 87. The addition reaction of 
commercially available 2-methyl-1-propenyl magnesium bromide 86 to 
phenacetaldehyde 85, afforded 4-methyl-l-phenyl-3-penten-2-ol 87 in 48% yield 
(Scheme 2.2).
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Schem e 2.2 Reagents and conditions: i) THF, -78 °C—>r.t., 2 hr: ii) O2, TTP,
CH2CI2, hv, 0 °C, 4 hr.
Photooxygenation of the benzyl substituted substrate 87, gave the expected product, 
3-hydroperoxy-4-methyl-1 -phenyl-4-penten-2-ol 88. However, no significant 
increase in yield was observed.
2.1.2 Synthesis o f Racemic 1,2,4-Trioxanes
Jefford10’11 previously demonstrated that acid-catalysed cyclisation o f hydroperoxy 
alcohols with aldehydes and ketones afforded monocyclic and spirocyclic 1,2,4- 
trioxanes respectively. Previously employed Lewis acid catalysts include Amberlyst- 
15,10 TM SOTf12 and BF3.Et20 .8 W ith two hydroperoxy alcohol intermediates in 
hand, 79 and 88, we attempted the final peroxyacetalisation to give the desired 1,2,4- 
trioxanes 89a-f (Scheme 2.3).
The allylic hydroperoxy alcohols 79 and 88 were treated with cyclic ketones: 
cyclopentanone, cyclohexanone and 2-adamantanone to obtain the six racemic 1,2,4- 
trioxanes 89a-f in moderate yield. Initially, BF3.Et20 was used to catalyse the 
reaction, but p-TsOH was found to be more convenient and afforded up to a 20% 
increase in yield in some cases.
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R1 = Me 79 R1 = Me R2 = cyclopentyl 89a 26%
R1 = Bn 88 R1 = Me R2 = cyclohexyl 89b 40%
R1 = Me R2 = adamantyl 89c 42%
R1 = Bn R2 = cyclopentyl 89d 42%
R1 = Bn R2 = cyclohexyl 89e 20%
R1 = Bn R2 = adamantyl 89f 12%
Schem e 2.3 Reagents and conditions: i) TsOH, R 2C = 0 , CH2CI2, -10 °C, 30 min. 
Hashed and bold wedged bonds differentiate between diastereoisomers.
2.2 Enantioselective Synthesis of 1,2,4-Trioxanes via Diastereoselective Ene 
Reaction of Chiral cis-Allylic Alcohols
W e then wanted to apply the highly efficient, stereoselective ene reaction to a chiral 
substrate in order to synthesise enantiomerically enriched 1,2,4-trioxanes. A cis- 
allylic alcohol was identified as a suitable substrate as it would only allow allylic H- 
abstraction from its single methyl substituent ensuring consistent regiochemistry 
between the desired products. Although the ene reaction is reported as demonstrating 
proficient regioselectivity, favouring H-abstraction from the most congested side of 
the olefin, we chose to make certain o f H-abstraction from  only one position.
2.2.1 Synthesis o f the Chiral cis-Allylic Alcohol via Enantioselective Reduction o f a 
Propargyl Ketone
W e initially intended to synthesise propargyl alcohol J?-93a by following a procedure 
outlined by M idland13 and co-workers (Scheme 2.4).
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90 91a : R = Ph 92a : R = Ph 100% 9 3 a :R  = Ph21%
91b : R = i-Pr 92b : R = i-Pr 100% 93b : R = i-Pr 97% 94b : R = i-Pr 70%
(3R,4R)-95b : R = i-Pr 47% (5R,6R)-96b : R = i-Pr 26%
Scheme 2.4 Reagents and conditions: i) AICI3, CH2CI2, 0 °C, 30 min: iia) (R)- 
Alpine-borane, propanai, H2O2, r.t., 16 hr: iib) [Cp*RhCl2]2, (/?,/?)-TsDPEN, H2O, 
NaOOCH, r.t., 2 hr: iii) Lindlar catalyst, 2,6-lutidine, H2, n-Hex: iv) O2, TTP, 
CH2CI2, hv, 0 °C, 4 hr: v) p-TsOH, R2C = 0 , CH2C12, -10 °C, 30 min.
The synthesis started with the treatment of trimethylsilylpropyne 90 with benzoyl 
chloride 91a and A1C13 in dichloromethane at 0 °C for 30 minutes. This afforded 
l-phenyl-2-butyn-l-one 92a in quantitative yield.
It is well documented that during the asymmetric reduction of ketones by Alpine- 
borane, isopropyl groups impart additional selectivity. Therefore, isobutyryl chloride 
91b was selected for treatment with 1-trimethylsilylpropyne 90. Similar reaction 
conditions and purification by Kugelrohr distillation furnished 2-methyl-hex-4-yn-3- 
one 92b in quantitative yield.
At this point a sample of racemic alcohol was also synthesised, again using U A IH 4 
reduction conditions. Use of this expendable substrate in further reaction steps was 
informative in determining their efficiency without wasting valuable chiral material.
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The racemic alcohol was also useful as a control for analysis o f the enantiomeric 
purity of our chiral substrates by GC and NMR.
1 -Phenyl-2-butyn-1 -one 92a was treated with concentrated (R)-Alpine-borane and 
allowed to react overnight at room  temperature. Propionaldehyde was then added to 
destroy the Alpine-borane adduct, and the liberated (+)-a-pinene was removed in 
vacuo. The reaction was then quenched and purified by an oxidative work-up, 
colum n chromatography and Kugelrohr distillation at 100°C. This afforded 1-phenyl- 
2-butyn-l-ol R-93a in 21% yield.
The reduction of 2-methyl-4-hexyn-3-one 92b by (R)-Alpine borane was also 
attempted; however, we had limited success. The desired product was observed on 
t.l.c. but could not be isolated and characterised.
As a result of the poor yields and the problematic workup, involving an inert nitrogen 
atmosphere throughout, we decided to explore alternative methods of asymmetric 
acetylenic ketone reduction. A Sharpless kinetic resolution of the secondary allylic 
alcohol was discounted as Z-disubstituted allylic alcohols were reported to be poor 
substrates and loss of half o f our material was not ideal.14
An alternative synthetic route was chosen which involved Rh catalysed asymmetric 
transfer hydrogenation (ATH). Noyori and co-workers15 first reported the ATH of 
acetylenic ketones using a chiral Ru(II)/diamine catalyst complex and 2-propanol as 
the hydrogen donor. For our purposes, we followed a procedure outlined by Wu et 
al.16 It was reported that the ATH of aromatic ketones, catalysed by the Ru(II), 
Rh(III) and Ir(III) complexes of P-amino alcohols, can be carried out smoothly in 
water using NaOOCH as a hydrogen donor.
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Scheme 2.5 Reagents and conditions: i) H2O, 40 °C, 1 hr: ii) NaOOCH, r.t., 2 hr.
The pre-catalyst 99 was formed by stirring [Cp*RhCl2]2 97 and the ligand, (R,R)- 
TsDPEN 98 in water at 40 °C for an hour until a clear orange solution was formed 
(Scheme 2.5). Sodium formate, the hydrogen source, and 2-methyl-4-hexyn-3-one 
92b were finally added and the m ixture was allowed to react for 2 hours with fast 
stirring. The product was extracted with ether and then purified by Kugelrohr 
distillation at 100 °C to give (/?)-93b as a clear oil. Facile synthesis o f the opposing 
enantiomer (S)-93b was performed using the (S,S)-TsDPEN/[Cp*RhCl2]2 catalyst 
complex.
Analysis by chiral gc showed a conversion o f >97% and showed the formation of 
one single enantiomer. This was confirmed by NM R analysis o f the corresponding 
M osher’s ester (Scheme 2.6).17
100 101 (S)-93b (S)-102 6%
Scheme 2.6 Reagents and conditions: i) SOCI2, NaCl, reflux, 16 hr: ii) pyridine, 
CH2CI2, r.t., 12 hr.
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Firstly the acid chloride was prepared by refluxing M TPA 100 with thionyl chloride 
and NaCl overnight. The thionyl chloride was removed in vacuo and the acid 
chloride 101 was used immediately to synthesise M osher’s esters ((S)-102 and rac­
ia l)  of both the 5-configured substrate (S)-93b and an analogous racemic sample 
rac-93b.
19F NM R analysis of (S)-102 showed a single peak at 5 -71.56 ppm. In contrast, the 
racemic product rac-102 shows peaks at 8 -71.56 ppm and 8 -71.58 ppm  confirming 
the enantiomeric purity o f (S)-93b.
Lindlar catalyst, Pd/CaC03 , is well known for the reduction of alkynes to alkenes in 
100% cii-geometry. The presence of the alkyne moiety in our substrate gave us the 
geometric control needed to introduce the cw-alkene (Scheme 2.4). The control of 
the catalyst to only reduce to the alkene level is brought about by poisoning of the Pd 
with Pb and the inclusion of small amounts of 2,6-lutidine in the reaction mixture.
A solution o f (R)- or (S)-93b, Lindlar catalyst and 2,6-lutidine in hexane was stirred 
vigorously under a H2 atmosphere. H2 uptake was monitored throughout the reaction 
and the reaction stopped once the required volume of H2 was consumed. The reaction 
could not be monitored by t.l.c. as both substrate and product had identical Rf values. 
Full consumption of the starting material was important as the similarity in boiling 
point and polarity between the substrate and the product made purification by 
distillation or chromatography impossible. The reaction mixture was filtered through 
Celite to remove the catalyst and the organic extracts were washed with dil. HC1 to 
remove the 2,6-lutidine. Finally, Kugelrohr distillation ensured complete removal of 
any remaining catalyst and impurities giving (R)- or (S)-94b as a pale yellow oil in 
70% yield.
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It is worth noting that a major hindrance, up to this point of the synthesis, was the 
low m olecular weight and volatility of the substrates. All solvents had to be removed 
by simple distillation and at no point could a vacuum be applied without risking 
evaporation of the products.
2.2.2 Photooxygenation o f the Chiral cis-Allylic Alcohol and a Modified Reaction 
Set-up.
Photooxygenation (Scheme 2.4) of the cis-allylic alcohol rac-94b was initially
carried out as described in Scheme 2.1. Under these conditions, compound rac-94b
yielded only 9% of the hydroperoxy alcohol rac-95b. As a result o f this poor yield,
we revised the equipment used for the photooxygenation reaction.
Some of the implications of practical photochemistry have been discussed by Hook 
18and Booker-M ilbum.
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They cite commonly used batch apparatus as the immersion well reactor (Figure 2.1). 
The light source is placed in a well, effectively “inside” the reaction mixture, with a 
water cooling jacket separating the lamp from the reaction medium.
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As the majority o f the photochemistry occurs within a short radius o f the lamp, this 
setup allows for minimal distance between the light source and any part o f the 
reaction solution and therefore an efficient reaction.
However, for our purposes we needed a setup that would also allow for aeration by 
O2. W ith the apparatus available to us we constructed an elongated reaction vessel 
from  a Liebig condenser which was sealed at the bottom (Figure 2.2).
Figure 2.2 Modified photooxygenation apparatus with an elongated, cooled reaction
vessel.
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This was ideal as the volume of the reaction m ixture was spread through a long 
narrow tube. The benefit o f this was that more lamps could be fitted in close 
proxim ity around the vessel and no part of the reaction mixture was ever more than 
an inch away from a light source. Also, the use o f the condenser supplied a ready­
m ade sealed water jacket to cool the reaction. A cold finger condenser, cooled with 
acetone and dry ice, was also fitted onto the Liebig condenser to limit the 
evaporation o f the solvent and starting material which worked very efficiently. 
Narrow bore PTFE tubing was passed through both condensers to the base o f the 
reaction vessel where it delivered the O2 gas which could then bubble up through the 
solvent, efficiently aerating the solution.
Four lamps were used in this set-up to furnish the ds-ally lic hydroperoxy alcohol 
rac-95b in 43-47% yield. These conditions were then applied to the enantiomerically 
pure material (/?)- and (S)-94b to furnish (3/?,4/?)-95b and (3S,4S)-95b in similar 
yields. This modified set up was also tried with the mesityl alcohol 78 but no net 
increase in yield was observed. The harsher conditions increased the rate o f the 
reaction and led to the production of the polar by-product in a shorter time. However, 
this m eant the reaction time could be reduced to 2.5-3 hours.
2.2.3 Synthesis o f Enantioenriched cis-Substituted 1,2,4-Trioxanes 
W ith samples of the ds-hydroperoxy alcohols, (3i?,4/?)-95b, (3S,4S)-95b and rac- 
95b in hand we continued to the final step, peroxyacetalisation with a cyclic ketone 
(Schem e 2.4; step v.). The hydroperoxy alcohols were treated with 2-adamantanone 
and p-TsOH to give the target, enantiomerically enriched, 1,2,4-trioxanes. The R-
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configured, S-configured, and racemic substrates furnished (5/f,6/?)-96b, (5S ,6 S)- 
96b  and rac-96b in 26%, 34% and 23% yield respectively (Figure 2.3).
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rac-96b 30% (5ft,6R)-96b 26% (5S,6S)-96b 34%
Figure 2.3 Racemic and chiral cis-substituted 1,2,4-trioxanes.
2.3 The Interaction of Phosphite Ozonide Adducts (POAs) with Allylic Alcohols 
The use o f dye-sensitised photooxygenation as method of generating singlet oxygen 
in order to introduce a hydroperoxide moiety has its lim itations.8,9’18 As previously 
m entioned, removal of dye stuffs can be problematic. M ore importantly, scale up of 
the process is impractical as photooxygenation is restricted to a batch process rarely 
used in an industrial setting. Chemical methods of generating singlet oxygen have 
been explored in the literature20"25 but more specifically the use o f phosphite ozonide 
adducts26,27 piqued our interest. Previous work within our group demonstrated the 
use o f phosphite ozonide adducts in the synthesis o f endoperoxide anti-malarial
agents and led to the successful synthesis o f analogues of yingzhaosu A. However,
28its application in the synthesis of a Fenozan analogue proved problematic.
To our knowledge there are no reports in the literature of the use o f phosphite 
ozonides as a source o f singlet oxygen in the targeted synthesis o f biologically active
1,2,4-trioxanes. W e initially wanted to establish if the diastereoselectivity witnessed 
via photooxygenation was maintained when using phosphite ozonides, and if  so,
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hoped to employ the technique in a novel enantioselective synthesis of 1,2,4- 
trioxanes. In the following sections we will firstly discuss the nature and reactivity of 
phosphite ozonides reported in the literature and then proceed to our investigations of 
the suitability o f phosphite ozonide adducts in the synthesis of 1,2,4-trioxanes.
2.3.1 POAs as a Source o f Singlet Oxygen
In 1961 Thompson29 reported on the remarkable oxidising properties o f a phosphite- 
ozone system. It was observed that some triaryl phosphites 103 formed stable 1:1 
adducts with ozone 104 at low temperatures and that upon warming to room 
temperature, molecular oxygen was liberated and the phosphate ester 106 formed in 
quantitative yield. Addition of heteroatomic compounds, e.g. dimethyl sulphide and 
tributyl phosphine, to the low temperature adducts resulted in oxidation to dimethyl 
sulfone and tributyl phosphate respectively. 31P NM R studies of the adduct indicated 
a pentavalent phosphorous centre and a cyclic structure 105 (Figure 2.4) was
in
proposed.
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-30-0°C 10 2
106
Figure 2.4 Formation o f the triaryl phosphite ozonide adduct with a pentavalent
structure.
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It was later shown by M urray and Kaplan26,27 that oxygen released from POAs has 
singlet multiplicity. Treatment o f 1,3-dienes and tetrasubstituted ethylene with POA 
conditions gave products typical of singlet oxygen photooxidation.
Literature throughout the 1970s highlighted two reaction modes o f POAs, the direct 
and free reaction. The synthesis was originally thought to proceed solely via a free 
reaction whereby warming of the adduct to room  temperature would release free 
singlet oxygen, able to react with the substrate in very much the same m anner as in 
the photochemical process. However, it was noted that tetramethylethylene 
underwent the typical transformation to the hydroperoxide when treated with POAs 
at a temperature of -60 °C.31 However, extrusion of singlet oxygen from the adduct 
was known to only occur at temperatures >-15 °C, thus indicating a direct reaction 
between the adduct and substrate. This bimolecular reaction mode has implications 
for the mechanism, and correspondingly, the regio- and stereoselectivity o f the 
oxygenation reaction due to the steric bulk o f the phosphite ligands in close vicinity 
o f the reaction centre.
A stark example of this is the oxygenation of cis- and frans-diethoxy ethylene, 107 
and 108 (Figure 2.5).32 It was observed that ' 0 2 generated photochemically adds 
stereospecifically to these substrates providing the cis- and trans-dioxetanes 
respectively, 109 and 110. Via the direct ozonide reaction the same products are 
given but as a mixture of isomers of the same ratio, irrespective of the starting 
material. As expected the less sterically hindered trans-product 110 is the major 
component.
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Figure 2.5 Dioxetane product distribution from  the treatment o f diethoxy ethylene 
with photochemically generated singlet oxygen and a direct reaction with a POA.
A  proposed mechanism is stepwise via a zwitterionic intermediate in which rotation 
around the single bond results in a mixture o f isomers, the m ajor product being the 
m ost conformationally stable (Figure 2.6).
OEt
c .
,OEt
OR
PhOs ,0  
PhO-P - / 1(PhO)3P 03 ,
CFCI3, -78°C Ph0 0 _0xs^ O E t
OEt
0 - 0  +
' TOEt
OEt
OEt EtO
Figure 2.6 Proposed stepwise zwitterionic mechanism fo r  the direct reaction o f a
POA.
Additional support for a zwitterionic/biradical intermediate was shown by Mori and 
co-workers33 who have successfully isolated a peroxy phosphate 114 from the direct 
reaction o f the triphenyl phosphite ozonide 112 with a silyl dienol ether 111 (Figure 
2.7). The zwitterionic intermediate 113 is proposed, formed from  nucleophilic attack 
on the central oxygen atom of the ozonide 112. Theoretical electrostatic charge
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calculations o f 112 have also indicated the central oxygen atom as the most 
positively charged.
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Figure 2.7 Isolation o f a peroxy phosphate supports a zwitterionic intermediate.
Bartlett and Chu34 have also reported that the polarity o f the reaction m edia has no 
effect on product distribution of the direct reaction implying a biradical process: the 
substrate dihydropyran 115 formed the dioxetane 116 product over the ene-product 
117 with a 10:1 preference in all cases (Figure 2.8). This is in conflict with the 
reaction of free singlet oxygen which favours the dioxetane product as solvent 
polarity increases.
117 10%
Figure 2.8 Solvent polarity has no effect on the distribution o f products 
formed via POAs.
ac
Some researchers have also found evidence for a perepoxide intermediate. As 
previously discussed, isotope effect studies on tetramethyl ethylenes-d6 have shown
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that during photochemical singlet oxygen reactions, substituents positioned in a cis- 
relationship are in competition for H-abstraction by the nucleophilic tailing oxygen. 
This observed competition supports a mechanism involving a perepoxide 
intermediate, and has in fact similarly been observed for direct oxygenation reactions 
o f POAs.
For the most part the predicted influence of the steric bulk of the phosphite portion 
has not been observed in practice and many examples show comparable regio- and 
stereoselectivity between both the free and direct reaction modes. The exceptions 
that have been reported are for substrates with considerable steric influence 
them selves.34,36,37 For example, bulky bisadamantyl did not react under direct 
conditions, which was attributed to the hindrance o f the large adamantyl groups to 
the phosphorous part of the ozonide.34
This trend was encouraging and we were optimistic that the selectivity displayed by 
the photooxygenation reaction for our substrates would be maintained through both 
the free and direct POA oxygenations.
2.3.2 Synthesis ofAscaridole via POA Conditions
In 1969 Murray and Kaplan26 demonstrated that the treatment of a-terpinene 118 
with triphenyl phosphite ozone adducts gave the classic photooxygenation [4+2]- 
cycloaddition product ascaridole 119 (Scheme 2.7). W e chose to repeat this 
experiment as an initial study o f the chemistry and conditions. Firstly, a solution of 
triphenyl phosphite in dichloromethane was cooled to -78 °C. The POA was then 
prepared by saturating the solution with O3 indicated by the blue colour o f the 
solution. Once completed the system was purged with N2 to remove any excess 0 3.
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The a-terpinene 118 was then added dropwise and allowed to react with stirring at - 
78 °C generating direct reaction conditions.
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118 119 61%
Schem e 2.7 Reagents and conditions: i) P(PhO)3, O3, CH2CI2, -78 °C, 30 min.
Consumption of the starting material was monitored by t.l.c and found to be 
complete after 30 minutes. Purification by column chromatography yielded 
ascaridole 119 in 61%.
2.3.3 Synthesis o f Hydroperoxy Alcohols via POA Conditions
Mesityl alcohol 78 was subjected to this source of singlet oxygen to confirm  that it 
would furnish the hydroperoxy alcohol 79 and to establish its diastereoselectivity 
(Scheme 2.8). The allylic alcohol was added dropwise to a prepared solution of the 
cooled phosphite ozonide adduct at -78 °C consistent with direct conditions. The 
reaction was monitored by t.l.c. and after 2.5 hours product formation was observed 
accompanied by some impurities. The reaction mixture was warmed to ambient 
temperature and purified by column chromatography to give 79 in 40% yield. We 
also explored the progression of the reaction under free POA conditions; however it 
proved less efficient than the direct reaction furnishing the hydroperoxy alcohol in 
only 23% yield. From here on, oxidation via POAs were performed under direct 
conditions unless otherwise stated.
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The diastereoselectivity o f this reaction was comparable to that of photooxygenation. 
Analysis by *H NMR showed a product consistent with that obtained by 
photooxygenation. A major doublet was observed at 5 4.17 (J  = 8.3 Hz) indicating 
H a coupling to Hp in the threo-conñgured product 79. A smaller m inor doublet at 8 
4.30 (7 = 5.1 Hz) indicates the presence of the m inor erythro-conftgared product 80. 
These peaks appear in a 90:10 ratio indicating diastereoselectivity comparable to the 
m ethodology using TPP and O2.
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78 79 (threo) 40% yield 80 (erythro)
d.r., threo:erythro = 70:30
Schem e 2.8 Reagents and conditions: i) P(PhO)3, O 3, CH2CI2, -78°C, >2 hr.
Finally, conversion of the racemic ds-allylic alcohol 94b to its corresponding 
hydroperoxy alcohol 95b using the phosphite ozonide adduct conditions was 
attempted (Scheme 2.8). Aware that this substrate tended to need very harsh reaction 
conditions, a good yield was not expected for this reaction, however no reaction was 
observed which was disappointing in light o f the excellent diastereoselectivity 
demonstrated by POA conditions.
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2.3.4 Revaluation o f the Synthetic Route
From these studies it became apparent that the cw-allylic alcohol was not a suitable 
singlet oxygen acceptor, whether via photooxygenation or treatment with phosphite 
ozonide adducts. This, coupled with the volatility of the substrates, m eant we were 
obliged to return to the synthesis o f disubstituted allylic alcohols, ideally via a more 
direct enantioselective synthesis. A route fulfilling these criteria was the 
enantioselective addition of various dialkyl zinc reagents to an appropriate aldehyde. 
This would furnish a variety of chiral allylic alcohols with methyl, ethyl, butyl, i- 
propyl and phenyl moieties, suitable for reaction with singlet oxygen (Figure 2.9).
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Chiral cat. 102
v ia  Photooxygenation 
or POA
Acid cat. 
Condensation
R  = Me, Et, Bu, /-Pr, Ph
Figure 2.9 Overview o f enantioselective synthesis via aldehyde-organozinc coupling.
2.3.5 Reactivity o f Disubstituted Allylic Alcohols under POA Conditions 
Initially, we wanted to compare the oxidation o f the chiral disubstituted allylic 
alcohols by singlet oxygen, under photooxygenation and POA conditions, to 
establish whether POAs were a viable alternative. To avoid wasting valuable chiral 
material, analogous racemic allylic alcohols o f 122a and 122b were synthesised via 
addition o f the relevant Grignard reagent to 3-methylbut-2-en-al (Scheme 2.9).
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0 OH OH
X + RMgBr — Î . A .  ii.A R. iii or iv _. " ° ° y k R
120 121a: R=Ph 122a: R=Ph 81% 123a: R=Ph
121b: R=Et 122b: R=Et 66% 123b: R=Et
Schem e 2.9 Reagents and conditions: i) THF, 0 °C, 1 hr: ii) O2, TTP, CH2CI2, hv, 0 
°C, 4 hr: iii) P(PhO)3, 0 3, CH2C12, -78 °C, >2 hr: iv) P(PhO)3, 0 3, CH2C12, -78 ° C ^  
r.t..
The phenyl substituted allylic alcohol 122a was synthesised by the addition of 
commercially sourced phenyl magnesium bromide 121a to the aldehyde 120. The 
completed reaction was initially quenched with dil. HC1, however these acidic 
conditions caused a rearrangement o f the product to give compound 124 (Scheme 
2.10). Quenching instead with milder NH4CI safely furnished the desired allylic 
alcohol 122a. The ethyl magnesium bromide reagent 121b was synthesised in situ 
and the aldehyde added directly. Again a mild acidic workup allowed allylic alcohol 
122b. The methyl substituted allylic alcohol 78, was obtained through the reduction 
o f mesityl oxide 84.
The desired allylic alcohols were then oxygenated under photochemical, direct POA 
and free POA conditions. The results are shown in the Table 2.1.
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POA
Schenk-ene product Photooxygenation Direct Free
123a
OH
H O O ^
91% 7% _
123b
OH
HOO,^ A ^ '
85% 25% 36%
123c
OH
100% 28% 18%
123d
OH
" X r
86% _
79
OH
H O O , ^ \
59% 40% 23%
Table 2.1 Reactivity o f disubstituted allylic alcohols under photochemical, direct
POA and free POA conditions.
All the substrates afforded the desired hydroperoxy-product in excellent yield via 
photooxygenation. However, when subject to phosphite ozonide adducts in both free 
and direct conditions, the yield was very poor and many byproducts were observed. 
W hen one compares the performance of the racemic mesityl hydroperoxy alcohol
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compound 79 to the other four substrates, however, a trend appears. Compound 79 is 
given in a moderate yield of 59% under photooxygenation conditions. It also gives a 
slightly lower, yet still acceptable yield of 40% when treated with POA. This 
indicates that it is not as reactive when photooxygenated but also that its ene-product 
is stable enough to withstand POA conditions to give a moderate yield. The readily 
photooxygenated allylic alcohols, 122b and 122c give excellent yields via 
photooxygenation. Correspondingly their ene-products 123b and 123c are more 
reactive and consequently too unstable to give acceptable yields via POA conditions. 
An interesting result was obtained from the POA reaction of the aromatic allylic 
alcohol 122a (Scheme 2.10). After treatment o f 122a with the POA for 2.5-3 hours at 
-78 °C, it was observed by t.l.c. that some hydroperoxy alcohol product had been 
formed but that a lot o f starting material remained. The reaction was stopped and the 
desired product 123a was isolated in only 7% yield. W hat was believed to be starting 
material, from t.l.c., underwent analysis by 'H  NMR. This was in fact a by-product 
with structure 124, obtained in 90% yield. Surprisingly, this was the same product 
observed through the harsh acidic workup of the previous Grignard reaction (Scheme
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Schem e 2.10 Reagents and conditions: i) O2, TTP, CH2CI2, hv, 2 hr: ii) P(PhO)3, O3, 
CH2CI2, -78 °C, >2 hr.
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The *H NM R spectrum of 124 showed the presence o f aromatic protons, two roofed 
doublets at 5 6.65 and 5 6.40 typical of olefinic hydrogens, and a singlet integrating 
for six equivalent protons. The compound determined as 124 was therefore proposed 
to be the result of an acid catalysed rearrangement o f the starting material facilitated 
by the presence of an aromatic ring. Conversely, the photooxygenation of 122a 
proceeded in 97% yield to give the desired product 123a.
It can be postulated, that the conditions of the phosphite ozonide adduct are strongly 
acidic causing rearrangement o f the starting material in this case. This was 
disappointing as the phenyl substituted 1,2,4-trioxane is a valuable candidate for 
SAR studies. However, despite these results we still planned to synthesise an 
optically pure sample of 123a via photooxygenation, and to continue to the desired 
aromatic 1,2,4-trioxane.
As a result o f these preliminary studies it was concluded that phosphite ozonide 
adducts were not a viable alternative to dye-sensitised oxygenation as a source of 
singlet oxygen. Although the observed diastereoselectivity of the Schenk-ene 
reaction2 was also maintained through POA oxygenations, the yields were on the 
whole poor and in the case of the m -substitu ted  allylic alcohols no reaction was 
observed whatsoever.
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2.4 An Enantioselective Route to Disubstituted 1,2,4-Trioxanes: Synthesis of 
Disubstituted Allylic Alcohols via Aldehyde-Organozinc Coupling using a Chiral 
MIB Catalyst
As discussed in Section 2.3.4., we planned to synthesise a series o f enantiomerically 
enriched allylic alcohols ((!?)- and (S)-122) through the coupling of the aldehyde 120 
with a range o f dialkyl zinc reagents 125. W e then intended to subject this enantio- 
enriched series to the highly diastereoselective ene-reaction to furnish the respective 
hydroperoxy alcohols ((31?,41?)- and (3S,4S)-123). The hydroperoxy alcohols would 
then undergo acid catalysed cyclisation with cyclic ketones to yield the desired 
enantio-enriched, spirocyclic 1,2,4-trioxanes ((31?,4/?)- and (3S,4S)-126) (Scheme 
2 . 11) .
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120 125 (/?)-122 (3R,4R)-123 1 R1
(3R,4R)-126
R1 = Me, Et, Bu, /-Pr, Ph
Schem e 2.11 Reagents and conditions: i) (+)-MIB, ZnR2, 0 °C, Hexane or Toluene: 
ii) 0 2, TTP, CH2C12, hv, 2 hr: iii) TsOH, R2C = 0 , CH2C12, -10 °C, 30 min. Synthesis 
o f (R)-configured alcohol is shown using (+)-MIB.
2.4.1 The Chiral MIB Catalyst
The first example of a highly enantioselective addition of dialkylzincs to aldehydes 
was reported by Noyori in 1986 with the advent of the chiral ligand (-)-3-
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exodimethylaminoisobomeol (DAIB) derived from  (/?)-camphor.38 DAIB continues 
to be a popular chiral catalyst particularly for the enantioselective promotion of 
addition to aromatic aldehydes. However more recently a novel camphor derivative, 
(2/?)-(+)-exo-(morpholino)isobomeol ((+)-MIB), has been presented as a more stable 
alternative, more suited to a-branched aliphatic aldehydes.3 ;
(-)-M IB, derived from (tf)-camphor, is commercially available. The (S)-derived (+)- 
MIB (+)-131 was synthesised as outlined by Chen and Nugent in three steps 
(Scheme 2.12).40
Schem e 2.12 Reagents and conditions: i) KOtBu, /-amyl nitrite, Et2Ü, -30 °C, 16 hr:
ii) LiAlH4, THF, reflux, 30 min: iii) bis(2-bromoethyl) ether, NEt3, DMSO, r.t., 72
hr.
(S)-Camphor 128 was treated with potassium r-butoxide and isoamylnitrite 
successively and stirred overnight. The solution was then extracted with water and 
the aqueous mixture was acidified to give camphorquinone oxime 129 as an off- 
white solid in 66% yield. The camphorquinone oxime was then reduced with UAIH4 
to give 130 in 95% yield. Compound 130 was finally treated with triethylamine and 
bis(2-bromoethyl) ether and stirred for 72 hours to give the desired product (+)-131 
in 25% yield.
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2.4.2 Synthesis o f Chiral Disubstituted Allylic Alcohols
A solution of dialkyl zinc (1M in hexane or toluene) was added to a solution o f (-)- 
M IB at 0 °C, followed by the addition of 3-methylbut-2-en-al 120. The mixture was 
stirred at 0 °C until complete consumption of the starting material was observed by 
t.l.c. The reaction was quenched with sat. NH4CI followed by a standard work-up and 
purification by column chromatography to give compounds (5)-122a-d and (S)-78 
(Scheme 2.13). The opposing (fl)-enantiomers (i?)-122a-d and (R)-78 were provided 
by catalysis with (+)-MIB and excepting (R)-122d were kindly synthesised by Dr. S 
Sabbani o f the University of Liverpool. The subsequent (R)-configured derivatives 
(3/?,4/f)-123b-d, (3/?,4/?)-126b-d and (3/i,4/?)-132b-c were also synthesised by Dr. 
S. Sabbani.
The yield and enantiomeric excess (ee) for each reaction is summarised in the table 
below (Table 2.2).
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120 125a: R=Ph
125b: R=Et 
125c: R=Bu 
125d: R=/-Pr 
125e: R=Me
OH
(R)-122a: R=Ph 
(R)-122b: R=Et 
(/?)- 122c: R=Bu 
(R)-122d: R=/-Pr 
(R)-78 : R=Me
Schem e 2.13 Reagents and conditions: i) (+)-MIB, ZnR2, 0 °C, Hexane or Toluene. 
Synthesis o f (R)-configured alcohol is shown using (+)-MIB.
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OH
XR
Reaction
Time Yield (+)-ee (-)-ee
78 R = Me 144 hrs 14% 79% 77%
122a R = Ph 3 hrs 34% - 79%
122b R = Et 8 hrs 30% 94% 93%
122c R = Bu 3 hrs 72% 90% 90%
122d R = ¿-Pr 3 hrs 67% 98% 98%
Table 2.2 Yield and ee o f chiral disubstituted allylic alcohols.
The ee of the ethyl, butyl and ¿-propyl products, 122b, 122c and 122d were all above 
90% with the ¿-propyl allylic alcohol displaying an excellent ee of 98%. W e 
therefore chose ethyl, butyl and ¿-propyl allylic alcohols to undergo the Schenk-ene 
reaction.
The methyl and phenyl alcohols (78 and 122a) displayed poor ee and yield and so 
were discounted for further study. According to the literature, a highly 
enantioselective diphenylzinc addition reaction has always been notoriously 
difficult.38 Dialkylzinc addition to aldehydes is known to proceed very slowly in the 
absence a catalyst, whereas diphenylzinc additions can continue smoothly even 
without a catalyst. This “background” reaction can therefore circumvent coordination 
with the chiral catalyst and addition to the aldehyde can continue without any chiral 
control resulting in a diminished ee.
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The very long reaction time of the dimethylzinc addition to aldehyde 120 was 
consistent with similar reactions reported in the lierature.38 This could probably be 
attributed to the lower nucleophilicity of the methyl substituent in comparison to the 
larger electron donating groups such as ethyl, butyl, /-propyl etc. However this does 
not explain the poor enantioselectivity of this reaction.
2.4.3 Synthesis o f Enantioenriched Disubstituted 1,2,4-Trioxanes
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(5R,6R)-126b : R1=Et (5R,6R)-123b : R1=Et (5R,6R)-127b : R1=Et
(5R,6R)-126c : R1=Bu (5R,6R)-123c : R1=Bu (5R,6R)-127c : R1=Bu
(5ft,6R)-126d : R1=/-Pr (5R,6R)-123d : R1=/-Pr (5R,6R)-127d R1=/-Pr
Schem e 2.14 Reagents and conditions: i) /?-TsOH, 2-adamantanone, CH2CI2, -10 °C, 
30 min: ii) p-TsOH, cyclohexanone, CH2C12, -10 °C, 30 min. Synthesis o f  (5R,6R)- 
configured 1,2,4-trioxanes shown.
The chiral allylic alcohols, (/?)- and (S)-122b-d underwent photooxygenation, as 
discussed in Section 2.3.5, to give the hydroperoxyalcohols (3R,4R)- and (3S,4S)- 
123b-d in excellent yield. The concluding step o f this synthesis, the condensation of 
the hydroperoxy substrates with a cyclic ketone, was then carried out with 
cyclohexanone and 2-adamantanone. The reactions with cyclohexanone and 2- 
adamantanone progressed in moderate yield to afford the desired enantiomerically 
enriched 1,2,4,-trioxanes, (5R,6R)- and (5S,6S)-126b-d, (5R,6R)- and (5S,6S)-127c
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and d  as pale yellow oils. The ethyl substituted spiroadamantyl trioxane (5R,6R)- 
and (5S,6S)-127b was isolated as a white solid (Scheme 2.14). M y co-worker Dr. S. 
Sabbani also carried out the successful condensation of the hydroperoxy alcohols, 
(3/f,4/?)-123b-c, with AT-Boc-4-piperidone to give trioxanes (5/?,6/?)-132b and 
(5/?,6/?)-132c respectively. Yields and optical rotations are summarised in Table 2.3.
Endoperoxides as Antimalarials and the Application o f Singlet Oxygen to the Synthesis of
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Yield Optical Rotation 
(c 1.0, CH Cb)
(5/?,6/f)-126b R 1 = Et
spirocyclohexyl
76% -123.1
(5S,6S)-126b 66% +102.9
(5/f,6/?)-127b R 1 = Et
spiroadamantyl
74% -86.4
(5S,6S)-127b 55% +59.3
(5/?,6/?)-126c R 1 = n-Bu 
spirocyclohexyl
78% -102.6
(5S,6S)-126c 73% +73.1
(5J?,6/?)-127c R 1 = n-Bu 
spiroadamantyl
78% -57.4
(5S,6S)-127c 65% +89.5
(5/î,6/î)-126d R 1 = i-Pr 
spirocyclohexyl
44% -95.7
(5S,6S)-126d 61% +102.0
(5R,6R)- 127d R 1 = i-Pr 
spiroadamantyl
64% -100.3
(5S,6S)-127d 57% +100.1
Yield Optical Rotation
(5/i,6/?)-132b R 1 = Et
N-Boc-4-piperidyl
16% -85.0 (c 1.0, CH Cb)
(5/?,6/?)-132c R 1 = n-Bu 
AMBoc-4-piperidyl
18% -64.0 (c 0.3, CH Cb)
Table 2.3 Yields and optical rotations o f the target chiral 1,2,4-trioxanes.
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The crystallisation of (5/?,6/?)-127b allowed for X-ray crystallographic data to be 
obtained of the 1,2,4-trioxane structure (Figure 2.10).
The X-ray crystal structure shows the central trioxane ring in a chair conformation in 
accordance with that reported by Griesbeck8 and confirms the trans-relationship 
between H3 and H4. The structure also demonstrates the syn-relationship across the 
C3-C16 bond between the peroxy (0 2 ) and olefinic (C17) groups, thereby 
corroborating with the reported suprafacial nature o f the ene-reaction and showing 
the m aintenance of its stereospecificity through the peroxyacetalisation step.
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Figure 2.10 X-ray crystal structure o f chiral 1,2,4-trioxane (5R,6R)-127b.
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2.5 Antimalarial Activity
The antimalarial activity of individual conformers of enantioenriched 1,2,4-trioxanes 
((5R,6R)- and (5S,6S)-126b-d, (5R,6R)- and (5S,6S)-127b-d and (5/i,6/?)-132b-c)
was evaluated in vitro against chloroquine-sensitive 3D7 strains o f P. falciparum  
using artemisinin as a positive control (Table 2.4). The spiroadamantyl analogues, 
(5R,6R)- and (5S,6S)-127b-d, consistently showed potent activity in comparison to 
the spirocyclohexyl analogues, consistent with data trends reported in the literature. 
The JV-Boc-4-piperidone analogues, (5Æ,6fl)-132b-c, proved to be the most potent 
compounds of this series.
W hen comparing the antimalarial activity of the enantiomeric pairs o f the 1,2,4- 
trioxanes there are small differences in the IC50 values. O f the straight chain 
analogues, with n-Bu or Et substituents, the (5/?,6fl)-configured structures show 
slightly better activity than those with the (55,65)-configuration. The branched, i-Pr 
substituted analogues, show improved activity of the (55,65)-configured trioxanes 
compared to the (5/?,6/?)-configured structures.
However, replication of this in vitro testing is ongoing from which we will be able to 
draw some more conclusions.
Endoperoxides as Antimalarials and the Application of Singlet Oxygen to the Synthesis of
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IC50
(nM)
IC50
(nM)
(5R ,6R)-
127b )^ 0.oO>
Et'
156
(5R,6R)
-126b H°X>
Et
252
(5S,6S)-
127b
v\
Et
173
(5S,6S)-
126b
Et
-
(SR ,6R>
127c k :*>
n-Bu
121
(5R,6R)
-126c HX>
n-Bu
378
(5S,6S)-
127c
n-Bu
219
(55,6S)- 
126c y^ xz)
n-Bu
536
(5R,6R)-
127d H7>
/-Pr
222
(5R,6R)
-126d H°X>
/-Pr
> 1 0 0 0
(55,65)-
127d
\\ p - O  / < \  
/-Pr
176
(5S,65)-
126d
v\  p - 0  /— v
' iV - 0  '— '  
/- Pr
185
- A rtem isin in 9
(5R ,6R)-
132b HXH
n-Bu
114
(5R,6R)
-132c HXK
- A
119
Table 2.4 In vitro antimalarial activities o f enantiomerically enriched spirocyclic 
1,2,4-trioxanes against 3D7 strains o f P. falciparum.
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2.6 Conclusion
Herein we have explored two enantioselective routes to the synthesis o f 1,2,4- 
trioxanes implementing the diastereoselective ene-reaction of chiral allylic alcohols 
and thereafter peroxyacetalisation with cyclic ketones to furnish the enantioenriched 
trioxanes.
In the former we demonstrated the successful synthesis of cw-substituted 1,2,4- 
trioxanes with high enantioselectivity, however, the route proved problematic due to 
the volatility of many of the intermediates and the poor reactivity o f the cis-allylic 
alcohol under photooxygenation conditions. The synthesis was thus deemed 
impractical for the synthesis of a series of opposing enantiomers o f 1,2,4-trioxanes. 
The latter, and ultimately more facile route, was carried out using (+)- and (-)-MIB 
catalysed addition of dialkylzincs to an a,p-unstaurated aldehyde to furnish 
disubstituted enantioenriched allylic alcohols in excellent yields. The allylic alcohols 
performed well under photooxygenation conditions to afford the desired hydroperoxy 
alcohols in excellent yield and subsequently a series o f enantioenriched pairs of 
chiral 1,2,4-trioxanes. Currently we are investigating the potential differences in the 
antimalarial activities of m irror image pairs o f enantiomers o f trioxanes.
Phosphite ozonide adducts were examined with the intention that they would prove 
to be a potent alternative to photooxygenation methods. Promisingly, the reaction 
under phosphite ozonide conditions maintained the excellent diastereoselectivity 
observed in the ene-reaction. However, we were disappointed when the phosphite 
ozonide conditions furnished the hydroperoxy alcohols in poor yield in contrast to 
the excellent yields of dye-sensitised photooxygenation. For these reasons
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oxygenation using phosphite ozonide adducts was ruled out as a viable source of 
hydroperoxy alcohols.
The concluding synthetic approach, by means of allylic alcohols derived from 
enantioselective addition o f organozinc reagents to aldehydes, has proved to be 
highly efficient and may lend itself to a cost effective synthesis o f chiral 1,2,4- 
trioxanes with high enantiomeric purity.
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3.0 Experimental Procedure - Endoperoxides as Antimalarials and the 
Application of Singlet Oxygen to the Synthesis of Key Synthetic Intermediates 
en Route to Synthetic 1,2,4-Trioxanes
3.1 Chemical Procedures
Reaction procedure: Air- and moisture-sensitive reactions were carried out in oven- 
dried glassware sealed with rubber septa under a positive pressure of dry nitrogen 
from  a balloon, unless otherwise indicated. Similarly, sensitive liquids and solutions 
were transferred via syringe or stainless steel cannula. Reactions were stirred using 
Teflon coated magnetic stir bars. Organic solutions were concentrated using a Buchi 
rotary evaporator with a diaphragm vacuum pump.
Purification o f reagents and solvents: Anhydrous solvents were either obtained from 
commercial sources or dried and distilled immediately prior to use under a constant 
flow of dry nitrogen. THF, diethyl ether were distilled from Na/Ph2CO, 
dichloromethane from CaH2. All other reagents were used as received from 
commercial sources unless otherwise indicated.
Purification o f products: Analytical thin layer chromatography was performed with 
0.25 mm silica gel plates (Merck 60 F254). Plates were visualised by ultraviolet light 
or by treatment with iodine, p-anisaldehyde, ninhydrin or potassium permanganate 
followed by gentle heating. Chromatographic purification of products was 
accomplished by flash chromatography performed on silica gel (BDH 60 230-400 
mesh).
Analysis: NM R spectra were measured on a Bruker AMX 400 ( 'H , 400 MHz and 
13C, 100 M Hz) nuclear magnetic resonance spectrometer. Solvents are indicated in 
the text. Solids and liquids were used directly without any further treatment to record 
IR spectra using a JASCO FT/IR-4100 spectrometer. Mass spectra (MS) and high
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resolution mass spectra (HRM S) were recorded on a VG analytical 7070E machine 
and a Fisons Trio 1000 quadrupole GC mass spectrometer using electron ionisation 
(E l) or chemical ionisation (Cl) respectively. Reported mass values are within error 
lim its o f ±5 ppm. Microanalyses were determined by the University of Liverpool 
M icroanalysis Laboratory.
Enantiomeric excesses of compounds (S)-78, (S)-122b-d and (/?)-122b-d were 
determined using GC Varian 3800GC (Supelco P-Dex-120 column, 30 m  x 0.25mm; 
He, 5 bar; air, 4 bar); GC Varian CP-3380 (Chromapack Chirasil Dex CB column, 25 
m  x 0.25mm; He, 5 bar) and Shimadzu GC-14B (Supelco a-Dex-120 column, 30 m 
x 0.25 x 0.25 pm; He, 50 KPa). Optical rotations were determined using a Perkin- 
Elm er polarimeter 343 plus instrument. Absolute configurations of enantiomerically 
enriched allylic alcohols (S)-78, (S)-122b-d and (R)-122b-d were determined by 
comparison of the optical rotations with the published optical rotations. X-ray 
analyses were carried out at the University of Liverpool.
4-Methyl-3-penten-2-ol 78
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OH
M esityl oxide 84 (1.17 g, 10.18 mmol) was stirred in diethyl ether (25 mL) at 0 °C. 
LiAlH4 (0.43 g, 11.21 mmol) was added over 15 minutes and the mixture was 
allowed to react for a further 15 m inutes at room temperature.
The reaction was quenched sequentially with water (0.5 mL), NaOH 15% w/v (0.5 
mL) and again water (1.5 mL). After stirring for another 30 minutes, the mixture was
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filtered through a layer of celite, removing the Lithium precipitate. The solvent was 
rem oved in vacuo in a cold water bath to give 78 (0.82 g, 82%) as a yellow oil.
78: IR Vmax 3386 (v0.H), 2977, 2932 (vC-h) cm '1; !H NM R (400 MHz, CDCI3) 5 5.21 
(1H, dsept, 7=8.4, 1.3 Hz, -CH=C(CH3)2), 4.60 (1H, dq, 7=8.4, 6.2 Hz, - 
HC(OH)CH3), 2.70 (1H, brs, -OH), 1.71 (3H, d, 7=1.4 Hz, -CH=C(CH3)2) 1.69 (3H, 
d, 7=1.3 Hz, -CH=C(CH3)2), 1.23 (3H, d, 7=6.4 Hz, -HC(OH)CH3) ppm; 13C NMR 
(100 MHz, CDC13) 8 134.5, 129.8, 65.2, 26.0, 24.0 and 18.4 ppm; mJz (Cl) 
100.11289 ([M + NH4]+); requires 100.11263.
4-Methyl-l-phenyl-3-penten-2-ol 87
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Phenacetaldehyde 85 (2.50 g, 20.80 mmol) was stirred in THF (50 mL) at -78 °C. 2- 
M ethyl-l-propenyl magnesium bromide 86 (41.6 ml, 0.25 mmol) was added. The 
mixture was stirred for 30 minutes then allowed to warm to room  temperature over
1.5 hours. The mixture was quenched with sat. NH4CI solution until effervescence 
ceased. W ater (50 mL) was then added, the product extracted with ethyl acetate (3 x 
50 m l.) and the combined organic extracts then washed with brine (50 mL) and dried 
over M gS 04. The solvent was removed in vacuo and the residue purified by column 
chromatography (90:10 Hexane: EtOAc) to give 87 (1.76 g, 48%) as yellow oil.
87: IR Vmax 3375 (v0-h), 3062, 3027 (vC-h, at), 2970, 2916 (vC-H), 1602, 1495 (vc=c, Ar) 
cm '1; NM R (400 MHz, CDC13) 5 7.22 (5H, m, Ar-H), 5.21 (1H, dsept, 7=8.5, 1.1 
Hz, -CH=C(CH3)2), 4.54 (1H, dt, 7=8.8, 6.6 Hz, -HC(OH)CH2-), 2.77 (2H, d, 7=7.0
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Hz, -CHzAr), 1.71 (3H, d, 7=1.4 Hz, -CH=C(CH3)2), 1-57 (3H, d, 7=1.1 Hz, - 
CH=C(CH3)2) ppm; 13C NM R (100 M Hz, CDC13) 5 138.6, 135.7, 129.8, 128.8,
126.5, 121.0, 70.4, 43.1, 25.7 and 20.1 ppm; m/z (Cl) 194.15471 ([M + NH4]+); 
requires 194.15448.
3-Methyl-l-phenyl-2-buten-l-ol 122a
3.0 - Experimental Procedure
Endoperoxides as Antimalarials and the Application o f Singlet Oxygen to the Synthesis of
Key Synthetic Intermediates en Route to Synthetic 1,2,4-Trioxanes
OH
A solution of phenyl magnesiumbromide (1 M, 3.57 mL, 3.57 mmol) in THF was 
cooled in an ice-bath. A solution of 3-methylbut-2-en-al 120 (0.34 mL, 3.41 mmol) 
in TH F (20 m l,) was then added dropwise with stirring. The m ixture was allowed to 
react for an hour, until complete consumption o f the starting material was observed. 
The mixture was then poured into sat. NH4CI, and the aqueous mixture extracted 
with diethyl ether. The combined organic layers were washed with water and brine, 
dried over M gS 04 and the solvents removed in vacuo. The crude product was 
purified by column chromatography (90:10 Hexane: EtOAc) to give 122a (0.45 g, 
81%) as a colourless oil.
122a: IR vmax 3413 (v0-h), 3060, 3027 (vC-h, At), 2970, 2916 (vc.H), 1602, 1495 (vc=c, 
at) cm '1; !H NMR (400 MHz, CDC13) 5 7.38-7.18 (5H, m, Ar-H), 5.46 (1H, d, 7=8.7 
Hz, -HC(OH)Ar), 5.42 (1H, dsept, 7=8.7, 1.1 Hz, -CH=C(CH3)2), 1.79 (3H, d, 7=1.1 
Hz, -CH=C(CH3)2), 1.74 (3H, d, 7=1.1 Hz, -CH=C(CH3)2) ppm; 13C NM R (100 
M Hz, CDC13) 8 144.7, 135.6, 128.9, 128.2, 127.7, 126.3, 71.2, 26.2 and 14.6 ppm.
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General Procedure 1
Photooxygenation of Allylic Alcohols in Solution
The allylic alcohol (ca. 5.0 mmol) and TPP (ca. 2 mg) was stirred in dichloromethane 
(80 mL). The reaction vessel was kept at 0 °C to reduce evaporation of the solvent. A 
stream of O2 was then passed through the reaction mixture and the vessel irradiated 
with two tungsten lamps for 4 hours. The solvent was then removed in vacuo and the 
residue purified by column chromatography eluting with mixtures of hexane and 
ethyl acetate.
General Procedure 2
Photooxygenation of Allylic Alcohols on Solid Support
To load the sensitiser onto the solid support, TPP (ca. 2 mg) in dichloromethane was 
added to the polystyrene-divinylbenzene beads (60 ± 1 5  pm diameter unswelled) 
(ca. 1.5 g). The slurry like mixture was transferred to a watch glass once the 
polystyrene had fully expanded, and the solvent allowed to evaporate. The loaded 
support media was then placed in a glass Petri dish (10 cm) and a solution of the 
allylic alcohol (1.0 - 5.0 mmol) in diethyl ether (10 mL) was applied to the loaded 
polystyrene. Once again the solvent was allowed to evaporate. The lid of the Petri 
dish was replaced loosely and irradiated with a tungsten lamp for 4 hours. In order to 
protect the volatile substrate from the heat produced by the lamp, a glass plate was 
placed between the lamp and the dish and the set-up cooled by a fan. The support 
media was then washed with methanol (3 x 20 mL) to remove the product while 
leaving the TPP absorbed to the polystyrene. The solvent was removed in vacuo and
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the residue was purified by column chromatography eluting with hexane and ethyl 
acetate.
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General Procedure 3
Preparation of Phosphite Ozonides (POA)
A flask fitted with a Drechsel head was charged with a solution (0.2 M) o f triphenyl 
phosphite in DCM. The vessel was cooled to -78 °C while a stream o f 0 3 was 
bubbled through the mixture. Once the mixture turned blue, thus indicating the 
solution was saturated with 0 3, the flask was flushed with N2 for at least 20 minutes. 
The singlet oxygen acceptor was then added in a solution of DCM, and stirring was 
continued at -78 °C.
3-Hydroperoxy-4-methyl-4-penten-2-ol 79
OH
via Photooxygenation1
Using the method outlined in General Procedure 1, photooxygenation o f 4-methyl-3- 
penten-2-ol 78 (0.50 g, 4.90 mmol) for 4 hrs, and after chromatography (80:20 
Hexane: EtOAc), gave a yellow oil 79 (0.36 g, 54%, d.r. 90:10 {threo\erythro}).
79: IR vmax 3360 (vo-h)> 2980 (vc-h)> 1648(vc=c), 873, 830 (vperoxide) cm > H NM R 
(400 MHz, CDCI3) 8 5.09 (1H, m, -C=CH2), 5.08 (1H, m, -C=CH2), 4.15 (1H, d, 
7=8.3 Hz, -HCOOH), 3.87 (1H, dq, 7=8.1, 6.3 Hz, -HC(OH)CH3), 1.75 (3H, m, 
= C Q J3), 1.14 (3H, d, 7=6.4 Hz, -HC(OH)CH3) ppm;
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13C NMR (100 MHz, CDCI3) 8 144.7, 116.9, 96.6, 67.4, 19.2 and 18.3 ppm; m/z (Cl) 
150.11307 ([M + NH4D ;  requires 150.11301. 
via Irradiation on Solid Support2
Using the method outlined in General Procedure 2, photooxygenation o f 4-methyl-3- 
penten-2-ol 78 (0.38 g, 3.70 mmol) on solid support media for 4 hrs, and after 
chromatography (80:20 Hexane: EtOAc), afforded a yellow oil 79 (0.25 g, 47%, d.r. 
70:30 {threo'.erythro}).
Spectral data as above.
via Phosphite Ozonide Conditions: Direct Reaction
A  solution of POA (triphenyl phosphite (1.57 mL, 6.00 mmol) in dichloromethane 
(30 mL)) was prepared as outlined in General Procedure 6 . 4-Methyl-3-penten-2-ol 
78 (0.20 g, 2.00 mmol) was then added dropwise and allowed to react for 4 hours at - 
78 °C. The solvents were removed in vacuo and the crude mixture purified by 
column chromatography (90:10 Hexane: EtOAc) to afford 79 (Direct reaction: 0.10 
g, 40%, d.r. 90:10 {threo'.erythro}) as a clear oil.
Spectral data as above.
via Phosphite Ozonide Conditions: Free Reaction
A solution o f POA (triphenyl phosphite (1.11 mL, 4.22 mmol) in dichloromethane 
(20 mL)) was prepared as outlined in General Procedure 3. 4-Methyl-3-penten-2-ol 
78 (0.14 g, 1.41 mmol) was added dropwise and the vessel allowed to warm  to room 
temperature over 20 minutes. The solvents were removed in vacuo and the crude 
m ixture purified by column chromatography (90:10 Hexane: EtOAc) to afford 79 
(Free reaction: 0.04 g, 23%, dr 90:10 {threo'.erythro}) as a clear oil.
Spectral data as above.
3.0 - Experimental Procedure
Endoperoxides as Antimalarials and the Application of Singlet Oxygen to the Synthesis of
Key Synthetic Intermediates en Route to Synthetic 1,2,4-Trioxanes
96
3.0 - Experimental Procedure
Endoperoxides as Antimalarials and the Application of Singlet Oxygen to the Synthesis of
Key Synthetic Intermediates en Route to Synthetic 1,2,4-Trioxanes
3-Hydroperoxy-l-phenyl-4-methyi-4-penten-2-ol 88
HOC
Using the method outlined in General Procedure 2, photooxygenation of 4-m ethyl-1- 
phenyl-3-penten-2-ol 87 (0.30 g, 1.70 mmol) on solid support media for 4 hrs, and 
after chromatography (80:20 Hexane: EtOAc), afforded a yellow oil 88 (0.17 g, 47%, 
d.r. 70:30 {threo'.erythro}).
88 : IR vmax 3410 (v0.H), 3063, 3028 (vC-h, Ar), 2926 (vC-H), 1603, 1584, 1496 (vc=c, Ar) 
864 (Vperoxide) cm '1; !H NM R (200 MHz, CDC13) 5 7.26 (5H, m, Ar-H), 5.17 (1H, m, - 
C=CH2), 5.09 (1H, m, -C=CH2), 4.38 (1H, d, 7=7.4 Hz, -HCOOH), 3.97 (1H, m, - 
HC(OH)CH3), 3.01 (1H, dd, 7=13.8, 3.0 Hz, -CH2Ar), 2.75 (1H, dd, 7=13.8 9.1, - 
CHzAr), 1.85 (3H, m, =CCH3) ppm; 13C NMR (100 M Hz, CDC13) 8 141.7, 138.4,
129.9, 128.9, 127.0, 116.7, 91.7, 71.6, 39.5 and 19.3 ppm.
2-Hydroperoxy- 1-phenyl-3-methyl-3-buten-1 -ol 123a
OH
via Photooxygenation
Using the method outlined in General Procedure 6 , photooxygenation o f 3-m ethyl-1- 
phenyl-2-buten-1 -ol 122a (0.16 g, 0.99 mmol) for 1.5 hours, and thereafter 
purification by flash column chromatography (95:5 DCM: MeOH), gave a yellow oil 
123a (0.19 g, 97%, d.r. 90:10 {threo-.erythro}).
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123a: lH NM R (400 MHz, CDC13) 5 7.38-7.25 (5H, m, Ar-H), 4.92 (1H, m, - 
C=CH2), 4.88 (1H, m, -C=CH2), 4.71 (1H, d, 7=8.4 Hz, -HCOOH), 4.51 (1H, d, 
7=8.5 Hz, -HC(OH)Ar), 1.52 (3H, m, -CCH3) ppm; 13C NM R (100 MHz, CDC13) 5
140.9, 136.8, 130.2, 128.6, 127.7, 116.6, 93.8, 75.8 and 19.8 ppm. 
via Phosphite Ozonide Conditions: Direct Reaction
A  solution of POA (triphenyl phosphite (0.96 mL, 3.69mmol) in dichloromethane 
(20 m l.) was prepared as outlined in General Procedure 3. 3-M ethyl-l-phenylbut-2- 
en -l-o l 122a (0.168 g, 1.04 mmol) was then added dropwise and allowed to react 
with stirring. The reaction was monitored by t.l.c. and stopped after 2.5 hours. The 
solvents were then removed in vacuo and the crude mixture purified by column 
chromatography (90:10 Hexane: EtOAc) to afford 123a (0.014 g, 7%, d.r. 90:10 
{threo:erythro}) as a clear oil.
Spectral data as above.
(l? )-3 -M eth yl-l-p henyl-l-b uten-3-o l 124
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via Phosphite Ozonide Conditions: Direct Reaction
A solution of POA (triphenyl phosphite (0.96 mL, 3.69 mmol) in dichloromethane 
(20 m l .) was prepared as outlined in General Procedure 3. 3-M ethyl-l-phenyl-2- 
buten-l-o l 122a (0.168 g, 1.04 mmol) was then added dropwise and allowed to react 
with stirring. The reaction was monitored by t.l.c. and stopped after 2.5 hours. The
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solvents were then removed in vacuo and the crude mixture purified by column 
chromatography (95:5 Hexane: EtOAc) to afford 124 (0.15 g, 90%) as a clear oil.
124: !H NMR (400 MHz, CDC13) 8 7.25-7.14 (5H, m, Ar-H), 6.65 (1H, d, 7=16.1 
Hz, Ar-CH=CH-), 6.40 (1H, d, 7=16.1 Hz, Ar-CH=CH-), 3.20 (1H, s, OH), 1.41 (6H, 
s, -CH3) ppm; 13C NM R (100 MHz, CDC13) 8 137.9, 137.3, 129.0, 127.9, 126.8,
126.8, 71.5 and 30.3 ppm; m/z (Cl) 145.1021 ([(M - H20 )  + H]+); requires 145.1017.
General Procedure 4
Preparation of 1,2,4-Trioxanes via Peroxyacetalization
The hydroperoxyalcohol (0.80 -  2.3 mmol) and the cyclic ketone (1.1 eq.) were 
stirred in dichloromethane (25 mL) at -10 °C. This was treated with catalytic 
amounts of p-TsOH (ca. 2 mg). This was allowed to react for 30 minutes at -10 °C 
then warmed to room temperature to react overnight. The solvent was removed in 
vacuo and the crude product purified by column chromatography eluting with hexane 
and ethyl acetate.
5-M eth yl-6 -(p rop -l-en -2-y l)sp iro-[l,2 ,4 -tr ioxacycloh exan e-3 ,2 ’-cyclohexane]3
89b
3.0 - Experimental Procedure
Endoperoxides as Antimalarials and the Application of Singlet Oxygen to the Synthesis of
Key Synthetic Intermediates en Route to Synthetic 1,2,4-Trioxanes
Condensation of 3-hydroperoxy-4-methyl-4-penten-2-ol 79 (0.16 g, 1.20 mmol) with 
cyclohexanone (0.14 ml, 1.32 mmol) for 30 minutes and purification by 
chromatography (90:10 Hexane: EtOAc), yielded 89b (0.10 g, 40%) as a yellow oil.
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89b: IR vmax 3083 (vc=c), 2926, 2854 (vC-h). 844 (Vperoxide) cm '1; ]H NM R (400 MHz, 
CDC13) 6 5.08 (2H, m, -C=CH2), 4.20 (1H, d, 7=9.7 Hz, -HCOOC-), 4.11 (1H, dq, 
7=9.5, 6.1 Hz, -HCOC-), 2.24 (2H, m), 1.97 (2H, m), 1.76 (3H, m, =CCH3), 1.59 
(6H, m), 1.11 (3H, d, 7=6.3 Hz, -H C (0)C H 3) ppm; 13C NMR (100 MHz, CDC13) 5
142.2, 114.2, 103.3, 89.2, 75.0, 35.6, 30.0, 22.7 and 17.4 ppm; m/z (Cl) 213.14887 
([M  + NH4]+); requires 213.14906. Anal. C i2H2o03 requires C 67.89%, H 9.50%, 
found C 67.81%, H 9.53%.
5-Methyl-6-(prop-l-en-2-yl)spiro-[l,2,4-trioxacyclohexane-3,2’-cyclopeiitane]
89a
Condensation of 3-hydroperoxy-4-methyl-4-penten-2-ol 79 (0.30 g, 2.28 mmol) with 
cyclopentanone (0.20 ml, 2.51 mmol) for 30 minutes, and purification by 
chromatography (90:10 Hexane: EtOAc), afforded 89a (0.09 g, 19%) as a yellow oil. 
89a: IR vmax 3084 (vc=c), 2976, 2875 (vC-h), 860 ( v ^ d e )  cm’1; 'H NMR (400 MHz, 
CDC13) 5 5.07 (2H, m, -C=CH2), 4.27 (1H, d, 7=9.5 Hz, -HCOOC-), 3.95 (1H, dq, 
7=9.5, 6.3 Hz, -HCOC-), 2.53 (2H, m), 1.76 (3H, m, =CCH3), 1.62 (6H, m), 1.10 
(3H, d, 7=6.3 Hz, -H C (0)C H 3) ppm; 13C NM R (100 MHz, CDC13) 8 139.6, 118.0,
115.1, 89.1, 68.8, 37.8, 33.4, 25.1, 23.5, 19.9 and 17.2 ppm; m/z (Cl) 199.13371 ([M 
+ NH4]+); requires 199.13342.
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5-Methyl-6-(prop-l-en-2-yl)spiro-[l,2,4-trioxacyclohexane-3,2'-adamantane]3
86c
3.0 - Experimental Procedure
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Condensation of 3-hydroperoxy-4-methyl-4-penten-2-ol 79 (0.30 g, 2.28 mmol) with 
2-adamantanone (0.38 g, 2.51 mmol) for 30 minutes, and after purification by 
chromatography (90:10 Hexane: EtOAc), gave 89c (0.25 g, 42%) as a pale yellow oil 
which crystallised upon drying.
89c: m.p. 42-44 °C; IR vmax 3082 (vc=c), 2916, 2857 (vc.H), 869, 803 (Vperoxide) cm '1; 
!H NM R (400 MHz, CDC13) 8 5.07 (2H, m, -C=CH2), 4.20 (1H, d, 7=9.5 Hz, - 
HCOOC-), 4.09 (1H, dq, 7=9.5, 6.3 Hz, -HCOC-), 2.93 (2H, m), 2.41-1.55 (12H, 
m), 1.76 (3H, m, =CCH3), 1.10 (3H, d, 7=6.2 Hz, -HC(0 )C£b) ppm; 13C NM R (100 
M Hz, CDCI3) 5 139.8, 113.8, 105.3, 86.8, 75.0, 65.5, 38.8, 37.7, 30.3, 27.4 and 18.1 
ppm; m/z (Cl) 265.18012 ([M + NH4]+); requires 265.18039. Anal. C i6H2403 requires 
C 72.69%, H 9.15%, found C 72.17%, H 9.41%.
5-Benzyl-6-(prop-l-en-2-yl)spiro-[l,2,4-trioxacyclohexane-3,2’-cyclohexane] 89e
Condensation of 3-hydroperoxy-l-phenyl-4-methyl-4-penten-2-ol 88 (0.27 g, 1.30 
mmol) with cyclohexanone (0.15 mL, 1.43 mmol) for 30 minutes and after
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purification by chromatography (90:10 Hexane: EtOAc), gave a pale yellow oil 89e 
(0.07 g, 20%) which later crystallised upon drying.
89e: m.p. 43-45 °C; IR vmax 3081 (vc=c), 3064, 3028 (vC-h, Ar), 2937, 2858 (vC-H), 
1603, 1496, 1454 (vc=c.Ar), 874, 823 (vperoxide) cm'1; 'H  NM R (400 MHz, CDCI3) 5 
7.26 (5H, m, Ar-H), 5.17 (2H, m, -0 = 0 1 ^ ), 4.38 (1H, d, 7=9.6 Hz, -HCOOC-), 4.17 
(1H, td, 7=9.6, 3.1 Hz, -HCOC-), 2.79 (1H, dd, 7=14.4, 3.1 Hz, -CH2Ar), 2.70 (1H, 
dd, 7=14.4, 8.2 Hz, -ClfcAr), 2.23-1.17 (10H, m), 1.80 (3H, m, =CCH3) ppm; 13C 
NM R (100 MHz, CDCI3) 8 142.2, 138.4, 129.4, 128.4, 126.6, 119.0, 103.5, 87.6, 
70.6, 37.8, 35.4, 29.8, 26.0, 22.6 and 20.1 ppm; m/z (Cl) 306.20762 ([M + NH4D ;  
requires 306.20694.
5-Benzyl-6-(prop-l-en-2-yl)spiro-[l,2,4-trioxacyclohexane-3,2’-cyclopentane]
89d
3.0 - Experimental Procedure
Endoperoxides as Antimalarials and the Application of Singlet Oxygen to the Synthesis of
Key Synthetic Intermediates en Route to Synthetic 1,2,4-Trioxanes
Condensation of 3-hydroperoxy-l-phenyl-4-methyl-4-penten-2-ol 88 (0.30 g, 1.44 
mmol) with cyclopentanone (0.20 mL, 1.58 mmol) for 30 minutes, and after 
purification by chromatography (90:10 Hexane: EtOAc), gave a pale yellow oil 89d 
(0.24 g, 60%).
89d: IR vmax 3080, 3070 (vc=c), 3026 (vC-H, Ar), 2954 (vc.H), 1496, 1454 (vc=c,Ar), 912 
(Vperoxide) cm '1; *H NMR (400 MHz, CDC13) 8 7.28-7.19 (5H, m, Ar-H), 5.14 (1H, s, - 
C=CH2), 5.12 (1H, m, -C=CH2), 4.43 (1H, d, 7=9.5 Hz, -HCOOC-), 4.10 (1H, td,
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7=9.7, 3.0 Hz, -HCOC-), 2.79 (1H, dd, 7=14.6, 2.8 Hz, -CH2Ar), 2.70 (1H, dd, 
7=14.6, 8.4 Hz, -C ^ A r) , 1.87-1.58 (8H, m), 1.76 (3H, m, =CCH3) ppm; 13C NM R 
(100 M Hz, CDC13) 8 139.4, 138.4, 129.8, 128.5, 126.7, 119.2, 115.3, 87.6, 73.1, 
37.7, 37.5, 33.3, 25.1, 23.5 and 19.9 ppm; m/z (ES) 297.1481 ([M + Na]+) requires 
297.1467. Anal. C17H22O3 requires C 74.42%, H 8.08%, found C 75.12%, H 8.22%.
5-Benzyl-6-(prop-l-en-2-yl)spiro-[l,2,4-trioxacyclohexane-3,2'-adamantane] 89f
Condensation of 3-hydroperoxy-l-phenyl-4-methyl-4-penten-2-ol 88 (0.17 g, 0.81 
m m ol) with 2-adamantanone (0.19 g, 0.90 mmol) for 30 minutes, and after 
purification by chromatography (90:10 Hexane: EtOAc), afforded a pale yellow oil 
89f (0.03 g, 12%).
89f: IR vmax 3081 (vc=c), 3064, 3028 (vc-h, at), 2937, 2858 (vc .H), 1603, 1496, 1454 
(Vc=c, Ar), 874, 823 (vperoxide) cm '1; 'H  NM R (400 MHz, CDCI3) 6 7.31 (5H, m, Ar-H),
5.02 (1H, m, -C=CH2), 4.93 (1H, m, -C=CH2), 4.09 (1H, d, 7=8.4 Hz, -HCOOC-), 
3.99 (1H, m, -HCOC-), 2.87 (2H, m, -CH2Ar), 1.99 (4H, m), 1.83 (3H, m), 1.74 (3H, 
s, =CCH3), 1.69 (7H, m) ppm; 13C NM R (100 MHz, CDCI3) 5 142.6, 138.7, 130.0,
128.5, 126.7, 114.8, 112.1, 84.5, 79.1, 39.1, 38.7, 38.1, 37.7, 35.4, 35.1, 34.8, 30.1,
27.3 and 17.7 ppm. m/z (ES) 363.1940 ([M + Na]+) requires 363.1936.
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General Procedure 4 
Preparation of the Propargyl Ketone
Trimethylsilylpropyne 90 (1.33 mL, 8.91 mmol) was stirred in DCM at 0  °C. The 
acid chloride (1.1 eq.) was added, followed by anhyd. A lC b (1.1 eq.). The reaction 
was stirred for a further 30 minutes at 0 °C. This was quenched with a mixture of 
10% aq. HC1 and ice (10 mL, 50:50). The aqueous phase was extracted with 
dichloromethane (3 x 10 mL) and the organic extracts combined and washed with 
sat. N aH C 03 solution (10 mL) and dried over M gS 04. The solvent was removed in 
vacuo in a cold water bath to leave an oil residue.
l-Phenyl-2-butyn-l-one 92a
O
Trimethylsilylpropyne 90 (1.33 mL, 8.91 mmol) was stirred with benzoyl chloride 
91a (1.14 mL, 9.80 mmol) for 30 minutes at 0 °C. This afforded l-phenyl-2-butyn-l- 
one, 92a (1.16 g, 90%), as a green oil.
92a: IR vmax 3091, 3065 (vc.H, Ar), 2925, 2862 (vC-h), 1714 (vc=o), 2249, 2212 (voc), 
1655, 1570, 1496 (vc=c, Ar) cm '1; *H NM R (400 MHz, CDC13) 8 7.47 (5H, m, Ar-H), 
2.15 (3H, s, =CCH3) ppm; 13C NM R (100 MHz, CDCI3) 8 178.8, 137.5, 134.5,
130.2, 129.0, 93.0, 79.6 and 4.9 ppm. m/z (Cl) 145.06510 ([M + NH4]+); requires 
145.06534.
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2-Methyl-4-hexyn-3-one 92b
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Trimethylsilylpropyne 90 (1.33 mL, 8.91 mmol) was stirred with isobutyryl chloride 
91b (1.03 mL, 9.80 mmol) for 30 minutes at 0 °C. This afforded 2-methyl-4-hexyn-
3-one, 92b (0.92 g, 92%), as an orange oil.
For 92b: IR vmax 2974 (vC-h), 2218 (voc), 1674 (vc=o) cm '1; ]H NMR (400 MHz, 
CDCI3) 5 2.54 (1H, sept, 7=7.0 Hz, -CH(CH3)2), 1.97 (3H, s, =CCH3), 1.10 (6H, d, 
7=7.0 Hz, -CH(CH3)2) ppm; 13C NM R (100 MHz, CDC13) 190.4, 88.7, 77.3, 41.0,
29.0, 16.0 and 2.1 ppm. m/z (Cl) 128.10787 ([M + NH4]+); requires 128.10753.
2-Methyl-4-hexyn-3-ol4 rac-9 3b
OH
2-Methyl-4-hexyn-3-one 92b (0.50 g, 4.45 mmol) was stirred in diethyl ether (10 
mL) at 0 °C. LiAlH4 (0.19 g, 4.95 mmol) was added over 15 minutes and the mixture 
was allowed to react for a further 15 minutes at room  temperature.
The reaction was quenched sequentially with water (0.5 mL), NaOH 15% w/v (0.5 
mL) and again water (1.5 mL). This was stirred for 30 minutes. The mixture was 
filtered through a layer of celite, removing the Li precipitate. The solvent was 
rem oved in vacuo in a cold water bath to give rac-93b (0.48 g, 96%) as a yellow oil.
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rac-93b: IR vmax 3374 (v0-h), 2962 (vC-h), 2223 (v o c )  cm '1; ’H NM R (400 MHz, 
CDCI3) 5 4.13 (1H, m, -CH(OH)-), 1.85 (3H, d, 7=2.3 Hz, C C H 3), 1.90-1.70 (1H, 
m, -CH(CH3)2), 0.99 (6H, t, 7=3.7 Hz, -CH(CH3)2), ppm; 13C NM R (100 MHz, 
CDC13) 8 81.9, 79.5, 74.5, 34.7, 18.5, 17.8 and 3.8 ppm; m/z (Cl) 130.12349 ([M + 
NH4D ;  requires 130.12318.
l-Phenyl-2-butyn-l-ol (/?)-93a
OH
f
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A 3-necked round bottom flask was charged with (/?)-Alpine Borane (0.5 M in THF, 
15 mL, 7.58 mmol). Under nitrogen, the vessel was transferred to a rotary evaporator 
where the TH F was removed under vacuum at 40 °C. The flask was then released 
from  the vacuum under nitrogen and cooled to 0 °C. l-Phenyl-2-butyn-l-one 92a 
(0.69 g, 4.77 mmol) was added and the vessel was allowed to warm to room 
temperature and left to react overnight.
Freshly distilled propionaldehyde (0.36 mL, 5.01 mmol) was added and the mixture 
allowed to stir for an hour at room temperature. The flask was again transferred to 
the rotary evaporator under nitrogen and the liberated (+)-a-pinene was removed in 
vacuo at 40 °C. Once removed from the rotary evaporator, THF (4.00 mL) was 
added, NaOH (3 M, 2.50 mL) and finally H20 2 (30%, 2.50 mL). The latter was 
added dropwise at 0 °C as the reaction is exothermic. This was allowed to warm to 
room  temperature, then heated to 40 °C and stirred for 3 hours. At this point the 
vessel was removed from the nitrogen atmosphere, the product was extracted with
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diethyl ether (3 x 10 mL) and the extracts combined and dried over MgSCU. The 
solvent was removed in vacuo in a cold water bath and the residue was purified by 
colum n chromatography (70:30 DCM: Pet. Ether) to give a yellow oil. This was 
further distilled from a Kiigelrohr oven (100 °C) to give R-93a (0.15 g, 21%) as a 
colourless liquid. The absolute configuration was determined by comparison with the
report that R-Alpine borane derived from (+)-a-pinene gives exclusively the R­
. 4enantiomer.
R -93a: IR vmax 3418 (v0-h), 3063, 3031 (vC-H, at), 2919, 2856 (vc.H), 2243, 2206 
(Voc), 1643, 1580, 1494 (vc=c, at) cm '1; 'H  NMR (400 MHz, CDC13) 8 7.36 (5H, m, 
Ar-H), 5.38 (1H, q, 7=2.1 Hz, -CH(OH)-), 1.87 (3H, d, 7=2.3 Hz, C C H 3) ppm; 13C 
NM R (100 MHz, CDCI3) 8 141.8, 129.0, 128.5, 127.0, 83.3, 79.8, 65.0 and 4.0 ppm; 
m/z (Cl) 146.09644 ([M + NH4]+); requires 146.09697.
(S)-2-Methyl-4-hexyn-3-ol (S)-93b
The precatalyst was formed in situ by stirring (5,S)-TsDPEN (S,S)-98 
(13 mg, 0.04 mmol), with [Cp*RhCl2]2 97 (18 mg, 0.03 mmol) in H20  (10 mL) at 40 
°C for 1 hr. Sodium formate (0.99 g, 14.54 mmol) and 2-methyl-4-hexyn-3-one 92b 
(0.40 g, 3.63 mmol) were added sequentially. The mixture was stirred vigorously at 
room  temperature overnight. Finally, additional sodium formate was added to 
increase conversion and stirred for a further 2 hrs. The organic phase was then 
extracted with diethyl ether (3 x  10 mL) and filtered through celite. The solvent was
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rem oved by simple distillation to give (S)-93b as a pale yellow oil (97% conversion, 
93% ee). The absolute configuration was determined by comparing the optical 
rotations o f a series o f similar alcohols and it is reported that the handedness of 
diphenylethylene diamine ligand is transferred to the alcohol product.5,6 
(S)-93b: NM R and other analytical data were similar to that of rac-93b.
(/?)-2-M ethyl-4-hexyn-3-ol (R)-93b
9 H
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The precatalyst was formed in situ by stirring (R,R)-CsDPEN (R,R)-98 
(13 mg, 0.04 mmol), with [Cp*RhCl2]2 97 (18 mg, 0.03 mmol) in H2O (10 mL) at 40 
°C for lhr. Sodium formate (0.99 g, 14.54 mmol) and 2-methyl-4-hexyn-3-one 92b 
(0.40 g, 3.63 mmol) were added sequentially. The mixture was stirred vigorously at 
room  temperature overnight. Finally, additional sodium formate was added to 
increase conversion and stirred for a further 2 hrs. The organic phase was then 
extracted with diethyl ether (3 x  10 mL) and filtered through celite. The solvent was 
removed by simple distillation to give (R)-93b as a pale yellow oil (97% conversion, 
93% ee).
(R)-93b: NM R and other analytical data were similar to that o f rac-93b.
108
3.0 - Experimental Procedure
Endoperoxides as Antimalarials and the Application o f Singlet Oxygen to the Synthesis of
Key Synthetic Intermediates en Route to Synthetic 1,2,4-Trioxanes
a-Methoxy-a-trifluoromethylphenylacetyl chloride 101
A mixture of MTPA 100 (0.09 g, 0.34 mmol), SOCl2 (ca. 1.5 mL) and NaCl (ca. 1 
mg) was allowed to reflux overnight. The SOCl2 was then removed in vacuo in 
preparation for the acid chloride 101 to be used immediately.
2-M ethyl-4-hexyn M TPA  este r rac-102
A mixture of 2-methyl-4-hexyn-3-ol rac-93b (0.10 g, 0.89 mmol), anhyd. pyridine 
(0.5 mL) and DCM (0.5 mL) was added to the acid choride 101 (0.34 mmol) and 
allowed to stir for 12 hours. The reaction was quenched by adding water (1 mL) and 
the mixture was extracted with diethyl ether (20 mL). The organic extracts were then 
washed with dil. HC1 (20 mL), N aH C 03 (20 mL) and water (20 mL) and dried over 
M gS 04. The M osher’s ester was then isolated by column chromatography (80:20 
Hexane: EtOAc) to furnish clear oil rac-102 (0.030 g, 10%). 
rac-102: !H NMR (400 MHz, CDC13) 5 7.59 (1H, m, Ar-H), 7.42-7.36 (4H, m, Ar­
H), 5.36 (1H, m, -CH (0)-), 3.59 (3H, s, -OCH3)s, 3.55 (3H, s, -OCH3)*, 2.02-1.94 
(1H, m, -CH(CH3)2), 1.87 (3H, d, 7=2.3 Hz, C C H 3)S, 1.83 (3H, d, 7=2.1 Hz,
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=CCH 3)*, 1.02 (3H, d, 7=6.6, -CH(CH3)2)/e, 1.01 (3H, d, 7=6.6, -CH(CH3)2)/e, 0.95 
(3H, d, 7=6.6 Hz, -CH(CH3)2)S, 0.93 (3H, d, 7=6.6 Hz, -CH(CH3)2)S; 13C NMR (100 
M Hz, CDC13) 8 166.2, 133.0, 129.9, 128.7, 127.8, 124.1, 83.7, 74.8, 72.1, 55.8, 33.0,
30.1, 18.2, 18.0 and 3.8 ppm; 19F (376 MHz, CDC13) 8 -71.56, -71.58 ppm; m/z (ES) 
351.1183 ([M + Na]+); requires 351.1184.
2-Methyl-4-hexyn MTPA ester (S)-102
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A mixture of 2-methyl-4-hexyn-3-ol (S)-93b (0.10 g, 0.89 mmol), anhyd. pyridine 
(0.5 mL) and DCM (0.5 mL) was added to the acid choride 101 (0.34 mmol) and 
allowed to stir for 12 hours. The reaction was quenched by adding water (1 mL) and 
the mixture was extracted with diethyl ether (20 mL). The organic extracts were then 
washed with dil. HC1 (20 mL), N aH C 03 (20 mL) and water (20 mL) and dried over 
M g S 0 4. The M osher’s ester was then isolated by column chromatography (80:20 
Hexane: EtOAc) to furnish clear oil (S)-102 (0.02 g, 6%).
(S)-102: *H NMR (400 M Hz, CDC13) 8 7.59 (1H, m, Ar-H), 7.42-7.36 (4H, m, Ar­
H), 5.36 (1H, dq, 7=5.7, 2.3 Hz, -CH(O)-), 3.59 (3H, s, -OCH3), 2.02-1.94 (1H, m, - 
CH(CH3)2), 1.87 (3H, d, 7=2.1 Hz, =CCH3), 0.95 (3H, d, 7=6.6 Hz, -CH(CH3)2), 0.93 
(3H, d, 7=6.6 Hz, -CH(CH3)2) ppm; 13C NM R (100 MHz, CDC13) 8 166.2, 133.0,
129.9, 128.7, 127.8, 124.1, 83.7, 74.8, 72.1, 55.8, 33.0, 30.1, 18.2, 18.0 and 3.8 ppm;
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,9F  (376 MHz, CDCI3) 5 -71.56 ppm; mJz (Cl) 346.16195 ([M + NH4D ;  requires 
346.16302.
General Procedure 5 
(Z)-Selective Reduction of an Alkyne
A solution o f 2-methyl-4-hexyn-3-ol 93b (approx. 9 mmol), Lindlar catalyst (100 
mg) and 2,6-lutidine (50 pi) in hexane was stirred vigorously while exposed to H2 
atmosphere. M ore catalyst was periodically added for up to 3 hours, until H2 uptake 
ceased, monitored by Hg-bubbler column. The catalyst was then removed by 
filtration through celite and the mixture washed with dil. HC1 to remove the 2,6- 
lutidine. The organic layer was dried over M gS 04 and the solvent removed in vacuo 
in a cold water bath to give a yellow oil. Due to similar Rf values o f the starting 
material and product, the resulting (Z)-2-methyl-4-hexen-3-ol could not be purified 
so full analysis was carried out on the crude product and this was taken on to the next 
step.
(Z)-2-Methyl-4-hexen-3-ol4rac-94b
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OH
A solution of 2-methyl-4-hexyn-3-ol rac-93b (1.00 g, 8.92 mmol) was treated with 
Lindlar catalyst (100 mg) and 2,6-lutidine (50 pi) following General Procedure 5 to 
give (Z)-2-methyl-4-hexen-3-ol ra c -94b as a yellow oil.
I l l
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rac-94b: IR v,™ 3443 (v0-h), 2968 (vC-h); *H NM R (400 MHz, CDC13) 6 5.63 (1H, 
dqd, 7=11.0, 6 .8, 0.9 Hz, -CH=CHCH3), 5.42 (1H, ddq, 7=11.0, 8.9, 1.7 Hz, - 
CH=CHCH3), 4.18 (1H, dd, 7=8.9, 6.6 Hz, -CH(OH)-), 1.76-1.68 (1H, m, - 
CH(CH3)2), 1.69 (3H, dd, 7=6.8, 1.7 Hz, -CH=CHCH3), 1.35 (1H, br, OH), 0.96 (3H, 
d, 7=6.8 Hz, -CH(CH3)2), 0.88 (3H, d, 7=6.8 Hz, -CHCCikh) ppm; 13C NM R (100 
M Hz, CDC13) 8 131.8, 127.1, 72.3, 34.2, 18.5, 18.3 and 13.5 ppm.
*H NM R confirmed the product to have 100% (Z)-double bond geometry.
(S,Z)-2-Methyl-4-hexen-3-ol4 (S,Z)-94b
OH
A solution o f (S)-2-methyl-4-hexyn-3-ol (S)-93b (1.00 g, 8.92 mmol) was treated
with Lindlar catalyst (100 mg) and 2,6-lutidine (50 pi) following General Procedure
5 to give (5,Z)-2-methyl-4-hexen-3-ol (S,Z)-94b as a yellow oil.
(S,Z)-94b: NM R and other analytical data were similar to that of rac-94b.
(R,Z)-2-Methyl-4-hexen-3-ol4 (R,Z)-94b
OH
f
O '
A solution of (S)-2-methyl-4-hexyn-3-ol (R)-93b (1.00 g, 8.92 mmol) was treated 
with Lindlar catalyst (100 mg) and 2,6-lutidine (50 pi) following General Procedure 
5 to give (R,Z)-2-methyl-4-hexen-3-ol (R,Z)-94b as a yellow oil.
(R,Z)-94b: NM R and other analytical data were similar to that of rac-94b.
112
3.0 - Experimental Procedure
Endoperoxides as Antimalarials and the Application of Singlet Oxygen to the Synthesis of
Key Synthetic Intermediates en Route to Synthetic 1,2,4-Trioxanes
General Procedure 6
Modified General Procedure for the Photooxygenation of Allylic Alcohols
A standard B24 Liebig condenser was sealed off at the lower end and fitted with a 
cold-finger trap condenser containing dry ice and acetone. PTFE tubing was fed 
through the equipment in order to deliver O2 from the bottom of the Liebig 
condenser. The reaction mixture consisting of the allylic alcohol (ca. 0.9 mmol) and 
TPP (ca. 2 mg) in dichloromethane (50 mL), filled the condenser and was cooled 
externally by the water jacket. This was then aerated with O2 and irradiated with 4 
tungsten lamps (2-4 hours). The solvent was removed in vacuo and the crude product 
purified by column chromatography eluting with dichloromethane and methanol.
4-Hydroperoxy-2-methyl-5-hexen-3-ol1 rac-95b
OH
The allylic alcohol (Z)-2-methyl-4-hexen-3-ol rac-94b (0.5 g, 4.38 mmol) underwent 
photooxygenation for 4 hours as outlined in General Procedure 1. This was then 
purified by column chromatography (99:1 DCM: MeOH) to give rac-95b (0.06 g, 
9%, d.r. 90:10 {threo:erythro}) as a clear oil.
rac-95b: XH NMR (400 MHz, CDCI3) 8 5.89 (1H, ddd, 7=17.4, 10.4, 8.0 Hz, - 
HC=CH2), 5.47 (1H, d, Jtrans =17.2 Hz, -C=CH2), 5.42 (1H, d, Jcis =10.4 Hz, - 
C=CH2), 4.35 (1H, t, 7=8.0 Hz, -HCOOH), 3.51 (1H, dd, 7=7.8, 3.8 Hz, -CH(OH)-), 
2.54 (1H, br, OH), 1.80 (1H, m, -CH(CH3)2), L02 (3H, d, 7=6.8 Hz, -CH(CH3)2), 
0.92 (3H, d, 7=6.8 Hz, -CH(CH3)2) ppm;
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13C NM R (100 MHz, CDC13) 8 133.9, 121.2, 89.4, 76.8, 29.9, 19.1 and 15.7 ppm.
(35.45) -4-Hydroperoxy-2-methyl-5-hexen-3-ol (3S,4S)-95b
OH
HOO/„,
The allylic alcohol (S,Z)-2-methyl-4-hexen-3-ol (S,Z)-94b (0.10 g, 0.88 mmol) 
underwent photooxygenation for 4 hours as outlined in General Procedure 6 . This 
was then purified by column chromatography (99:1 DCM: MeOH) to give (3S,4S)- 
95b (0.06 g, 43%, d.r. 90:10 {threo\erythro}) as a clear oil.
(35.45) -95b: NMR and other analytical data were similar to that of rac-95b.
(3/?,4/?)-4-Hydroperoxy-2-methyl-5-hexen-3-ol (3/?,4/?)-95b
The allylic alcohol (R,Z)-2-methyl-4-hexen-3-ol (R,Z)-94b (0.25 g, 2.19 mmol) 
underwent photooxygenation for 4 hours as outlined in General Procedure 6 . This 
was then purified by column chromatography (99:1 DCM: MeOH) to give (3/?,4i?)- 
95b (0.15 g, 47%, d.r. 90:10 {threo:erythro}) as a clear oil.
(3/i,4/i)-95b: NMR and other analytical data were similar to that of rac-95b.
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5-Isopropyl-6-(vinyl)spiro-[l,2,4-trioaxcyclohexane-3,2'-adamantane] rac-9 6b
Condensation of 4-hydroperoxy-2-methyl-5-hexen-3-ol rac-9Sb (0.06 g, 0.41 mmol) 
with 2-adamantanone (0.07 g, 0.45 mmol) overnight and after purification by 
chromatography (90:10 Hexane: EtOAc), yielded rac-96b as a pale yellow oil 
(0.03 g, 30%).
rac-96b: JR vmax 2906, 2856 (vc.H), 925 (vperoxide); 'H  NM R (400 MHz, CDC13) 5
5.67 (1H, ddd, 7=17.4, 10.4, 7.8 Hz, HC=CH2), 5.49 (lH ,d , 7<rani=17.5 Hz, - 
C=CH2), 5.39 (1H, d, 7C,5=9.9 Hz, -C=CH2), 4.53 (1H, dd, 7=9.6, 7.6 Hz, -HCOOC-),
3.67 (1H, dd, 7=9.6, 2.8 Hz, -CHOC-), 2.14-1.23 (14H, m), 1.78 (1H, m, - 
CH(CH3)2), 1.02 (3H, d, 7=7.0 Hz, -CH(CH3)2), 0.93 (3H, d, 7=6.8 Hz, -CH(CH3)2) 
ppm; 13C NMR (100 MHz, CDC13) 5 131.6, 123.1, 105.0, 83.4, 73.9, 37.7, 37.01,
34.0, 33.7, 33.4, 32.0, 29.9, 28.6, 27.7, 20.5 and 15.6 ppm; mJz (Cl) 279.19510 ([M + 
NH4]+); requires 279.19600. Anal. C n H260 3 requires C 73.34%, H 9.41%, found C 
74.47%, H 9.69%.
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(5S,6S)-(-)-5-Isopropyl-6-(vmyl)spiro-[l,2,4-trioaxcyclohexane-3,2'- 
adamantane] (5S,6S)-96b
Condensation o f 4-hydroperoxy-2-methyl-5-hexen-3-ol (3S,4S)-95b (0.08 g, 0.55 
mmol) with 2-adamantanone (0.09 g, 0.60 mmol) overnight and after purification by 
chromatography (90:10 Hexane: EtOAc), yielded (5S,6S)-96b as a pale yellow oil 
(0.05 g, 34%).
(5S,6S)-96b: [a]20o -163.0 (c 1.4, CHCI3). NMR and other analytical data were 
similar to that of rac-96b.
(5/?,6/?)-(+)-5-Isopropyl-6-(vinyl)spiro-[l,2,4-trioaxcyclohexane-3,2'- 
adamantane] (5R,6R)-96b
Condensation of 4-hydroperoxy-2-methyl-5-hexen-3-ol (3R,4R)-95b (0.15 g, 1.03 
mmol) with 2-adamantanone (0.17 g, 1.13 mmol) overnight, and after purification by 
chromatography (90:10 Hexane: EtOAc), yielded (5R,6R)-96b as a pale yellow oil
(0.08 g, 26%).
(5R,6R)-96b: [a]2°o +115.0 (c 1.5, CHCI3); NM R and other analytical data were 
sim ilar to that of rac-96b.
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l-Isopropyl-4-methyl-2,3-dioxabicyclo[2.2.2]oct-5-ene7 119
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A solution of the POA (triphenyl phosphite (0.68 mL, 2.59 mmol) in DCM  (10 mL)) 
was prepared as outlined in General Procedure 3. a-Terpinene 118 (0.24 mL, 1.28 
mmol) was then added dropwise and allowed to react with stirring. The reaction was 
monitored by t.l.c. and reached completion after 30 minutes. The solvents were then 
removed in vacuo and the crude mixture purified by column chromatography (90:10 
Hexane: EtOAc) to afford 119 (0.13 g, 61%) as a colourless oil.
119: NM R (400 MHz, CDCI3) 8 6.51 (1H, d, 7=8.5 Hz, CH=CH), 6.42 (1H, d,
7=8.5 Hz CH=CH), 2.07-1.98 (4H, m, -CH2-CH2-), 1.97 (1H, sept, 7=7.0 Hz, - 
CH(CH3)2), 1.37 (3H, s, -CC£b), L00 (6H, d, 7=6.5 Hz, -CH(CH3)2) ppm; 13C NMR 
(100 MHz, CDC13) 8 136.8, 133.5, 79.8, 74.3, 32.5, 29.9, 26.0, 21.8, 17.6 and 17.5 
ppm.
a
Camphorquinone Oxime 129
A solution of potassium l-butoxide (2.21 g, 19.71 mmol) in diethyl ether (20 mL) 
was purged with N2 and cooled to -3 0  °C. To this was added a solution of S- 
camphor 128 (2.00 g, 13.13 mmol) in diethyl ether (10 mL), the reaction mixture was
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then allowed to warm to room temperature and stirred for 30 minutes. The reaction 
vessel was again cooled to -30 °C and i-amyl nitrite (2.31 g, 19.71 mmol) added. The 
m ixture was warmed to room  temperature and allowed to stir overnight. The solution 
was then extracted with water (3 x 10 mL), and the combined aqueous layers were 
cooled in an ice bath with stirring. The aqueous mixture was acidified to pH 4 by 
drop-wise addition of cone. HC1. As the pH approached 4, an off-white solid 
precipitated out. The mixture was extracted with dichloromethane (3 x 20 mL) and 
the combined organic extracts were washed with sat. NaHCC>3 (20 mL), water (20 
mL) and brine (20 mL). The organic layers were then dried over MgSCL and the 
solvent removed in vacuo to give camphorquinone oxime 129 (1.58 g, 66%) as an 
off-white solid. The crude product was carried through to the next step o f the 
synthesis without further purification.
129: mp 114-116 °C; IR vmax 3423 (v0-H), 2958 (vc.H), 1738 (vc=o), 1641 (vc=N) cm’1; 
*H NMR (400 MHz, CDCI3) Anti: 8 8.50 (1H, brs, =NOH), 3.26 (1H, d, 7=4.4 Hz, - 
HCC=NOH), 2.08 (1H, m, -CH2-), 1.80 (1H, m, -CH2-), 1.60 (2H, m, -CH2-), 1.03 
(3H, s, -C(CH3)2), 1.01 (3H, s, -C(CH3)2), 0.89 (3H, s, -CCH3) ppm; 13C NMR (100 
M Hz, CDCI3) 8 204.6, 160.4, 58.9, 47.0, 45.3, 31.1, 24.2, 21.1, 18.0 and 9.4 ppm. 
Syn: !H NM R (400 MHz, CDC13) 8 8.50 (1H, br, =NOH), 2.72 (1H, d, 7=4.2 Hz, - 
HCC=NOH), 2.16 (1H, m, -C H r), 1.87 (1H, m, -CH2-), 1.68 (2H, m, - Q l 2-), 1.02 
(3H, s, -C(CH3)2), 1.01 (3H, s, -C(CH3)2), 0.93 (3H, s, -CCH3) ppm; 13C NM R (100 
M Hz, CDCI3) 8 205.3, 156.6, 60.0, 50.0, 47.4, 30.3, 25.4, 21.0, 18.4 and 8.8 ppm; 
m/z (Cl) 199.14517 ([M + NH4]+); requires 199.14465.
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(2/?)-(+)-3-exo-Aminoisoborneol8 130
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A flask charged with camphorquinone oxime 129 was fitted with a liebig condenser 
and the system purged with N2. TH F (10 mL) was added via syringe and the solution 
cooled to 0 °C. A solution o f UAIH4 in TH F (3.5 M, 3.70 mL, 13.25 mmol) was 
added drop-wise, and once H2 evolution had ceased the reaction vessel was allowed 
to warm to room temperature and then heated to reflux for 30 minutes. The solution 
was again cooled to 0 °C, diluted with diethyl ether and the LiAlH4 quenched with 
successive addition o f water (0.5 mL), NaOH 10% w/v (0.5 mL) and finally water 
(1.0 mL). The reaction mixture was filtered through a pad o f celite and the filter cake 
was washed with THF (3 x 10 mL). The filtrate was combined and the solvents 
rem oved in vacuo to afford (2/?)-(+)-3-exo-aminoisoborneol 130 (1.43 g, 95%) as a 
pale yellow wax. The compound was used in the next step without further 
purification.
130: m.p. 123-125 °C; IR vmax 3289 (v0.H), 2954 (vc.H), 1612 (vN.H) c m 1; ‘H NMR 
(400 M Hz, CDCI3) 8 3.41 (1H, d, 7=7.4 Hz, -HCOH), 3.06 (1H, d, 7=7.4 Hz, - 
HCNH2), 1.92 (1H, m, -HCHCNH2), 1.74 (2H, m, -CH2-), 1.43 (2H, m, -CH2-), 1.08 
(3H, s, -C(CH3)2), 0.95 (3H, s, -C(CH3)2), 0.79 (3H, s, -CCH3) ppm; 13C NM R (100 
M Hz, CDC13) 8 79.5, 58.0, 54.0, 49.2, 47.0, 33.6, 27.3, 22.4, 21.6 and 11.8 ppm;
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- - - Q(2/?)-(+)-exo-(Morpholino)isoborneol 131
To a flask charged with (2R)-(+)-3-exo-aminoisoborneol 130, was added reagent 
grade DM SO (10 mL) and triethylamine (3.52 mL, 25.34 mmol). Bis(2-bromoethyl) 
ether (1.27 mL, 10.14 mmol) in DM SO (10 mL) was then added drop-wise and the 
reaction mixture stirred at ambient temperature, under N2, for 72 hours. The solution 
was poured into water (100 mL), the aqueous mixture was extracted with diethyl 
ether (3 x 20 mL) and the combined organic extracts washed with water (20 mL), 
brine (20 mL) and dried over M gS04 . The solvent was then removed in vacuo and 
the crude m ixture purified by column chromatography (80:20 Hexane: EtOAc) to 
give (2/?)-(+)-exo-(morpholino)isoborneol 131 (0.42 g, 25%) as a pale yellow 
crystalline solid.
131: m.p. 58-60 °C; IR vmax 3356 (v0.H), 2951 (vC-h), 2883 (vN.CH-) cm '1; ]H NMR 
(400 MHz, CDCI3) 8 4.26 (1H, brs, -OH), 3.68 (4H, brs, -CH2OCH2), 3.47 (1H, d, 
7=7.1 Hz, -HCOH), 2.61 (4H, brs, -Q fc N C ^ -) , 2.42 (1H, d, 7=7.0 Hz, -HCN-), 2.02 
(1H, d, 7=4.8 Hz, -HCHCN-), 1.78 (2H, m, -CH2-), 1.46 (2H, m, -Clfc-), 1.03 (3H, s, 
-CCHs), 0.96 (3H, s, -CCH3), 0.77 (3H, s, -CCH3) ppm; 13C NM R (100 MHz, 
CDC13) 5 79.0, 73.3, 67.4, 49.5, 46.9, 45.5, 32.6, 28.1, 22.4, 21.3 and 11.8 ppm; m/z 
(Cl) 240.19668 ([M + H]+); requires 240.19635.
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General Procedure 7
Asymmetric Addition of Diaikylzincs to 3-Methylbut-2-en-al
A 100ml. flask containing (+)- or (-)-exo-(morpholino)isobomeol ((+)- or (-)-MIB) 
131 (ca. 1.00 mmol) and anhydrous toluene (20 mL) was flushed with N2 then cooled 
to 0  °C. A solution of the desired dialkylzinc reagent 125 in toluene (1.0 M, ca. 35.00 
mmol) was then added, followed by addition o f freshly distilled 3-methylbut-2-en-al 
120 (ca. 18.00 mmol). The reaction was stirred at 0 °C until complete consumption of 
the starting material was observed. The reaction mixture was quenched with sat 
NH4CI (10 mL) and extracted with diethyl ether (3 x  20 mL). The combined organic 
extracts were washed successively with brine (20 mL), water (20 mL) and dried over 
MgSCL. The solvents were removed in vacuo and the crude mixture purified by 
column chromatography.
(S)-4-Methyl-3-penten-2-ol (S)-78
OH
3-Methylbut-2-en-al 120 (1.71 mL, 17.83 mmol) was treated with ZnMe2 in toluene 
(1.2 M, 29.70 mL, 35.66 mmol) and (-)-MIB (0.17 g, 0.71 mmol) as outlined in 
General Procedure 7, with complete consumption of the starting material taking 6 
days. Purification of the crude mixture was performed by column chromatography 
(85:15 Hexane: EtOAc) to give (-)-4-methyl-3-penten-2-ol (S)-78 (0.25 g, 14% yield, 
77% ee) as a colourless oil. The absolute configuration was determined by 
comparing the optical rotations for a series o f similar alcohols and the fact that
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(+)-MIB has demonstrated selectivity to give (Reconfigured alcohols.9,10 
(S)-78: IR vmax 3435 (v0-h), 2949, 2879 (vc.H), 1679 (vc=c) cm'1; *H NM R (400 MHz, 
CDC13) 8 5.23 (1H, dsept, 7=8.5, 1.5 Hz, -CH=C(CH3)2), 4.60 (1H, dq, 7=8.5, 6.3 
Hz, -HC(OH)CH3), 2.70 (1H, brs, -OH), 1.71 (3H, d, 7=1.1 Hz, -CH=C(CH3)2), 1.69 
(3H, d, 7=1.1 Hz, -CH=C(CH3)2), 1.24 (3H, d, 7=6.3 Hz, -HC(OH)CH3) ppm; 13C 
NM R (100 MHz, CDC13) 8 134.7, 129.7, 65.2, 26.1, 24.0 and 18.4 ppm; m/z (Cl) 
100.11253 ([(M-H20 )  + NH4]+); requires 100.11262.
(S)-(-)-5-Methyl-4-hexen-3-ol9 (S)-122b
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OH
3-Methylbut-2-en-al 120 (1.71 mL, 17.83 mmol) was treated with ZnEt2 in toluene 
(1.0 M, 35.66 mL, 35.66 mmol) and (-)-MIB (0.17 g, 0.71 mmol) as outlined in 
General Procedure 7, with complete consumption of the starting material taking 8 
hours. Purification of the crude mixture was performed by column chromatography 
(88:12 Hexane: EtOAc) to give (S)-(-)-5-methyl-4-hexen-3-ol (S)-122b (0.56 g, 30% 
yield, 93% ee) as a colourless oil. The absolute configuration was determined by 
comparing the optical rotation of (S)-12 2 b with the published optical rotation of the 
same enantiomer.9
(S)-122b: [a]20D -1.7 (c 1.0, CHC13); Lit.9 [a]20D -10.5 (c. 0.002, CHC13, 95% ee); IR 
Vmax 3338 (vo-h), 2962, 2925 (vC-h), 1678 (vc=c) c m 1; ’H NM R (400 MHz, CDC13) 8 
5.17 (1H, dsept, 7=8.7, 1.3 Hz, -CH=C(CH3)2), 4.30 (1H, dt, 7=8.7, 6.7 Hz, - 
gC (O H )E t), 1.74 (3H, d, 7=1.3 Hz, -CH=C(CH3)2), 1.69 (3H, d, 7=1.3 Hz, -
122
CH=C(CH3)2), 1.65-1.40 (2H, m, -HC(OH)CH2CH3), 0.91 (3H, t, 7=7.4 Hz, - 
HC(OH)CH2CH3) ppm; 13C NMR (100 MHz, CDC13) 8 135.7, 128.3, 70.5, 31.0,
26.2, 18.7 and 10.1 ppm; m/z (Cl) 114.1281 ([M + NH4]+); requires 114.1283.
(/?)-(+)-5-M ethyl-4-hexen-3-ol (/?)-122b
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OH
3-Methylbut-2-en-al 120 (3.00 mL, 31.20 mmol) was treated with ZnEt2 in toluene 
(1.0 M, 62.40 mL, 62.40 mmol) and (+)-MIB (0.30 g, 1.25 mmol) as outlined in 
General Procedure 7, with complete consumption of the starting material taking 4 
hours. Purification by column chromatography (88:12 Hexane: EtOAc) to give (+)-5- 
methyl-4-hexen-3-ol (R)- 122b (2.97 g, 83% yield, 94% ee) as a colourless oil. 
(/?)-122b: [a]20D +1.3 (c 1.0, CHC13). NM R and other analytical data were similar to 
that o f (S)-122b.
(S)-(-)-2-M ethyl-2-octen-4-ol (S)-122c
OH
3-Methylbut-2-en-al 120 (1.71 mL, 17.83 mmol) was treated with ZnBu2 in heptane 
(1.0 M, 35.66 mL, 35.66 mmol) and (-)-MIB (0.17 g, 0.71 mmol) as outlined in 
General Procedure 7, with complete consumption of the starting material taking 3 
hours. Purification o f the crude mixture was done by column chromatography
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(88:12 Hexane: EtOAc) to give (S)-(-)-2-methyl-2-octen-4-ol (S)-122c (1.83 g, 72% 
yield, 90% ee) as a colourless oil. The absolute configuration was determined by 
comparing the optical rotations for a series o f similar alcohols and the fact that (+)- 
MIB has demonstrated selectivity to give (Æ)-configured alcohols.9,10 
(S)-122c: [<x]20d -15.8 (c 1.0, CHCI3); IR vmax 3309 (v0-h), 2927, 2862 (vc.H), 1678 
(vc=c) cm '1; *H NM R (400 MHz, CDC13) 5 5.18 (1H, dsept, 7=8.7, 1.3 Hz, - 
CH=C(CH3)2), 4.36 (1H, dt, 7=8.7, 6.6 Hz, -HC(OH)n-Bu), 1.73 (3H, d, 7=1.3 Hz, - 
CH=C(CÜ3)2), 1.69 (3H, d, 7=1.3 Hz, -CH=C(CH3)2), 1.63 (2H, m, -HC(OH)CH2-), 
1.46-1.21 (4H, m, -CH2CH2CH3), 0.92 (3H, t, 7=7.0 Hz, -CH2CH2CH3) ppm; 13C 
NM R (100 MHz, CDCI3) 5 135.3, 128.7, 69.1, 37.8, 28.0, 26.2, 23.1, 18.6 and 14.5 
ppm; m/z (Cl) 142.1596 ([M + NH4]-H20 ] +); requires 142.1596.
(/?)-(+)-2-M ethyl-2-octen-4-ol (R)- 122c
3.0 - Experimental Procedure
Endoperoxides as Antimalarials and the Application of Singlet Oxygen to the Synthesis of
Key Synthetic Intermediates en Route to Synthetic 1,2,4-Trioxanes
OH
3-Methylbut-2-en-al 120 (2.00 mL, 20.80 mmol) was treated with ZnBu2 in heptane 
(1.0 M, 41.60 mL, 41.60 mmol) and (+)-MIB (0.20 g, 0.83 mmol) as outlined in 
General Procedure 7, with complete consumption of the starting material taking 3 
hours. Purification of the crude mixture was done by column chromatography (88:12 
Hexane: EtOAc) to give (+)-(/?)-2-methyl-2-octen-4-ol (J?)-122c (2.80 g, 95% yield, 
90% ee) as a colourless oil.
(/?)- 122c: [a]20o +15.4 (c 1.0, CHCI3). NM R and other analytical data were similar to 
that of (5)-122c.
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(S)-(+)-2,5-Dimethyl-4-hexen-3-ol (S)-122d
3.0 - Experimental Procedure
Endoperoxides as Antimalarials and the Application of Singlet Oxygen to the Synthesis of
Key Synthetic Intermediates en Route to Synthetic 1,2,4-Trioxanes
3-Methylbut-2-en-al 120 (0.57 mL, 5.94 mmol) was treated with Zm-Pr2 in toluene 
(1.0 M, 11.88 mL, 11.88 mmol) and (-)-MIB (0.06 g, 0.24 mmol) as outlined in 
General Procedure 7, with complete consumption of the starting material taking 3 
hours. Purification by column chromatography (85:15 Hexane: EtOAc) gave (S)-(+)- 
2,5-dimethyl-4-hexen-3-ol (S)-122d (0.51 g, 67% yield, 98% ee) as a colourless oil. 
(S)-122d: [a]20D +17.0 (c 1.0, CHC13); IR vmax 3325 (v0_H), 2958, 2914 (vC-h), 1676 
(vc=c) cm '1; lH NM R (400 MHz, CDC13) 5 5.21 (1H, dsept, 7=8.9, 1.3 Hz, - 
CH=C(CH3)2), 4.06 (1H, dd, 7=8.9, 6.8 Hz, -HC(OH)i-Pr), 1.74 (3H, d, 7=1.3 Hz, - 
CH=C(CH3)2), 1.72-1.63 (1H, sept, 7=6.8 Hz, -HC(OH)CH(CH3)2), 1.69 (3H, d, 
7=1.5 Hz, -CH=C(CH3)2), 1.35 (1H, s, -OH), 0.96 (3H, d, 7=6.8 Hz, - 
HC(OH)CH(CH_3)2), 0.87 (3H, d, 7=6.8 Hz, -H CX O H iC H iQ kk) ppm; 13C NMR 
(100 MHz, CDC13) 8 136.0, 126.9, 74.1, 34.8, 26.2, 18.7 and 18.5 ppm; m/z (Cl) 
128.14358 ([M + NH4]-H20 ] +); requires 128.14392.
(R)-(-)-2,5-Dimethyl-4-hexen-3-ol (R)-I22d
OH
3-Methylbut-2-en-al 120 (0.77 mL, 8.00 mmol) was treated with Zm-Pr2 in toluene 
(1.0 M, 16.00 mL, 16.00 mmol) and (+)-MIB (0.08 g, 0.32 mmol) as outlined in
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3.0 - Experimental Procedure
Endoperoxides as Antimalarials and the Application of Singlet Oxygen to the Synthesis of
Key Synthetic Intermediates en Route to Synthetic 1,2,4-Trioxanes
General Procedure 7, with complete consumption o f the starting material taking 3 
hours. Purification o f the crude mixture was done by column chromatography (85:15 
Hexane: EtOAc) to give (/?)-(-)-2,5-dimethyl-4-hexen-3-ol (R)-122d (0.87 g, 85% 
yield, 98% ee) as a colourless oil.
(R)-122d: [a]20D -13.8 (c 1.0, CHC13). NM R and other analytical data were similar to 
that o f (S)-122d.
(3S,4S)-4-Hydroperoxy-5-methyl-5-hexen-3-ol (3S,4S)-123b
OH
via Photooxygenation
(5)-(-)-5-M ethyl-4-hexen-3-ol (S)-122b (0.20 g, 1.75 mmol) underwent
photooxygenation as outlined in General Procedure 6. Complete consumption of the 
starting material was observed after 1.5 hours. The solvent was removed in vacuo 
and the crude mixture purified by column chromatography (99:1 DCM: MeOH) to 
give (35,45)-4-hydroperoxy-5-methyl-5-hexen-3-ol as a pale yellow oil (3S,4S)-123b 
(0.22 g, 85% yield, d.r. 90:10 {threo:erythro}).
(3S,4S)-123b: IR vmax 3323 (v0_H), 2968, 2877 (vc.H), 1668 (vc=c), 816 (Vperoxide) c m 1;
NM R (400 MHz, CDCI3) 5 5.11 (1H, m, -C=CH2), 5.09 (1H, s, -C=CH2), 4.24 
(1H, d, 7=8.4 Hz, -HCOOH), 3.66 (1H, dt, 7=8.5, 3.4 Hz, -HC(OH)Et), 1.75 (3H, s, 
=CCH3), 1.59-1.32 (2H, m, -HC(OH)CH2CH3), 1.00 (3H, t, 7=7.4 Hz, - 
HC(OH)CH2CH3) ppm; 13C NMR (100 MHz, CDC13) 5 141.7, 117.0, 93.8, 72.4,
26.0, 18.6 and 10.1 ppm; mJz (Cl) 164.12917 ([M + NH4]+); requires 164.12867.
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(3/?,4K )-4-H ydroperoxy-5-m ethyl-5-hexen-3-ol (3/?,4R)-123b
3.0 - Experimental Procedure
Endoperoxides as Antimalarials and the Application of Singlet Oxygen to the Synthesis of
Key Synthetic Intermediates en Route to Synthetic 1,2,4-Trioxanes
OH
via Photooxygenation
(rt)-(+)-5-M ethyl-4-hexen-3-ol (R)-I22b  (1.53 g, 13.42 mmol) underwent 
photooxygenation as outlined in General Procedure 6. Complete consumption of the 
starting material was observed after 1.5 hours. The solvent was removed in vacuo 
and the crude mixture purified by column chromatography (99:1 DCM: M eOH) to 
give (3/?,4/?)-4-hydroperoxy-5-methyl-5-hexen-3-ol as a pale yellow oil (3R,4R)- 
123b (1.28 g, 66% yield, d.r. 90:10 {threo:erythro}).
(3/?,4/i)-123b: NMR and other analytical data were similar to that o f (3S,4S)-123b. 
via Phosphite Ozonide Conditions
A solution o f POA (triphenyl phosphite (1.11 mL, 4.22 mmol) in dichloromethane 
(20 mL)) was prepared as outlined in General Procedure 3. 5-Methyl-4-hexen-3-ol 
rac-12 2 b (0.16 g, 1.41 mmol) was added dropwise and allowed to react with stirring. 
The solvents were then removed in vacuo and the crude mixture purified by column 
chromatography (90:10 Hexane: EtOAc) to afford rac-123b as a clear oil (Free 
reaction: 0.08 g, 36% yield, d.r. 90:10 {threo:erythro}\ Direct reaction: 0.05 g, 25% 
yield, d.r. 90:10 {threo:erythro}).
Spectral data as above.
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(3S,4S)-3-Hydroperoxy-2-methyl-l-octen-4-ol (3S,4S)-123c
3.0 - Experimental Procedure
Endoperoxides as Antimalarials and the Application of Singlet Oxygen to the Synthesis of
Key Synthetic Intermediates en Route to Synthetic 1,2,4-Trioxanes
via Photooxygenation
Using the method summarised in General Procedure 6, (S)-(-)-2-methyl-2-octen-4-ol 
(S)-122c (0.20 g, 1.40mmol) underwent photooxygenation for 1.5 hours. Purification 
by column chromatography (99:1 DCM: MeOH) afforded (3S,4S)-3-hydroperoxy-2- 
m ethyl-1 -octen-4-ol (3S,4S)-123c (0.24 g, 100% yield, d.r. 90:10 {threo:erythro}) as 
a pale yellow oil in quantitative yield.
(3S,4S)-123c: IR vmax 3357 (v0.H), 2952, 2864 (vc.H), 1712 (vc=c), 901 (vperoxide) cm '1; 
*H NMR (400 MHz, CDC13) 5 5.11 (1H, m, -C=CH2), 5.07 (1H, s, -C=CH2), 4.21 
(1H, d, 7=8.4 Hz, -HCOOH), 3.71 (1H, dt, 7=8.4, 3.0 Hz, -HC(OH)n-Bu), 2.15 (1H, 
br, -OH), 1.75 (3H, s, =CCH3), 1.52-1.25 (6H, m, -CH2CH2CH2CH3), 0.91 (3H, t, 
7=7.2 Hz, -CH2CH2CH3) ppm; 13C NMR (100 MHz, CDC13) 5 141.7, 117.1, 94.1,
71.1, 32.7, 27.8, 23.0, 18.6 and 14.4 ppm; m/z (Cl) 192.16053 ([M + NH4D ;  requires 
192.15997.
via Phosphite Ozonide Conditions
A solution o f POA (triphenyl phosphite (1.11 mL, 4.22 mmol) in dichloromethane 
(20 mL)) was prepared as outlined in General Procedure 3. (5)-(-)-2-Methyl-2-octen-
4-ol (S)-122c (0.20 g, 1.41 mmol) was added dropwise and allowed to react with 
stirring. The solvents were then removed in vacuo and the crude mixture purified by 
column chromatography (90:10 Hexane: EtOAc) to afford (3S,4S)-123c as a clear oil
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(Free reaction: 0.04 g, 18% yield, d.r. 90:10 {threo:erythro}\ Direct reaction: 0.07 
g, 28% yield, d.r. 90:10 {threo:erythro}).
Spectral data as above.
3.0 - Experimental Procedure
Endoperoxides as Antimalarials and the Application of Singlet Oxygen to the Synthesis of
Key Synthetic Intermediates en Route to Synthetic 1,2,4-Trioxanes
(3/?,4/f)-3-Hydroperoxy-2-methyl-l-octene-4-ol (3/?,4/?)-123c
OH
Using the method summarized in General Procedure 6, (7?)-(+)-2-methyl-2-octen-4- 
ol (J?)-122c (1.91 g, 13.42 mmol) underwent photooxygenation for 1.5 hours. 
Purification by column chromatography (99:1 DCM: M eOH) afforded (3/?,47?)-3- 
hydroperoxy-2-methyl-1 -octene-4-ol (3/?,4/?)-123c (1.67 g, 72% yield, d.r. 92.8 
{threo:erythro}) as a pale yellow oil in quantitative yield.
(3R,4R)-123c: NMR and other analytical data were similar to that of (3S,4S)-123c.
(3S,4S)-4-Hydroperoxy-2,5-dimethyl-5-hexen-3-ol (3S,4S)-123d
OH
The reaction was conducted as in General Procedure 6, with (,S)-(+)-2,5-dimethyl-4- 
hexen-3-ol (S)-122d (0.20 g, 1.56 mmol) undergoing photooxygenation for 1.5 
hours. The solvents were removed in vacuo and the crude mixture was then purified 
by column chromatography (99:1 DCM: M eOH) to yield (3S,4S)-4-hydroperoxy-2,5- 
dimethyl-5-hexen-3-ol (3S,4S)-123d (0.22 g, 86% yield, d.r. 91:9 {threo:erythro}) as
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3.0 - Experimental Procedure
Endoperoxides as Antimalarials and the Application of Singlet Oxygen to the Synthesis of
Key Synthetic Intermediates en Route to Synthetic 1,2,4-Trioxanes
a pale yellow oil.
(3S,4S)-123d: 'H  NMR (400 MHz, CDC13) 5 5.06 (2H, m, -C=CH2), 4.29 (1H, d, 
7=8.2 Hz, -HCOOH), 3.48 (1H, dd, 7=8.2, 3.2 Hz, -HC(OH)i-Pr), 2.40 (1H, br, - 
OH), 1.70 (3H, t, 7=1.6 Hz, =CCH3), 1.71-1.63 (1H, septd, 7=6.8, 3.2 Hz, - 
HC(OH)CH(CH3)2), 0.96 (3H, d, 7=6.9 Hz, -HC(OH)CH(CH3)2), 0.86 (3H, d, 7=6.8 
Hz, -HC(OH)CH(CH3)2) ppm; 13C NM R (100 MHz, CDC13) 8 141.5, 117.0, 92.2,
75.2, 29.7, 20.7, 18.6 and 15.5 ppm; m/z (Cl) 160.13412 ([M + NH4]-H20 ] +); 
requires 160.13375.
(3/?,4/?)-4-Hydroperoxy-2,5-dimethyl-5-hexen-3-ol (3/?,4/?)-123d
The reaction was conducted as in General Procedure 6, with (/?)-(-)-2,5-dimethyl-4- 
hexen-3-ol (R)-122d (0.64 g, 4.99 mmol) undergoing photooxygenation for 1.5 
hours. The solvents were removed in vacuo and the crude mixture was then purified 
by column chromatography (99:1 DCM: M eOH) to yield (3/?,4/?)-4-hydroperoxy- 
2,5-dimethyl-5-hexen-3-ol (3/?,4/?)-123d (0.80 g, 97% yield, d.r. 92:8
{threo\erythro}) as a pale yellow oil.
(3/?,4/?)-123d: NMR and other analytical data were similar to that o f (3S,4S)-123d.
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(5S,6S)-(+)-5-Ethyl-6-(prop-l-en-2-yl)spiro-[l,2,4-trioxacyclohexane-3,2'-
cyclohexane] (5S,6S)-126b
3.0 - Experimental Procedure
Endoperoxides as Antimalarials and the Application of Singlet Oxygen to the Synthesis of
Key Synthetic Intermediates en Route to Synthetic 1,2,4-Trioxanes
Using the method described in General Procedure 4, (3S,4S)-4-hydroperoxy-5- 
methyl-5-hexen-3-ol (3S,4S)-123b (0.10 g, 0.68 mmol) underwent condensation with 
cyclohexanone (0.07 g, 0.75 mmol) catalysed by p-TsOH (ca. 2 mg). Purification by 
colum n chromatography (98:2 Hexane: EtOAc), afforded (5S,6S)-(+)-5-ethyl-6- 
(prop- l-en-2-yl)spiro-[ 1,2,4-trioxacyclohexane-3,2'-cyclohexane] (5S,6S)-126b
(0.10 g, 66%) as a clear oil.
(5S,6S)-126b: [a]20D +102.9 (c 1.0, CHCI3); IR v max 2933 (v C-h ), 1649 (v c=c) 850 
(Vperoxide) c m 1; ’H NMR (400 MHz, CDCI3) 5 5.08 (2H, m, - C = C m  4.29 (1H, d, 
7=9.7 Hz, -HCOOC-), 3.86 (1H, dt, 7=9.1, 3.0 Hz, -HCOC-), 2.20 (1H, m), 2.07 (1H, 
m), 1.77 (3H, t, 7=1.3 Hz, =CCH3), 1.66-1.43 (8H, m), 1.51-1.26 (2H, m, - 
HC(0 )CH2CH3), 1.00 (3H, t, 7=7.4 Hz, -H C (0)C H 2CH3) ppm ; 13C NM R (100 MHz, 
CDC13) 5 139.8, 118.2, 103.3, 87.9, 70.9, 35.5, 29.9, 26.1, 24.3, 22.9, 22.8, 20.2 and
10.5 ppm ; m/z (Cl) 244.19142 ([M + NH4]+); requires 244.19127. Anal. C 13H22O3 
requires C 68.99%, H 9.80%, found C 68.82%, H 9.84%.
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3.0 - Experimental Procedure
Endoperoxides as Antimalarials and the Application of Singlet Oxygen to the Synthesis of
Key Synthetic Intermediates en Route to Synthetic 1,2,4-Trioxanes
(5/f,6/?M-)-5-Ethyl-6-(prop-l-en-2-yl)spiro-[l,2,4-trioxacyclohexane-3,2'-
cyclohexane] (5/?,6/?)-126b
Using the m ethod described in General Procedure 4, (3/?,4/?)-4-hydroperoxy-5- 
methyl-5-hexen-3-ol (3/?,4jR)-123b (0.25 g, 1.72 mmol) underwent condensation 
with cyclohexanone (0.27 g, 2.72 mmol) catalysed by p-TsOH (ca. 2 mg). 
Purification by column chromatography (98:2 Hexane: EtOAc), afforded (5/?,6/?)-(- 
)-5-ethyl-6-(prop-l-en-2-yl)spiro-[l,2,4-trioxacyclohexane-3,2-cyclohexane] 
(5/f,6/?)-126b (0.30 g, 76%) as a clear oil.
(5fl,6J?)-126b: [a]20D -123.1 (c 1.0, CHCI3). NMR and other analytical data were 
similar to that of (5S,6S)-126b.
(5S,6S)-(+)-5-Ethyl-6-(prop-l-en-2-yl)spiro-[l,2,4-trioxacyclohexane-3,2’-
adamantane] (55,65)-127b
Condensation of (3S,4S)-4-hydroperoxy-5-methyl-5-hexen-3-ol (3S,4S)-123b (0.10 
g, 0.68 mmol) with 2-adamantanone (0.09 g, 0.75 mmol) overnight, and after 
purification by chromatography (98:2 Hexane: EtOAc), yielded (5S,6S)-(+)-5-ethyl-
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6-(prop- l-en-2-yl)spiro-[ 1,2,4-trioxacyclohexane-3,2'-adamantane] (5S,6S)-127b 
(0.11 g, 57%) as a pale yellow oil.
(5S,6S)-127b: [a]20D +59.3 (c 1.0, CHCI3); IR vmax 2913, 2856 (vC-h), 1643 (vc=c) 
741 (Vperoxide) cm’1; ’H NMR (400 M Hz, CDCI3) 8 5.08 (2H, m, -C=CH2), 4.28 (1H, 
d, 7=9.5 Hz, -HCOOC-), 3.86 (1H, dt, 7=9.5, 2.7 Hz, -HCOC-), 2.93 (1H, m), 2.15­
1.55 (13H, m), 1.76 (3H, t, 7=1.3 Hz, =CCH3), 1.51-1.30 (2H, m, -HC(0)CH2CH3),
1.02 (3H, t, 7=7.4 Hz, -H C (0)C H 2CH3) ppm. 13C NM R (100 MHz, CDC13) 5 139.9,
118.2, 105.2, 88.0, 70.4, 37.6, 37.1, 34.0, 33.8, 33.7, 33.4, 30.2, 27.6, 27.4, 24.4, 20.3 
and 10.2 ppm; m/z (Cl) 279.19580 ([M + NH4D ;  requires 279.19602. Anal. 
C 17H26O3 requires C 73.34%, H 9.41%, found C 74.10%, H 9.92%.
3.0 - Experimental Procedure
Endoperoxides as Antimalarials and the Application of Singlet Oxygen to the Synthesis of
Key Synthetic Intermediates en Route to Synthetic 1,2,4-Trioxanes
(5/?,6/?)-(-)-5-Ethyl-6-(prop-l-en-2-yl)spiro-[l,2,4-trioxacyclohexane-3,2'-
adamantane] (5/?,6/?)-127b
Condensation of (3/?,4/?)-4-hydroperoxy-5-methyl-5-hexen-3-ol (3R,4R)-123b (0.25 
g, 1.71 mmol) with 2-adamantanone (0.41 g, 2.70 mmol) overnight, and after 
purification by chromatography (98:2 Hexane: EtOAc), yielded (5/?,6/?)-(-)-5-ethyl- 
6-(prop-1 -en-2-yl)spiro-[ 1,2,4-trioxacyclohexane-3,2'-adamantane] (5R,6R)-127b 
(0.35 g, 74%) as a pale yellow oil.
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(5R,6fl)-127b: [a]20D -86.4 (c 1.0, CHC13). NMR and other analytical data were 
sim ilar to that of (5S,6S)-127b.
(5S,6S)-(+)-5-Butyl-6-(prop-l-en-2-yl)spiro-[l,2,4-trioxacyclohexane-3,2’-
cyclohexane] (5S,6S)-126c
3.0 - Experimental Procedure
Endoperoxides as Antimalarials and the Application of Singlet Oxygen to the Synthesis of
Key Synthetic Intermediates en Route to Synthetic 1,2,4-Trioxanes
(3S,4S)-3-Hydroperoxy-2-methyl-1 -octene-4-ol (3S,4S)-123c (0.10 g, 0.57 mmol) 
was condensed with cyclohexanone (0.07 g, 0.63 mmol) overnight as outlined in 
General Procedure 4. The solvents were then removed in vacuo and the crude 
mixture purified by column chromatography (98:2 Hexane: EtOAc) to afford
(55.65) -(+)-5-butyl-6-(prop-l-en-2-yl)spiro-[l,2,4-trioxacyclohexane-3,2'- 
cyclohexane] (5S,6S)-126c (0.10 g, 68%) as a colourless oil.
(55.65) -126c: [a]20D +73.1 (c 1.0, CHC13); IR vmax 2932, 2854 (vC-h), 1646 (vc=c) 
848 (Vperoxide) cm'1; ]H NM R (400 MHz, CDC13) 5 5.08 (2H, m, -C=CH2), 4.26 (1H, 
d, 7=9.7 Hz, -HCOOC-), 3.94 (1H, td, 7=9.5, 3.2 Hz, -HCOC-), 2.20 (1H, m), 2.06 
(1H, m), 1.77 (3H, m, =CCH3), 1.63-1.30 (14H, m), 0.92 (3H, t, 7=7.0 Hz, - 
H C (0)(C H 2)3CH3) ppm; 13C NM R (100 MHz, CDC13) 8 138.2, 116.7, 101.7, 86.6,
68.0, 33.9, 30.6, 28.9, 26.9, 22.9, 24.0, 21.3, 21.2, 21.1, 18.6 and 12.7 ppm; m/z (Cl) 
272.22180 ([M + NH4]+); requires 272.22257. Anal. C i5H260 3 requires C 70.83%, H 
10.30%, found C 70.93%, H 10.33%.
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(5/?,6/?)-(+)-5-Butyl-6-(prop-l-en-2-yI)spiro-[l,2,4-trioxacyclohexane-3,2'-
cyclohexane] (5R,6R)-126c
3.0 - Experimental Procedure
Endoperoxides as Antimalarials and the Application of Singlet Oxygen to the Synthesis of
Key Synthetic Intermediates en Route to Synthetic 1,2,4-Trioxanes
(3/?,4/?)-3-hydroperoxy-2-methyl-l-octen-4-ol (3/?,4/?)-123c (0.30 g, 1.71 mmol) 
was condensed with cyclohexanone (0.27 g, 2.70 mmol) overnight as outlined in 
General Procedure 4. The solvents were then removed in vacuo and the crude 
m ixture purified by column chromatography (98:2 Hexane: EtOAc) to afford 
(5/?,6i?)-(+)-5-butyl-6-(prop-1 -en-2-yl)spiro-[ 1,2,4-trioxacyclohexane-3,2'- 
cyclohexane] (5/?,6/?)-126c (0.34 g, 78%) as a colourless oil.
(5R,6R)-126c: [a]20D -102.6 (c 1.0, CHCI3). NM R and other analytical data were 
sim ilar to that of (5S,6S)-126c.
(5S,6S)-(+)-5-Butyl-6-(prop-l-en-2-yl)spiro-[l,2,4-trioxacyclohexane-3,2'- 
adamantane] (5S,6S)-127c
Condensation of (3S,4S)-3-hydroperoxy-2-methyl-1 -octen-4-ol (3S,4S)-123c (0.10 g, 
0.57 mmol) with adamantanone (0.10 g, 0.63 mmol) overnight, and after purification
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by chromatography (98:2 Hexane: EtOAc), yielded (5S,6S)-(+)-5-butyl-6-(prop-1 - 
en-2-yl)spiro-[l,2,4-trioxacyclohexane-3,2'-adamantane] (5S,6S)-127c (0.10 g, 56%) 
as a pale yellow oil.
(5S,6S)-127c: [a]20D +89.5 (c 1.0, CHC13); IR vraax 2908, 2856 (vC-h), 1649 (vc=c), 
732 (Vperoxide) cm'1; ]H NMR (400 MHz, CDC13) 8 5.08 (2H, m, -C=CH2), 4.27 (1H, 
d, 7=9.7 Hz, -HCOOC-), 3.94 (1H, dt, 7=8.7, 2.9 Hz, -HCOC-), 2.14-1.55 (14H, m), 
1.76 (3H, t, 7=1.1 Hz, =CCH3), 1.40-1.25 (6H, m), 0.92 (3H, t, 7=5.1 Hz, - 
H C (0)(C H 2)3CH3) ppm; 13C NM R (100 MHz, CDC13) 8 139.8, 118.3, 105.2, 88.1,
69.1, 37.6, 37.1, 34.0, 33.8, 33.7, 33.4, 30.2, 27.8, 27.7, 23.0, 20.3 and 14.5 ppm; m/z 
(Cl) 307.22736 ([M + H]+); requires 307.22732. Anal. C 19H30O3 requires C 74.47%, 
H 9.87%, found C 74.24%, H 10.03%.
(5R,6R)-(+)-5-Butyl-6-(prop-l-en-2-yl)spiro-[l,2,4-trioxacyclohexane-3,2'- 
adamantane] (5/?,6/?)-127c
3.0 - Experimental Procedure
Endoperoxides as Antimalarials and the Application of Singlet Oxygen to the Synthesis of
Key Synthetic Intermediates en Route to Synthetic 1,2,4-Trioxanes
Condensation of (3/?,4/?)-3-hydroperoxy-2-methyl-1 -octen-4-ol (3/?,4/?)-123c (0.30 
g, 1.71 mmol) with 2-adamantanone (0.41 g, 2.70 mmol) overnight, and after 
purification by chromatography (98:2 Hexane: EtOAc), yielded (5R,6R)-(+)-5-butyl-
6-(prop-1 -en-2-yl)spiro-[ 1,2,4-trioxacyclohexane-3,2'-adamantane] (5R,6R)-127c 
(0.41 g, 78%) as a pale yellow oil.
(5/?,6R)-127c: [a]20D -57.4 (c 1.0, CHCI3). NMR and other analytical data were
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sim ilar to that o f (5S,6S)-127c.
(5S,6S)-(+)-5-Isopropyl-6-(prop-l-en-2-yl)spiro-[l,2,4-trioxacyclohexane-3,2'-
cyclohexane] (5S,6S)-126d
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Using the method described in General Procedure 4, (3S,4S>4-hydroperoxy-2,5- 
dimethyl-5-hexen-3-ol (3S,4S)-123d (0.10 g, 0.62 mmol) underwent condensation 
with cyclohexanone (0.07 g, 0.69 mmol) catalysed by p-TsOH (ca. 2 mg). 
Purification by column chromatography (98:2 Hexane: EtOAc) gave (5S,6S)-(+)-5- 
isopropyl-6-(prop-1 -en-2-yl)spiro-[ 1,2,4-trioxacyclohexane-3,2'-cyclohexane]
(55.65) -126d (0.11 g, 73%) as a clear oil.
(55.65) -126d: [a]20D +102.0 (c 1.0, CHC13); IR vmax 2935 (vc.H), 1647 (vc=c), 849 
(Vperoxide) cm '1; *H NMR (400 MHz, CDCI3) 5 5.10 (2H, m, - 0 = W ) ,  4.47 (1H, d, 
7=9.8 Hz, -HCOOC-), 3.84 (1H, dd, 7=9.8, 2.5 Hz, -HCOC-), 2.25 (1H, m), 1.98 
(1H, m), 1.65-1.35 (8H, m) 1.78 (1H, septd, 7=6.9, 2.6 Hz, -HC(0 )CH2CH3), 1.77 
(3H, t, 7=1.1 Hz, =CCH3), 1.00 (3H, d, 7=7.0 Hz, -HC(OH)CH(CH3)2), 0.93 (3H, d, 
7=6.8 Hz, -HC(OH)CH(CH3)2) ppm; 13C NM R (100 M Hz, CDC13) 8 140.0, 118.2,
103.1, 86.1, 73.1, 37.1, 29.8, 28.5, 26.1, 22.8, 22.7, 20.5, 20.1 and 15.4 ppm; m/z 
(Cl) 258.20660 ([M + NH4]+); requires 258.20692. Anal. C i4H240 3 requires C 
69.96% , H 10.07%, found C 70.13%, H 10.11%.
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(5/?,6/?)-(-)-5-Isopropyl-6-(prop-l-en-2-yl)spiro-[l,2,4-trioxacyclohexane-3,2'-
cyclohexane] (5/?,6/?)-126d
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Using the method described in General Procedure 4, (3/?,4/?)-4-hydroperoxy-2,5- 
dimethyl-5-hexen-3-ol (3/?,4fl)-123d (0.06 g, 0.62 mmol) underwent condensation 
with cyclohexanone (0.07 g, 0.69 mmol) catalysed by p-TsOH (ca. 2 mg). 
Purification by column chromatography (98:2 Hexane: EtOAc) afforded (5/?,6/?)-(-)-
5-isopropyl-6-(prop-l-en-2-yl)spiro-[l,2,4-trioxacyclohexane-3,2'-cyclohexane]
(5/?,6/?)-126d (0.07 g, 45%) as a clear oil.
(5/?,6J?)-126d: [a]20D -95.7 (c 1.0, CHC13). NMR and other analytical data were 
sim ilar to that of (5S,6S)-126d.
(5S,6S)-(+)-5-Isopropyl-6-(prop-l-en-2-yl)spiro-[l,2,4-trioxacyclohexane-3,2'- 
adamantane] (5S,6S)-127d
Condensation of (3S,4S)-4-hydroperoxy-2,5-dimethyl-5-hexen-3-ol (3S,4S)-123d 
(0.10 g, 0.62 mmol) with 2-adamantanone (0.10 g, 0.69 mmol) overnight, and after 
purification by flash column chromatography (98:2 Hexane: EtOAc), yielded
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(5<S,6S)-(+)-5-isopropyl-6-(prop-l-en-2-yl)spiro-[l,2,4-trioxacyclohexane-3,2'- 
adamantane] (5S,6S)-127d (0.12 g, 64%) as a pale yellow oil.
(5S,6S)-127d: [a]20D +100.1 (c 1.0, CHC13); IR vmax 2904, 2856 (vC-h), 1649 (vc=c), 
742 (vperoxide) cm'1; 'H  NM R (400 MHz, CDCU) 8 5.02 (2H, m, -C=CH2), 4.40 (1H, 
d, 7=9.9 Hz, -HCOOC-), 3.78 (1H, dd, 7=9.8, 2.6 Hz, -HCOC-), 2.85-1.47 (15H, m), 
1.70 (3H, t, 7=1.1 Hz, =CCH3), 0.95 (3H, d, 7=6.9 Hz, -HC(OH)CH(CH3)2), 0.87 
(3H, d, 7=6.8 Hz, -HC(OH)CH(CH3)2) ppm; 13C NM R (100 MHz, CDC13) 8 140.0,
118.2, 104.9, 85.9, 72.5, 37.6, 37.0, 34.0, 33.7, 33.4, 30.2, 28.6, 27.7, 20.7, 20.2 and
15.2 ppm; m/z (Cl) 293.21077 ([M + NH4]+); requires 293.21167. Anal. C i8H280 3 
requires C 73.93%, H 9.65%, found C 74.83%, H 9.90%.
(5R,6/?)-(-)-5-Isopropyl-6-(prop-l-en-2-yl)spiro-[l,2,4-trioxacyclohexane-3,2'- 
adamantane] (5R,6R)-127d
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Condensation of (3R,4/?)-4-hydroperoxy-2,5-dimethyl-5-hexen-3-ol (3/?,4R)-123d 
(0.10 g, 0.62 mmol) with 2-adamantanone (0.10 g, 0.69 mmol) overnight, and after 
purification by flash column chromatography (98:2 Hexane: EtOAc) yielded 
(5R,6R)- (-)-5-isopropyl-6-(prop-1 -en-2-yl)spiro-[ 1,2,4-trioxacyclohexane-3,2'-
adamantane] (5R,6R)-127d (0.12 g, 64%) as a pale yellow oil.
(5Z?,6/?)-127d: [a]20D -100.3 (c 1.0, CHC13). NM R and other analytical data were 
similar to that of (5S,6S)-127d.
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3.2 Biological Testing
Plasmodium falciparum in vitro culture and parasite growth inhibition assays 
All parasite clones, isolates and strains were acquired from M R4 (Malaria Research 
and Reference Reagent Resource Center, Manassas, Virginia, USA). Strains/isolates 
used in this study were: the drug sensitive 3D7 clone of the NF54 isolate (unknown 
origin). In vitro culture of P. falciparum  was carried out following standard 
m ethods.11 In vitro parasite growth inhibition was assessed by the incorporation of 
[3H] hypoxanthine based on the method used by Desjardins.12 Briefly, stock drug 
solutions were dissolved in 100% dimethylsulfoxide (Sigma, Dorset, UK) and 50 pi 
o f a 3-fold dilution series (10.0, 3.33, 0.111, 0.0370, 0.0123, and 0.0041 pg/mL) of 
the drugs prepared in assay medium (RPMI 1640 supplemented with 0.5% Albumax 
II (Invitrogen), 0.2% w/v glucose, 0.03% L-glutamine, and 5 pM hypoxanthine) 
added to each well o f 96-well plates in triplicate. Fifty microlitres of asynchronous 
(65-75%  ring stage) P. falciparum  culture (0.5% parasitemia) or uninfected 
erythrocytes (blank) were added to each well reaching a final volume of 100 pL per 
well, a final hematocrit of 2.5% and final dimethylsulfoxide concentrations <0.01%. 
Plates were incubated at 37 °C in 5% C 0 2, and 95% air mixture for 24 h, at which 
point 10 pL (0.2 pCi/well) o f [3H]hypoxanthine (Perkin-Elmer, Hounslow, UK), was 
added to each well. After an additional 24 h incubation period, the experiment was 
terminated by placing the plates in a -80 °C freezer. Plates were thawed and 
harvested onto glass fibre filter mats using a 96-well cell harvester (Harvester 96, 
Tomtec, Oxon, UK) and left to dry. After the addition of MeltiLex solid scintillant
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(Perkin-Elm er, Hounslow, UK) the incorporated radioactivity was counted using a 
W allac 1450 Betalux scintillation counter (Wallac).
D ata acquired by the W allac BetaLux scintillation counter were exported into a 
M ICROSOFT EXCEL spreadsheet (Microsoft), and the IC5o values of each drug 
were calculated by using XLFit line fitting software (ID Business Solutions, UK). 
DHA, as a standard drug, and control wells with untreated infected and uninfected 
erythrocytes were included in all assays.
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4.0 Introduction - Synthesis and Biological Activity of Minor Groove Binding 
Artemisinin Conjugates
4.1 Artemisinin as an Anti-Cancer Agent
4.1.1 Artemisinin and Derivatives with Cytotoxic Activity
W oerdenbag and co-workers were the first to report the cytotoxic activity exhibited 
by artemisinin and its first generation derivatives.1 Their original aim was to use 
cytotoxicity towards Ehrlich Ascite tumour cells as a model for human cells to study 
the therapeutic index of these clinical antimalarial agents. Artemisinin and 
dihydroartemisinin (DHA) showed some cytotoxic effect (IC50 = 29.8 and 83.4 pM 
respectively). However, artemether, arteether, sodium artesunate, artelinic acid and 
sodium  artelinate were more potent, with IC50 values from 12.2 to 19.9 pM. The 
m ost active compound was an artemisinin ether dimer 133 (IC50 = 1 . 4  pM), which 
was more potent than m -p la tin  in this assay. The remarkable potency of these 
derivatives was in part attributed to their increased lipophilicty, compared to the 
parent compound. Artemistene 135, incorporating an exocyclic methylene group at 
the C-9 position, also performed well (IC50 = 6.8 pM). The endoperoxide bridge of 
artemisinin was shown to be crucial as desoxyartemisinin 10 exerted no effect up to 
concentrations of ImM .2 Artemisinin and its ether dimer 133 were shown to induce 
growth inhibition rather than cell death, whereas artemistene 135 exerted toxicity via 
cell death. The methylene group o f artemistene could potentially alkylate cellular 
macromolecules through a Michael Addition which may account for its cell killing 
effect.
Further examination o f the artemisinin ether dimers showed that stereochemistry had 
an effect on cytotoxicity.3 Symmetrical dimers 134 were less active than non­
symmetrical 133 (IC50 = 2.00 and 0.11 pM  respectively). Stereoisomers o f the
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epoxide o f artemistene were also tested with the fl-epoxide 136 (IC50 = 12.7 pM) 
being markedly more potent than the 5-epoxide 137 (IC50 = > 100 pM).
Figure 4.1 Artemisinin and derivatives tested fo r  cytotoxic activity by Woerdenbag
and co-workers.
Subsequent work by Posner has shown that this class of artemisinin dimer 
demonstrates particular cytotoxic specificity towards leukaemia cell lines and some 
types o f colon cancer, over the other 60 cell lines tested by the National Cancer 
Institute’s (NCIs) Developmental and Therapeutics Program.4'6 Hydrolytically labile 
C-10 acetal-linked dimers were synthesised and testing showed promising results in 
vitro as well as no acute toxicity to mice in vivo, even at a maximum tolerated dose 
o f 400 mg/kg.4 It is worth noting that two acetal linked dimers that had significant 
cytotoxic activity, both had 3-carbon linkers, namely glutarate diester and m- 
phthalate diester linkers.4 These structures also reflected the high activity of a 
glutarate diester of DHA.
Facile synthesis of chemically robust C-10 carba dimers became of interest. Dimer 
138 (Figure 4.2) was prepared and substantially reduced cancer cell mass in mice,
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suggesting greater stability in vivo.5'1'9 A new series o f acetal linked dimers have 
been recently reported with in vivo activity: a stereochemically symmetrical 
cyclohexane linked dimer having antitumour activity comparable with paclitaxel.10
Synthesis and Biological Activity of Minor Groove Binding Artemisinin Conjugates
Figure 4.2 A chemically robust C-10 carba linked dimer.
In a series of C-10 carba phosphate- and C-10 carba phosphonate-linked dimers, 
synthesised by the O ’Neill group, the influence of linker-length on activity was 
studied. Methyl, ethyl and propyl ester links were employed from phosphorus to 
artemisinin. As a general trend, an increase o f linker length led to an increase in 
potency against HL-60 cancer cell lines. An amide-linked dimer also showed 
significant antiproliferative activity.11
An artemisinin trimer 139 with a non-acetal C-10 linker was also successfully 
synthesised and tested (Figure 4.3).12 A carboxyethyl artemisinin intermediate was 
coupled with an L-glutamic diethylester linker using EDC/HOBt amide coupling 
reagents. The two ester groups were hydrolysed to give the diacid which then 
underw ent double coupling (EDC/HOBt) with 2 equivalents of aminoethyl 
artemisinin. The in vitro cytotoxicity o f the trimer 139 (IC50 = 0.09 pg/mL) was 
com parable to that of adriamycin (IC50 = 0.10 pg/mL), mitomycin (IC50 = 0.02
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Hg/mL) and taxol (IC50 = 0.01 pg/mL) againt HT-29 human colorectal 
adenocarcinoma.
A  corresponding C-10 carba dimer of deoxyartemisinin was also synthesised and 
tested to reiterate the importance of the endoperoxide bridge in cytotoxic potency. As 
expected, the deoxy-dimer showed no activity even at concentrations o f 1 pM.6
Synthesis and Biological Activity of Minor Groove Binding Artemisinin Conjugates
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Figure 4.3 Artemisinin trimer.
4.1.2 Specificity and Cytotoxic Potency o f Artemisinin
As previously discussed in Chapter 1.0, the artemisinin class of antimalarials agents 
exert their effect by iron mediated cleavage o f the endoperoxide bridge and 
subsequent formation of free radicals. This is supported by a body of work showing 
that removal of the peroxide bridge from artemisinin type compounds results in a 
loss of antimalarial and cytotoxic acivity.13 The iron content o f tumour cells is 
generally higher than that o f normal cells.14 Accordingly, bioactivation of artemisinin 
by iron, and differentiation between healthy and cancerous cells by iron 
concentration, provides a strategy for selective cytotoxicity by artemisinin and its 
derivatives.
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The elevated iron concentration of cancerous cells is a result of over-expression of 
transferrin receptors (TfR) on the cell surface. These trans-membrane proteins 
m ediate iron transport into cells resulting in high intracellular iron concentrations in 
cancer cells. Rapidly proliferating cancer cells lines, such as leukemic, lung, breast 
and colon cancers, have a high metabolic requirement for iron and show a 
particularly high distribution of TfR, elevating iron influx.14 Correspondingly, and 
supporting the iron activation hypothesis, artemisinin demonstrates a heightened 
cytotoxic affect upon these iron rich cell lines.
The specificity and activity of artemisinin were highlighted in studies carried out by 
Lai and co-workers. Co-administration o f artemisinin derivatives and ferrous 
compounds to tumour cells greatly augmented cytotoxic activity: whereas 
administration of artemisinin alone and administration of the combination to healthy 
cells resulted in significantly less cell death.15' 18 In a recent publication, 
holotransferrin was covalently tagged to artemisinin. This allowed artemisinin to be 
selectively picked up, endocytosed and concentrated by cancerous cells.19 
Futhermore, both artemisinin and iron would be transported into the cell in one 
package. Accordingly, artemisinin-tagged transferrin is highly selective and potent 
toward the human leukaemia cell line, M olt-4.19
4.1.3 Biological Targets and Cytotoxic Mechanism o f Action
It has been established, like many other cytotoxic agents, that artemisinin causes 
apoptosis o f tumour cells; however the precise biological target that artemisinin uses 
to exert its activity still remains elusive.20,21 Efferth has attempted to shed light on the 
response of cancerous cells to artemisinin using genetic pathways. mRNA profiles
Synthesis and Biological Activity of Minor Groove Binding Artemisinin Conjugates
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were m onitored in order to evaluate the cellular response to artesunate, arteether and 
artemether. It was found that a common mechanism o f action is implicated for all 
three i.e. the intervention o f cellular proliferation.22 Similar results have been 
reported by Hou.23
Efferth also looked at the correlation of mRNA expression of genes involved in 
oxidative stress response with the IC5o values o f artemisinin derivatives. Expression 
o f a group of these genes indicated that oxidative stress plays an important part in the
. . . .  24m echanism  of action of artemisinin.
Using similar methods, anti-angiogenesis and anti-lymphangiogenesis has also been 
implicated as a cytotoxic mode of action for artemisinin derivatives. Angiogenesis, 
can be defined as the formation of new blood vessels or lymphatic vessels from pre­
existing ones, and is essential for tumour growth. Consequently, anti-angiogenic 
therapy might be clinically useful for the treatment of tumours. Again a positive 
correlation was found between the activity o f artemisinin derivatives and the
25 26expression of angiogenesis related genes. ’
Evidence for DNA damage caused by artesunate, contributing to its therapeutic 
effect, has also been reported. A study by Li, measuring the level of y-H2AX (an 
indication of double strand breaks) and single cell gel electrophoresis, indicated 
induction o f DNA breakage in a dose dependent manner. In addition, mutant cells, 
deficient in certain polymerases responsible for repairing strand breaks, were more
27
sensitive to artesunate than the wild-type which are able to repair DNA damage.
Synthesis and Biological Activity o f Minor Groove Binding Artemisinin Conjugates
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4.2 Pyrrole-Amidine Antibiotics
4.2.1 Netropsin and Distamycin A: Discovery and Structural Motifs 
Netropsin (Nt) and Distamycin A (Dst) are the m ost widely known members o f the 
pyrrole-amidine class of naturally occurring oligopeptidic pyrrole chains. Netropsin, 
discovered in 1951 by Finlay, was isolated from the bacterium Streptomyces 
netropsis and initially showed an inhibitory effect on a number of microorganisms 
and toxicity in mice.28 W ithout the benefit o f NM R spectroscopy, Finlay correctly 
identified the presence o f amide linkages and a guanidine moiety. The structure of Nt 
140, as shown in Figure 4.4, was confirmed in 1963.29 Distamycin A 141, isolated 
from  Streptomyces distallicus, was reported seven years later30,31 and exhibited 
activity against bacteria and DNA-viruses such as herpes simplex, the vaccinia virus 
and Rous sarcoma.32 The chemical structure, as shown in Figure 4.4, was established 
by total synthesis29 and chemical analysis of Dst by Arcamone.33
Single-crystal X-ray diffraction data o f Nt sulphate indicated that its two pyrrole 
rings are not co-planar and have an angle o f 200.34,35 The regiochemistry of Nt also 
suggests a “bowed” oilgopeptide backbone with the concave side, containing amide
149
4.0 - Introduction
linkages, forming hydrogen bonds to water, and a hydrophobic convex side 
consisting of carbonyl and methyl groups. It later became apparent that the 
hydrophilic concave shape o f Nt and Dst made them a perfect fit for the floor o f the 
m inor groove o f B-DNA.
4.2.2 Properties o f Netropsin and Distamycin A
Early work indicated that biological damage caused by Nt and Dst was facilitated by 
interactions with DNA. Thus, extensive studies were carried out to confirm the 
interactions of oligopeptides with DNA in vitro, using the techniques of UV- 
absorption, thermal melting and circular dichroism experiments. A summary o f this 
work is included as follows.
4.2.2.1 Netropsin and Distamycin A bind to cellular DNA and not RNA
Chandra, Zimmer and Thrum initially studied the effects of Dst.36 It was firstly
observed that the UV-absorbance of E. Coli-DNA decreased in the presence o f Dst
and the melting temperature of native DNA increased with an increase of Dst
• 37concentration. Analogously, Nt also showed a protective effect against temperature.
It was concluded that there is a strong binding between Dst/Nt and native DNA.
In order to link this strong interaction with the toxic effect of these antibiotics, the 
effect of Dst on the template activity o f native DNA in the RNA-polymerase system 
was studied and showed an inhibitory effect. To prove that Dst was not causing 
enzyme inhibition by blocking the active site o f RNA-polymerase, Dst was pre­
incubated with DNA for increasing time periods, and correspondingly, inhibition of
Synthesis and Biological Activity o f Minor Groove Binding Artemisinin Conjugates
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template activity increased with incubation time. Therefore, inhibition o f RNA-
• • 36polymerase was attributed to DNA-Dst binding.
Krey and Hahn similarly found that the presence of Dst shifted the absorption 
m aximum  of duplex calf thymus DNA (ctDNA) from 303 nm to 321 nm.38 Dst was 
also shown to displace methyl green from its complex with DNA, as indicated by a 
decrease in absorbance at 642 nm and the loss of green colour. The displacement 
reaction was calculated to be second order with time, dependent on the concentration 
o f the two species, showing the binding of Dst to DNA has an effect on the 
displacement of methyl green.
N t and Dst are optically inactive and DNA itself does not absorb wavelengths past 
310nm. However, the optical rotatory dispersion (ORD) spectrum produced from the 
complexation of Nt and Dst with DNA showed additional optical transitions (Cotton 
effects) at 340nm and 350nm respectively.39 It was proposed, therefore, that upon 
complex formation there is perturbation of the chromophores of Nt and Dst and 
potentially a perturbation of the secondary structure of B-DNA.
Interestingly, Nt and Dst had no effect on the ORD of RNA indicating no binding 
affinity for RNA, and explaining the antiviral activity towards DNA-viruses and not 
RNA-viruses. Circular dichroism (CD) experiments by Luck and co-workers 
concurred with these results.40 Again an additional Cotton effect was observed in the 
long wavelength region of DNA-oligopeptide complexes, indicating the induced 
chirality o f the oligopeptides upon DNA-complexation. No such Cotton effect 
appeared in the case of RNA. RNA exists in the A-form, which is similar to the B- 
form DNA in that it is a right handed double helix and that it has m inor and major 
grooves. However, it has a tighter rotational angle giving a deepened major groove
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and a shallower minor groove. Nt and Dst lack o f binding affinity to RNA signified 
some sort of hindrance to the A-conformation. This is supported by the fact that Nt 
binding to DNA is diminished when DNA is in ethanol, and is known to transit from 
the B- to A-form.
4.2.2.2 Netropsin and Distamycin A Show Specificity to A and TRich DNA Tracts 
During the above work, it had been noted that the distribution of the adenine/thymine 
and guanine/cytosine base pairs affected Nt binding. The intensity o f ORD spectra of 
Nt- and Dst-DNA complexes increased with the adenine and thymine content of the 
DNA being used. For example ctDNA at 58 mole % AT produced a more intense 
spectrum than E. Coli DNA at 47 mole %. Viscosity tests were also used to compare 
Nt affinity and specificity for DNA as small additions of Nt to DNA lead to 
increased viscosity.37 DNA with a high AT content (e.g. S. maxima DNA = 71 mole 
% AT) showed a pronounced and immediate increase in viscosity. DNA which 
predominantly consists of GC (e.g. M. Lysodeikicus DNA = 28 mole % AT) showed 
an initial reduction in viscosity.
Extensive thermal melting experiments, performed at varying ionic strengths, were 
also carried out by Luck et al.40 Luck stated that in low ionic strength solutions, Nt 
and Dst will bind to both GC and AT tracts, but at moderate to high ionic strength ( > 
10'1 M Na+) both oligopeptides show specific binding towards AT rich regions. At 
0.1 and 0.5 M Na+ solutions N t and Dst bound tightly to synthetic alternating AT 
(poly(dA-T).(dA-T)) and IC (poly(dl-C).(dl-C)) tracts, and consecutive A-tracts 
complementary with T (poly(dA).(dT)). As expected, at the same ionic strengths, Nt 
and Dst did not show strong binding to the consecutive G-tract complementary with
Synthesis and Biological Activity o f Minor Groove Binding Artemisinin Conjugates
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C, (poly(dG).(dC)). More specifically, Nt showed the strongest binding affinity for 
the synthetic polynucleotide poly(dA).(dT). In 4M NaCl conditions the Nt- 
poly(dA).(dT) complex melted at ~95°C, whereas the Nt-poly(dA-T).(dA-T)
complex melted at ~80°C (Figure 4.5).
(a t  a  t\ / 1 c  i c \
\T A T A/'poiy \ C I C i; poly
po ly(dA -T).(dA -T ) po ly(d l-C ).(d l-C )
(a a  a  â \
\ T T T T /po,y
po ly(dA ).(dT)
G G G G 
C C C C poly
poly(dG ).(dC )
Figure 4.5 Qualitative diagram o f the synthetic polynucleotide tracts tested 
by Luck40 and W artelf1.
This trend was further developed by W artell et al.41 W artell studied the binding of Nt 
to synthetic DNA tracts of A-T, I-C and G-C. It was found that Nt bound strongly to 
A-T and I-C but not G-C. By process of elimination, the only feature missing from 
the two former, and present in the latter was the 2-amino group of guanine (Figure 
4.6). It was correctly theorised that steric hindrance o f the guanine 2-amino group, 
protruding into the m inor groove of DNA, blocked Nt binding. This theory 
implicated the minor groove as the Nt and Dst binding site which will be discussed in 
Section 4.2.2.4.
Major groove
A:T G:C
Figure 4.6 Molecular structure o f the A T  and GC base pairs with the 2- 
amino group o f guanine highlighted. Arrows indicate H-bond acceptors and donors.
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4 .2 .23  Netropsin and Distamycin A Bind to the DNA-Duplex via Hydrogen Bonding 
as well as Ionic Forces
Luck also hypothesised that two types o f binding interaction were taking place 
between the oligopeptides and DNA.40 Melting curves were taken at various molar 
ratios o f the antibiotic to DNA up to 0.1 moles Nt/DNA. Complex formation 
(association) was observed at 260nm shown as a sharp increase in absorbance as 
tem perature increases. Similarly dissociation o f the antibiotic from DNA was 
observed at 320nm producing a sharp decrease in absorbance as temperature 
increases. Association at 0.01 moles Nt/DNA showed two steps in the curve at 
~65°C and ~78°C. This suggested two types o f binding interactions of differing 
strengths. This was supported by the dissociation curve which showed release o f the 
antibiotic only at ~78°C i.e. the antibiotic is released when a more strongly stabilised 
fraction o f the DNA melts.
As discussed previously (Section 4.2.2.2), Nt and Dst bind tightly to AT-rich regions 
in very concentrated salt solutions (up to 4 M NaCl). This implies that recognition of 
AT-rich portions by the oligopeptide molecules probably occurs through hydrogen 
bonding, in addition to long range electrostatic interactions. Additional evidence is 
that hydrogen and hydrophobic bond breaking agents have been shown to cause 
partial or complete dissociation of the DNA-antibiotic complex.
4.2.2.4 Netropsin and Distamycin Bind to the Minor Groove o f DNA 
Luck went on to link hydrogen bonding to specificity for the m inor groove of 
DNA.40 Charged Nt has eleven H-bond donor and three H-bond acceptor sites and it 
was recognised that the m inor groove has suitable corresponding acceptor/donor sites
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in the form of oxygen from the phosphate backbone, deoxyribose groups and the C-2 
carbonyl groups of thymine. This theory was elucidated more clearly in later years 
with the availability o f x-ray crystal structures and 'H-NM R NOE experiments, 
which will be discussed in Section 4.2.2.5.
As discussed in Section 4.2.2.2, W artell’s theory also implicated the m inor groove in 
N t binding.41 The preference for AT-rich rather than GC-rich tracts o f DNA was 
explained by steric hindrance o f the bulky 2-amino group of guanine protruding into 
the m inor groove and blocking Nt binding. To prove further that Nt binds to the 
m inor groove, DNA-Nt binding was studied for tracts of synthetic DNA where dT 
was substituted for dU or dBrU and dC was substituted for dBrC. It was found that 
this change produced no detrimental effects to DNA-Nt binding. This confirmed that 
interaction with the minor groove as the Br atoms, with large atomic radii, occupy 
the m ajor groove. To further elucidate the mechanism of Nt binding, the interaction 
o f Nt with supercoiled DNA (M l3 RFI) was studied. Molecules which intercalate to 
D N A can unwind and rewind supercoiled DNA, which can be monitored by 
m easuring the respective fall and rise of sedimentation velocity o f the DNA as the 
am ount of bound ligand is increased. Nt binding showed no change in sedimentation, 
therefore not initiating unwinding and proving it does not interact with DNA via 
intercalation. Similar results were found with supercoiled PM2 DNA.
Finally, this attraction for the m inor groove is also consistent with the lack of affinity 
that N t and Dst show for RNA and DNA in the A-conformation. As previously 
m entioned the structure of the A-conformation renders the m ajor groove deeper and 
the m inor groove shallower; too shallow to facilitate successful binding of Nt and 
Dst.
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4.2.2.5 Visualising DNA-Oligopeptide Complexes via X-ray Crystallography and 
NMR Methods
To further elucidate the position N t and Dst adopt with the minor grove o f DNA, 
NM R, NOE and X-ray crystallographic experiments were performed throughout the 
1980s. DNA tracts focused on were various natural DNAs, (dA-dT) polynucleotides 
and dodecamers such as d(CGCGAATTCGCG), d(CGCAAATTTGCG) and 
alternating sequences d(CGCGATATCGCG).
The 4 base pair AT tract contained within d(CGCGAATTCGCG), has been the 
m inim um  length AT tract studied due to the findings of Dervan, who noted that Nt 
and Dst having n amides characteristically bind to n + 1 successive base pairs. 
Additionally, AT tracts in runs greater than four, display particular stabilising 
properties. One observes an increased propeller twist o f the base pairs of 170,43 
which is proposed to allow for deeper and narrower minor grooves, enhancing m inor 
groove binding.44
N O E experiments of the Nt and Dst complexed with d(CGCGAATTCGCG) 
demonstrated a 1:1 binding mode and highlighted several points of contact between 
the inner, concave surface o f the antibiotic and the minor groove o f the d(AATT) 
segment o f the dodecanucleotide.45'46 This unambiguously positions the drug 
spanning the central AATT segment.
In 1985 Kopka et al. performed X-ray crystallographic studies on Nt bound to 
d(CGCGAATTCGCG).42’47 It confirmed the N t molecule sits tightly within the 
m inor groove having displaced the spine of hydration. Its position is at the centre of 
the AATT tract. It was seen to widen the groove by 0.5-2.0 A and bent the helix axis 
by 8°, however there was no evidence of unwinding or elongation of the helix in
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agreement with the non-intercalative activity of Nt. Nt sits symmetrically in the 
centre o f the groove with its pyrrole rings slightly non-co-planar, as also previously 
observed for free Nt, so that each ring is parallel with its region o f groove wall. The 
amide NH forms bifurcated hydrogen bonds bridging the adenine N-3 and thymine 
0 -2  atoms (Figure 4.7). In fact Nt forms exactly the same hydrogen bonding pattern 
as the spine of hydration.
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Figure 4.7 Schematic diagram o f the interactions between Nt 140, adenine N- 
3 and thymine 0-2. Dot-dash lines indicate normal H-bonds (2.5-2.8À), Dotted lines 
indicate longer H-bonds (>3.0À). Figure taken from  reference 42.
Electrostatic interactions are also formed from the amidinium and guanidinium 
termini of Nt with the phosphate backbone, although both these cationic groups sit in 
the centre o f the m inor groove and do not interact with a specific phosphate group. 
The amidinium also forms normal length hydrogen bonds with adenine N-3 and the 
more rigid guanidinium forms longer hydrogen bonds with its adjacent adenine N-3.
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The synthetic dodecamer d(CGCAAATTTGCG), with a six base pair AT segment 
also shows a high propeller twist at adenine-6. From X-ray crystallography it was 
determined that Dst lies near the centre o f the DNA fragment covering five o f the six 
AT base pairs.48 The shorter Nt could occupy several positions along the lengthened 
AT tract but no sign of positional disorder was observed. The drug chooses a central 
position which must be one of the possible structures with lower energy i.e. almost 
all possible drug-DNA H-bonds are satisfied.
A  2:1 binding mode o f drug to AT-tract was also first observed through NOE 
experiments of Dst interacting with the d(CGCAAATTTGCG) dodecamer. At low 
drug-DNA ratios (0.5 equivalents), both one-drug and two-drug binding modes were 
observed. At higher ratios (2 equivalents), the two-drug complex was the primary 
species. The data was consistent with a model in which two drug molecules bind 
simultaneously, overlapping in the m inor groove with each drug sliding between 5 ’- 
A A TT-3’ and 5’-ATTT-3’, the minor groove expanded relative to the 1:1 complex.49 
It was also found that Nt occupies a more central position than Dst and the 
orientation of both drugs in the d(CGCAAATTTGCG) dodecamer is reversed when 
compared to that in the d(CGCGAATTCGCG) dodecamer.50
Alternating AT tracts were also examined, firstly in the form of dodecamer 
d(CGCGATATCGCG).51 In general, Nt shows better binding affinity for a d(A).d(T) 
tract than a d(AT) tract, but X-ray diffraction analysis showed Nt binding in the 
m inor groove of the central ATAT region as expected. However, unlike the last 
example, the drug binds in two different orientations equally well. Also individual to 
this case, is the finding that Nt binds by single hydrogen bonds rather than 
bifurcating bonds. This is believed to be caused by uneven spacing of H-bond
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acceptors along the floor o f the m inor groove in the alternating tract. This results in a 
reduced binding affinity. M oreover, two of the four AT base pairs in the ATAT 
stretch have very low propeller twists, potentially leading to a wider m inor groove. 
The longer alternating AT-tract, d(CGC AT AT ATGCG), was indeed confirmed to 
have a wider m inor groove in comparison to oligo(dA).d(T) tracts. This wider minor 
groove allowed Dst a preference for a 2:1 binding mode, with two drug molecules 
alongside each other in the groove. The 2:1 complex appears well below 
stoichiometric addition of the drug, indicating a positive cooperativity in binding. In 
fact this binding mode was observed at a lower stoichiometric amount then that 
needed to bind 2:1 at AAATTT tracts, suggesting especially facile binding in the 2:1 
m ode towards the alternating tract.52
4.2.3 Effect ofNetropsin and Distamycin on Plasmodium Falciparum 
Driven by the emerging resistance o f m alaria parasites to established antimalarial 
treatm ents, novel agents to combat the disease are o f great interest. Recently, Dst 
was found to possess antiprotozoal activity, particularly against both chloroquine 
sensitive and resistant strains o f Plasmodium falciparum. The DNA of the malaria 
parasite is significantly richer in A and T bases than that o f mammalian cells, being 
over 80% in most m alaria species compared to only 59% in man. Also the 
proliferation o f the m alaria parasite during blood stage o f its life-cycle, is reminiscent 
o f  malignant rather than healthy mammalian cells. Therefore this cytotoxic agent 
could potentially have a detrimental effect on the reproductive cycle o f the malaria 
parasite.
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4.2.3.1 Minor Groove Binders Exhibit Antiprotozoal Activity 
Ginsburg et al. initially studied the effect of a variety of m inor groove binding 
antibiotics, with a preference for AT-rich DNA tracts, on Plasmodium falciparum  
m alaria.53 Dst, Nt, 4 ’-6-diamidino-2-phenylindole (DAPI) and bis-benzimide 
(Hoechst 33258) were found to inhibit the growth and propagation o f P. falciparum. 
The toxicity of these AT-specific antibiotics towards parasites and mammalian cells 
was also compared to two GC-specific antibiotics chromomycin A3 and mithramycin 
A. It was found that the AT-targeting compounds were considerably more toxic to 
parasites than to mammalian cells and the compounds which bind preferentially to 
G C -rich  sequences, were either equally toxic or more harmful to mammalian cells. 
This data exhibits the selective power of these AT-specific agents and their potential 
as specific anti-malarial agents, but also highlights an important difference in 
parasite and mammalian physiology that could be exploited.
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Figure 4.8 The cytotoxic agents luzopeptin 142, U71184 143 and CC1065144 
demonstrate potent in vitro activity against P. falciparum.
160
4.0 - Introduction
Synthesis and Biological Activity of Minor Groove Binding Artemisinin Conjugates
In the same year Lee and Inselburg published the sensitivity o f P. falciparum  to 14 
cytotoxic agents in vitro.54 Dst exhibited an LD50 (lethal dose concentration for 50% 
o f parasites) of 3.3 x  10'7 M, however compounds having the m ost profound effect 
were luzopeptin 142, U71184 143 and CC1065 144 (Figure 4.8), all being active in 
the picomolar range.
Although Nt and Dst have shown a preference for parasitic cells over mammalian 
cells due to their AT-specificity, they still display very high toxicity in healthy
- • *32
human cells, thus prohibiting their development as drugs. Lombardi and Cnsanti 
hoped to maintain anti-malarial activity whilst reducing toxicity via a number of 
synthetic analogues of distamycin. This was achieved by replacement of the N- 
formyl group, situated at the terminus of Dst, with either an /V-formimidoyl (145­
148) or carbamoyl group (149-151), whilst varying the number o f pyrrole units from 
1 to 4 (Figure 4.9).
O
3
NH2
149-151 n = 2,3,4
Figure 4.9 Dst analogues designed to maintain antimalarial activity while reducing
■ • 32cytotoxicity.
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Dst and the synthetic analogues were tested against the chloroquine-sensitive IT 04 
strain of P. falciparum  and the ID5o estimated from dose-effect curves. DNA binding 
was studied using calf thymus DNA, as was cytotoxic effect by measuring cell 
proliferation in Hep-2 cell lines. The carbamoyl analogues showed a lower affinity 
for DNA than distamycin, suggesting that the formylamino group plays an important 
role in D N A -drug interactions. The carbamoyl analogues also showed very low 
cytotoxicity paired with excellent anti-parasitic activity (n = 3, ID50 = 0.25 pM). 
Elegantly, an increase in anti-parasitic activity directly follows an increase in the 
num ber of pyrrole units, irrespective of the terminal substituent or the other 
parameters studied. This can be explained by the hypothesis that the increased 
numbers of amide bonds provide more H-bonding interactions with AT rich regions, 
inducing tighter binding to the duplex.
4.2.3.2 P. falciparum Helicase Enzymes as a Target fo r  Antibiotic Agents 
M ore recently and more specifically, Pradhan and Tuteja have studied the effect of 
DNA-interacting compounds on the activity o f P. falciparum  helicase enzymes.55,56 
Helicases are a class of ubiquitous enzymes that catalyse the unwinding of duplex 
DNA and RNA, thereby allowing transcription and replication, powered by 
nucleoside triphosphate. This class of enzymes have been recognized as a potential 
drug target. A differential gene expression study in the presence of chloroquine has 
indicated that RNA helicase proteins may be involved in the anti-malarial action of 
the drug and it has been shown that helicases are essential for viability of various 
bacteria and viruses. DNA-interacting ligands, particularly intercalators, have been 
shown to inhibit the action of helicases either by causing a physical block to the path
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o f the helicase along the DNA duplex or by causing structural changes to the duplex
. • • 57-59thereby preventing efficient enzyme activity.
In 2006 Pradhan characterised Plasmodium falciparum  DNA helicase 60 (P/DH60) 
and tested various m inor groove binders (including netropsin in this case), 
intercalators and non-intercalating topoisomerase inhibitors against P/DH 60.55
Figure 4.10 Daunorubicin 152, actinomycin 153, ethidium bromide 154 and 
nogalamycin 155 demonstrate inhibition ofPfDH60.
These ligands were tested by including 50pM of each antibiotic in the standard 
helicase assay and daunorubicin 152, actinomycin 153, netropsin 140, ethidium 
bromide 154 and nogalamycin 155 inhibited DNA-unwinding activity o f P/DH60 
effectively (Figure 4.10). IC50 values of these ligands were calculated to be 0.3, 0.8,
1.2, 1.5 and 2 pM, respectively. These same five compounds also inhibited the 
ssDNA-dependent ATPase activity o f P/DH 60 in the standard ATPase assay. 
Calculation o f IC50 values showed nogalamycin as the most effective (IC5o = 0.5 pM) 
and netropsin at fourth most active (IC50 = 3.0pM). These five ligands were then
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tested for growth inhibition o f P. falciparum in vitro and although netropsin showed 
the poorest activity, it still slowed growth to only ~30% after 72hrs.
In 2008 Pradhan also tested a similar library o f DNA-interacting ligands on P/H45 
(Plasmodium falciparum  helicase 45), also including Dst.56 Again netropsin inhibited 
the DNA-unwinding and ssDNA dependent ATPase activity o f P/H45 effectively. 
Calculation o f IC50 values showed netropsin was the most potent P/H45 inhibitor 
(IC50 = 0.5 pM ) and the second m ost potent ATPase inhibitor (IC50 = 1.5pM) after 
nogalamycin (IC50 = 0.8 pM). Dst however showed no inhibitory activity towards 
either mode of P/H45.
4.3 Design and Biological Activity o f Netropsin/Distamycin Analogues and 
Hybrids
Since the elucidation of the remarkable binding properties of Nt and Dst and their 
preference for AT rich regions of DNA, the modification of these structures has been 
explored on two fronts: firstly, their affinity for specific base pairs, adenine and 
thymine, raised the question o f whether these molecules could be tailored to bind to 
specific DNA sequences, and secondly, their tethering to alkylating, intercalating and 
D N A cleaving agents in an attempt to “deliver” cytotoxic agents directly to the minor 
groove of DNA and enhance increase cytotoxicity. In this review we shall mainly 
concentrate on the latter category, with a brief summary o f the former.
4.3.1 Monomers, Dimers and Lexitropsins
Agents such as Nt and Dst exert their limited toxicity by binding to the minor groove 
o f  B-helical DNA and therefore blocking the path of transcription factors and
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enzymes, thus disrupting the DNA replication process. By increasing the binding 
affinity of these carboxamide chains to DNA, it was hoped to increase cytotoxicity. 
A design strategy for this was to increase the number o f pyrrole units so extending 
the chain and extending the length of the binding site allowing for more binding 
interactions.60
Tris, tetra, penta and hexa /V-methylpyrrolecarboxamide derivatives of Nt and Dst 
can bind to sequences containing five, six, seven and eight contiguous AT base pairs 
respectively.61,62 The tetrapyrrole Dst homologue is almost 20 times more potent than 
the parent natural product and increasing the number of pyrrolic units o f the 
oligopeptide frame increases the sequence specificity for longer tracts of DNA AT- 
rich sequences, as a result of the greater availability of hydrogen bonding and van der 
W aals surface.63 However, hepta /V-methylpyrrolecarboxamide derivatives were 
found not to fit with the natural twist of helix DNA, presumably because the 
m olecule becomes out o f phase with the base pairs along the minor groove floor of 
the double helix.64
An alternative strategy to circumvent the poor phasing between the DNA and ligand 
is to join two Nt or Dst molecules by a linker o f a suitable length to allow bidentate 
binding to DNA. A considerable number o f bis(netropsin) and bis(distamycin) 
compounds have been designed and synthesised including flexible polymethylene 
((CH2)i-io) linkers and also more rigid tethers incorporating a cyclic or unsaturated 
portion, allowing for bidentate ligand interactions with DNA. An important 
biological application o f these compounds has arisen with the synthesis o f two 
bis(distamycin) derivatives containing a 3,5-m-pyridyl or a trans-vinyl linker 156
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(Figure 4.11). These compounds were found to be the most effective bis-linked 
lexitropsins at inhibiting transcription by HIV-1 reverse transcriptase.65
Figure 4.11 Examples o f a potent bis(distamycin) 156 and a tren-microgonotropen
157.
One of the most recent strategies for the synthesis o f polyamide analogues with very 
high DNA binding affinity has involved linkage to polyamines to yield the 
“microgonotropens” e.g. 157.66’67 Replacement of the central pyrrole W-methyl 
m oiety with branched polyamines allows for the projection of the substituent out of 
the minor groove. DNA binding affinity is enhanced by the polyamine acting as a 
“hook”, forming bonding interactions with the phosphodiester backbone or the major
grove of DNA. This class o f compounds can efficiently compete with sequence
68specific binding of regulatory proteins to DNA.
As previously discussed, the intrusion of the 2-amino H-bond donor group of 
guanidine into the minor groove is a major facilitator of the AT preference exhibited 
by Nt, Dst and analogous V-methylpyrrolecarboxamide chains. It was therefore 
proposed that the introduction of a H-bond acceptor heteroatom in the pyrrole rings
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o f N t might permit the drug to bind to GC sequences. The so-called “lexitropsins” or 
“ information reading oligopeptides” were born and it was hypothesised that by 
substituting imidazole, thiazole, triazole, pyrazole or oxazole heterocycles for the N- 
m ethyl pyrrole ring, one could design drugs capable o f binding to sequences 
containing one or two GC pairs embedded in an AT sequence. Among the numerous 
lexitropsins synthesised so far, imidizole lexitropsins display the most pronounced 
capacity for binding to GC-containing sequences. However, the lexitropsin strategy 
based on a 1:1 binding complex has led to m inor groove binders with enhanced 
tolerance to GC base pairs in the binding site, but did not yield a purely GC specific 
molecule. The lexitropsin hypothesis took on a new direction with the discovery that 
the m inor groove o f DNA can expand to accommodate two distamycin molecules 
associated side-by-side in an antiparallel head-to-tail orientation. This development 
inspired the design of homo- and heterodimeric ligands. An imidazole-containing 
peptide (Figure 4.12) was found to bind specifically to GCGC sequences, the first 
m inor groove binding lexitropsin to be directed uniquely to GC sites.69
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Figure 4.12 A GC specific imidazole containing peptide.
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M em bers o f a structural class known as the hairpin polyamides have demonstrated 
affinities and specificities for DNA comparable with transcription factors and other 
D N A  binding regulatory proteins.70 The hairpin polyamide has proved to be a very 
successful template in the synthesis o f rationally designed ligands capable o f tight 
and specific binding to a target sequence o f double stranded DNA. Consisting o f two 
covalently linked lexitropsins connected via an amino-butyric acid linker, anti­
parallel pairing o f imidazole opposite a pyrrole residue recognises a GC base pair, 
whereas the opposite combination recognises the CG pair.71 Discrimination from TA 
and AT has been achieved by the use o f a bulkier 3-hydroxypyrrole unit instead of 
the original pyrrole.
Discrimination apparently arises from destabilisation o f interactions at the 
undesirable sequences i.e. position of the hydroxypyrrole opposite an adenine residue 
results in steric hinderance that destabilises polyamide binding.72 The effect of a 
targeted polyamide on a biological system was first fully illustrated by an eight ring 
hairpin polyamide. The polyamide was shown to enter the nucleus of cultured frog 
fibroblast cells, target the binding site of transcription factor TFIIIA and specifically 
inhibit the transcription of the 5S RNA gene.73
4.3.2 Minor Groove Binders as a DNA Delivery System
4.3.2.1 Minor Groove Binding-Alkylating Conjugates
Alkylating agents have arisen as very effective clinical agents. M ost alkylating drugs 
interact with DNA via formation of an electron deficient carbonium ion which then 
ungergoes electrophilic attack, thereby forming a covalent bond with the DNA target.
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The nitrogen at position 7 (N7) on guanine, being strongly nucleophilic, is probably 
the main m olecular target for alkylation in DNA. Bi-functionalised agents, having 
the ability to covalently bond at two points, can cause intra- or interstrand 
crosslinking, leading to disruption of transcription and replication.
However these compounds have also been shown to cause DNA damage in an 
unspecific manner, displaying toxicity to both neoplastic and normal tissues. In 
practise, unwanted effects are myelosuppression, nephrotoxicity, sterility and risk of 
non-lyphocytic leukaemia.74
W ith these incentives in mind, researchers have proposed that by tethering potent 
alkylating agents to a DNA delivery system, such as Nt and Dst, one can increase 
specificity for desired DNA targets, increase cytotoxicity and reduce adverse toxic 
effects. Early work focused on linkage o f Dst and its tetrapyrrole homologue to 
different electrophilic moieties, where the formyl group was substituted for benzoyl 
nitrogen mustard, nitrogen mustard, halogenoacryloyl, and epoxycarbonyl 
functionalities. Many derivatives have proved substantially more cyctotoxic than the 
m inor groove binders alone, often with a positive correlation between the number of 
pyrrole units and potency. This body of work has been comprehensively reviewed by 
Baraldi.75
A more specific SAR study was reported by both Baraldi76,77 and Lown 78 where the 
number o f pyrrole units tethered to the [2 ,l-c][l,4 ] benzodiazepine (PBD) moiety 
was compared with biological activity. Naturally occurring PBD-containing 
compounds, including anthramycin and DC-81, exert their alkylating activity via an 
N10-C11 carbinolamine/imine moiety, which covalently binds to the C-2 NH2 of 
guanine residues in the m inor groove (Figure 4.13).79 X-ray crystallography and
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DNA footprinting studies on covalent PBD-DNA adducts have shown a high 
specificity for G-C rich regions.
n = 2 ,158b  
n = 3 , 158c 
n = 4 , 158d
159
Figure 4.13 PBD polypyrrole conjugates synthesised and tested by Baraldi.
Novel hybrids consisting o f one, two, three or four pyrrole units linked to PBD 
through a spacer arm were synthesised, and the structure activity relationship studied 
between the length of the carboxamide chain and antiproliferative activity. The 
antiproliferative activity of the hybrids 158a-d, Dst and the PBD methyl ester 159 
(Figure 4.13) was evaluated in vitro using both human chronic myeloid leukaemia 
K562 and T-lymphoblastoid Jurkat cell lines. A direct positive relationship was 
found between the number of pyrrole rings present in the hybrids and the 
antiproliferative effect of each hybrid. The hybrid consisting of the tetrapyrrole was 
found to be the most active hybrid both against K562 and Jurkat cell lines and 
displayed greater activity than PBD alone. The analogue incorporating the dipyrrole 
chain exhibited, to some extent, antiproliferative activity (but no improvement on
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either parent compound) against the K562 cell line (IC50 = 6 pM), but was scarcely 
active on the Jurkat cell line (IC50 = 50 pM). Conclusions drawn were that an 
increased number o f pyrrole rings increased the stability o f the drug-DNA complex. 
(+)-CC-1065 is a natural product o f the class o f cyclopropylindole (CPI) antitumour 
antibiotics and consists of a long chain, heterocyclic structural m otif rem iniscent of 
Dst. It imparts its biological activity through binding to B-DNA within the m inor 
groove at AT rich sequences and selectively alkylates the N-3 position o f 3 ’-adenine 
by its cyclopropylindole subunit.80 Despite its high potency and broad spectrum of 
activity, (+)-CC-1065 was never developed clinically due to irreversible toxicity. 
Baraldi’s group have previously developed two CPI analogues duplicating the left 
hand portion o f (+)-CC-1065.63 Conjugation with a pyrazole-polypyrrole unit 160a-f 
(Figure 4.14) was proposed to increase the DNA specificity, affinity and water 
solubility o f such an analogue.
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n = 3, R1 = H, R2 = Me 160c 
n = 1, R1 = Bn, R2 = H 160d 
n = 2, R1 = Bn, R2 = H 160e 
n = 3, R1 = Bn, R2 = H 160f
Figure 4.14 CPI pyrazole-polypyrrole conjugates synthesised and tested by
Baraldi.
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Again the “longer” tripyrrole analogue 160c proved to be the most active against five 
different cancer cell lines in vitro especially against T- and B-lymphoblast cells with 
IC 5o values between 7.4 and 7.1 nM. Again for this series of hybrids, it is possible to 
correlate structure with biological activity, as increasing the number o f pyrrole rings 
from  one to three results in increased cyctotoxic activity.
Another aspect of the structure activity relationship was explored by Baraldi et al by 
varying linker length. Uramustine 162 (Figure 4.15), a clinically available alkylating 
agent, was tethered to the tripyrrole Dst, but in this case the linker length varied and 
the antiproliferative effect examined. A flexible polymethylene spacer was chosen, 
varying from one to six methylene units, allowing the nitrogen mustard of 
uramustine to interact more closely with the DNA target. All the hybrids showed 
enhanced activity compared to either parent compound when tested against the K562 
hum an leukaemia cell line. Optimum activity was displayed when methylene units 
numbered six (IC50 = 0.07 pM).
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Cl
Figure 4.15 Uramustine tripyrrole conjugates with varying linker length 
synthesised and tested by Baraldi.
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However, DNA footprinting studies on compounds 161a-f (Figure 4.15) showed that 
progressive enhancement in cytotoxic potency with the length o f polymethylene 
chain does not correspond to increased alkylation intensity and increased cytotoxicity 
m ay be attributed to increased cellular uptake.
4.3.2.2 Linkage o f Minor Grove Binders to Intercalating Agents: The Combilexins 
Intercalating drugs are planar aromatic molecules that bind to DNA by insertion of 
the aromatic system between base pairs. This leads to extension of the DNA duplex 
and local unwinding and inhibition of enzymes involved in transcription. M any 
naturally occurring intercalators have been successfully developed into antitumour 
drugs and have been used clinically in cancer treatment.
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Figure 4.16 An early combilexin. A phenoxazone chromophore fitted with
polypyrrole units.
In 1984 Krivtsora reported one of the earliest attempts to couple an intercalator with 
a m inor groove binding portion in a series o f “distactins” .60 Based on the structure 
and DNA binding mechanism o f the natural product actinomycin D, a phenoxazone 
chromophore was fitted with mono-, di- or tripyrroles at positions 1 and 9 163
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(Figure 4.16). A bidentate reaction with DNA was observed involving intercalation 
o f the chromophore and successful m inor groove interactions of the mono- and 
dipyrrole chains.
In 1988 Eliadis studied the effect of the variation of methylene spacers (2-, 3- and 4- 
carbon) o f a series of 9-amino acridine-netropsin and -distamycin hybrids. 
Lengthening o f DNA was observed, consistent with the intercalative action of 
acridine. Dissociation o f the ligand-DNA complex was 1000 times slower for the 
hybrid than for the acridine or m inor groove binder alone, suggesting a cooperative 
binding to DNA. It was reported the optimum linker length in this case was a 3- 
carbon chain 164 (Figure 4.17).
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Figure 4.17 Optimum spacer length in an SAR study o f acridine-minor groove
binder hybrids.
An example of a combilexin with a rigid linker was the amscarine derivative 165 
(Figure 4.18). Studies showed that the rigid linker did not permit optimal 
intercalation o f the acridine and apparently slightly restricted the netropsin moiety 
from  fitting deeply into the m inor groove.60 However despite this it is a potent 
topoisomerase II inhibitor and its interactions with DNA have been studied in depth
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including its action as a threading intercalator when acridine is substituted at the 4­
83-86position.
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Figure 4.18 An amsacrine-dipyrrole hybrid incorporating a rigid linker did not
permit optimal DNA binding.
M ore recently Hotzel reported on the synthesis of a series of intercalator- 
carboxamide hybrids, their cytotoxic activity, DNA binding affinity and 
topoisomerase inhibition profile.87 In the initial study the intercalating portion 
(heterocycles and anthraquinone), the pyrrole terminus and the number o f pyrrole 
units was varied. All the conjugates showed poor activity and DNA binding affinity. 
This highlighted the importance of the N,/V-dimethylamine terminus of other 
powerful minor groove binding ligands which in this case had been substituted for 
methyl ester, carboxylic acid or propionitrile groups.
In a later study, the same intercalating agents were coupled to synthetic carboxamide 
chains where the A,A-dimethylamine terminal group was reinstated.88 As expected 
the hybrids demonstrated good binding affinity confirming the importance o f the 
electrostatic interactions formed between a positively charged terminal; an amidine 
group on Nt and Dst, and the N, A-dimethylamine group on the synthetic analogues.
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In 2007 an in depth SAR study o f a series of combilexins was carried out by David- 
Cordonnier and co-workers.89 A flexible spacer at the N-terminal end o f a pyrrole 
chain, varying in length, was linked to acridone, acridine and anthraquinone. The 
m ost active tended to be the acridone conjugates with the m ost active consisting only 
o f  the monopyrrole unit 166 (Figure 4.19). From DNA melting studies, the best DNA 
binding affinity was exhibited by those hybrids incorporating the dipyrrole chain. 
Interestingly in these studies there was not always a direct correlation between 
activity and binding affinity. In the case of the acridine combilexins, lengthening of 
the linker had a considerable effect on the binding affinity causing an increase in 
m elt temperature; when the linker was 4-carbon, 167, and 2-carbon atoms in length, 
T m = 26 and 18 °C respectively (Figure 4.19).
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cytotoxic activity and structure 167 with strongest DNA binding affinity.
43 .2 .3  Linkage o f Minor Groove Binders to Free Radical-Generating Cytotoxic 
Agents
The AT specific, DNA delivery properties of N t and Dst have also been exploited to 
enhance the activity of photosensitive and photoactivated DNA cleaving agents. The 
triggering of these agents by photons o f light result in rearrangements that generate 
highly reactive radical species; oxy radicals, singlet oxygen, aryl radicals and Auger
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electrons, reminiscent o f the proposed DNA cleavage mechanism of artemisinin. Nt 
and its homologues have been previously conjugated to quinones, p-nitrobenzoyls, 
bromofurans, benzylsulphonamido groups and platinum to form photosensitive 
hybrids.60
Isoalloxazine is photoactivated in the presence of molecular oxygen, whereupon the 
flavin chromophore oxidises and generates oxy radicals capable of causing DNA 
breaks. Synthesis and biological testing on 5 ’-end-labeled DNA fragments, of an 
isoalloxazine-netropsin hybrid 168 (Figure 4.20), showed single-strand breaks at 
specific loci and a double-strand break at a specific locus in AT regions. This 
showed an asymmetric binding mode in one orientation and properties similar to a 
restriction endonuclease.
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Figure 4.20 Isoalloxazine-netropsin hybrid synthesised by Herfeld.
Photoinduced DNA cleavage has been reported with oligo-A- 
methylpyrrolecarboxamide derivatives substituted with a benzylsulfonamido group 
such as the p-chlorobenzenesulfonamide-polypyrrole hybrid 169 (Figure 4.21). In 
this case, the efficiency of single-strand cleavage under UV-A irradiation clearly
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depends on the length of the pyrrolecarboxamide chain. Tetrapyrrolesulfonamide 
conjugates are more efficient DNA cleavers than the corresponding analogues 
containing three or two pyrrole units, and conjugates with only one pyrrole are 
practically inactive.91
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Figure 4.21 p-Chlorobenzenesulphonamido-polypyrrole conjugate.
Diazenes, based on DNA cleavage agents trimethylenemethane (TMM), can form 
diyl radicals upon activation either thermally or photochemically. Bregant et al. 
synthesised the diazine-dipyrrole hybrid 170 which upon irradiation forms diyl 171 
(Figure 4.22).92
hv
pBR322
170 171
Figure 4.22 Photochemical activation o f diazene-netropsin hybrid to Diyl radical-
netropsin hybrid.
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Activation in the presence o f restriction fragments of pBR322 DNA showed that 
TM M  diyls are capable o f cutting DNA, with specificity for AT rich tracts facilitated 
by netropsin.
4-Bromoacetophenones, under photoinduced C-X bond cleavage, generate 
m onophenyl radicals capable of H-atom abstraction and have therefore been 
presented as a photoactivated DNA cleavage agent (Figure 4.23). A series of 4- 
bromoacetophenone analogues incorporating carboxamide chains o f various length 
(n = 1-3) 172a-c were synthesised and tested for DNA cleavage potency using 
supercoiled DNA.93
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Figure 4.23 Bromoacetophenone-carboxamide hybrids display DNA cleavage 
activity via photoinduced formation o f monophenyl radicals.
Again an increased number of pyrrole units resulted in an increase in DNA cleavage 
potency. The tripyrrole analogue demonstrated nicked and linear DNA at micromolar 
concentrations (3 and 20 pM respectively) compared to the millimolar concentrations 
o f the parent compound needed for a comparable effect. DNA footprinting studies 
also showed a preference for cleavage at AT-rich tracts.
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43 .2 .4  Linkage o f Minor Groove Binders to Enediyne Free Radical Generating 
Agents
A large body of research has collected surrounding the development o f enediyne- 
m inor groove binding hybrids. The enediyne class of natural products were first 
defined in the 1980s with the discovery o f calicheamicin 173, isolated from 
Micomonaspora echinospora ssp .calichensis (Figure 4.24).94
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Figure 4.24 Natural enediyne calicheamicin.
These natural products have shown remarkable biological activity including high 
antibacterial activity and extreme potency against murine tumors such as P388 and 
L1210 leukemias and solid neoplasms such as colon 26 and B16 melanoma with 
optimal doses of 0.15-5 pg/kg. The enediyne antibiotics are believed to exert their 
biological activity by acting as highly potent DNA cleaving agents giving rise to 
sequence-selective double-strand cuts. This class of compound exert their cytotoxic 
activity by rearrangement o f the enediyne moiety via Bergman cyclisation to form a 
reactive 1,4-benzeneoid diradical species (Figure 4.25).
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Figure 4.25 The Bergman thermal cycloaromatisation reaction.
In nature the cyclisation and subsequent radical formation is believed to be triggered 
by the trisulfide functionality situated in close proximity to the enediyne “warhead” . 
A nucleophile {e.g., glutathione or DNA) attacks the central sulfur atom of the 
trisulfide group, causing the formation of a thiolate or a thiol which adds 
intramolecularly to the adjacent a,p-unsaturated ketone. This change in structural 
geometry imposes strain on the 10-membered enediyne ring which is subsequently 
relieved by undergoing the Bergman reaction. The calicheamicin diradical abstracts 
hydrogen atoms from duplex DNA leading to double strand cleavage. Remarkably, 
naturally occurring calicheamicin is ready fitted with a m inor groove binding 
elem ent in the form of the aryloligosaccharide chain extending from the enediyne 
portion. This series of ring structures bind tightly to the m inor groove of B-DNA and 
display high specificity for sequences such as 5'-TCCT-3' and 5'-TTTT-3'.
Inspired by this natural molecular architecture, giving potent and specific DNA 
cleavage properties, a number of research groups have designed and synthesised 
hybrids incorporating enediyne model systems and DNA delivery systems such as Nt 
and Dst.
Tokuda et al.95 hoped to improve the DNA cleaving abilities of previously 
synthesised neocarzinostatin chromophore analogues 174 and 175, by conjugation to 
a DNA-binding group (Figure 4.26). Synthesis of an enediyne-netropsin hybrid 176
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followed, via amide coupling o f an activated ester intermediate with the netropsin 
amine previously synthesised by Shibuya’s m ethod.96 Diradical production and 
subsequent aromatisation of the hybrid was triggered in vitro by addition of 3 
equivalents of thioglycolate in methanol. DNA cleavage studies showed that the 
hybrid 176 cleaved the covalently closed supercoiled pBR322 DNA to the open 
circular DNA and the linear form  more effectively than the neocarzinostatin 
chromophore alone. These results demonstrate the importance of the m inor groove 
binder portion, delivering the radical source to the desired biological target.
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Figure 4.26 Neocarzinostatin analogues 174,175 and enediyne-netropsin hybrid
176.
Similarly, W ittman et al. hoped to improve the cytotoxic activity of simplified, 
synthetic enediynes such as 177, by incorporation of a carboxamide chain 178 
(Figure 4.27).97 M olecular modelling studies of calicheamicin 173 (Figure 4.24) 
suggested that the hydroxylamino saccharide, adjacent to the enediyne portion, acts 
as a scaffold-linker, directing the remaining saccharide chain to interact with the
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m inor groove. Based on these studies, W ittman hypothesised that insertion of a rigid 
spacer unit between the enediyne and carboxamide chain would perform a similar 
role. The m inor groove binding element would be allowed to fit closely to the floor 
o f the m inor groove while still preserving an optimal position for the enediyne 
portion to facilitate strand cleavage. A benzylic imidate with a p-methyl ester was 
used for a rigid linker, enabling ether formation with the propargylic alcohol o f the 
enediyne and amide coupling with the carboxamide amine respectively.
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Figure 4.27 Synthetic enediyne 177 and enediyne-netropsin hybrid 178 with benzylic
linker.
It was found that the addition of a binding domain improved the DNA cleavage 
potency 100 fold but an increase in cytotoxicity against HCT-116 human colon 
cancer cell lines was not observed. The hybrid was also inactive in vivo up to the 
tolerated dose. A possible explanation for the lack o f correlation in the data was that 
enediyne 177 has been shown to damage cellular proteins. By directing the synthetic 
enediyne to the DNA site, it had in fact eliminated its activity towards its actual 
cellular targets. Despite the queries raised by this publication, the remarkable 
increase in DNA binding affinity provided by the carboxamide chain again confirms 
its function as a potent DNA delivery system.
Semmelhack et al. synthesised two enediyne-netropsin hybrids with acetate and 
crontonate linkers (Figure 4.28).98 The synthetic enediyne 179 studied displayed
183
4.0 - Introduction
single strand DNA cleavage and was found to be 7 x 10'4 less potent than the natural 
product calicheamicin when the concentration needed to cause 50% DNA cleavage 
was compared. The acetate linked enediyne-netropsin hybrid 180 was synthesised via 
formation o f the enediyne carboxylic acid and subsequent amide coupling with the 
dipyrrole amine using DM AP and DCC.
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Figure 4.28 Synthetic enediyne 179, enediyne-Nt hybrid with acetate tether 180 and 
enediyne-Nt hybrid with crotonate tether 181.
However, CD (circular dichroism) spectroscopy showed that hybrid 180 binds 
weakly compared to netropsin and the dipyrrole amine intermediate. Again 
molecular modelling studies, carried out by Semmelhack, shed some light on this 
result.98 The molecular modelling showed that with the short acetate tether, it is 
difficult for the dipyrrole to simultaneously form H-bonding and van der Waals 
interactions with the m inor groove while orientating the enediyne into the minor 
groove. Steric interactions repulse the enediyne away from the minor groove so 
effectively “holding” back the pyrrole from interacting with the m inor groove.
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Correspondingly, it was also confirmed by molecular modelling, that having a longer 
tether would allow for the simultaneous placement o f both parts o f the hybrid.
To this end, a hybrid with a crotonate tether 181 was synthesised. The enediyne- 
alcohol was treated with the triflate o f methyl 4-hydroxycrotonate ester. Subsequent 
hydrolysis o f the ester and amide coupling with the dipyrrole chain afforded the 
desired hybrid. CD studies indicated that the hybrid 181 bound strongly to AT tracts. 
DNA cleavage studies showed that the hybrid was 2000-fold more potent than the 
enediyne alone and only 40-fold less potent than the natural enediyne calicheamicin. 
Com pared to the cleavage efficiency of the acetate linked hybrid 180, the crotonate 
analogue 181 is 150-fold more potent.
Propargyl sulfones are small synthetic molecules that mimic the chemical action of 
enediynes by cleaving DNA in a pH-dependent fashion. Xie e t  a l .  have synthesised 
and demonstrated the DNA cleavage ability o f a series of propargyl sulfone- 
carboxamide hybrids 182a-c (Figure 4 .29)."
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Figure 4.29 Propargyl sulphone-carboxamide hybrids.
M ore recently, Banfi and co-workers have synthesised lactenediyne-carboxamide 
conjugates in an effort to achieve double-strand cutting efficiency comparable to that
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o f calicheam icin.100 The Banfi group have previously designed and studied an 
enediyne prodrug class, the lactenediynes, which can be characterised by the fusion 
o f  a |}-lactam with a cyclodeca-3-ene-l,5-diyne 183 (Figure 4.30).
Figure 4.30 Synthetic lactenediyne warhead 183, 5-carbon tethered netropsin-hybrid 
184 and 2-carbon tethered netropsin hybrid 185.
In this system the role o f the lactam is as a “safety catch” , completely suppressing 
cycloaromatisation of the enediyne. Opening o f the (i-lactam ring by hydrolysis, 
unfastens the warhead so leading to the typical diradical species. One of the main 
m otivations o f this research is the high potency o f calicheamicin diplayed by its 
ability to cause double strand cleavage o f plasmid DNA, preferring this cleavage 
m ode to single strand breaks in a 2:1 ratio.101 This ability, rarely observed in 
cyctotoxic agents (e.g. bleomicin has a ratio of 1:9), leads to apoptosis in cells. The 
warhead o f calicheamicin, when isolated from its saccharide binding domain, has 
shown a single to double strand break ratio o f 30:1, indicating the remarkable 
influence of the oligosaccharide. The studied lactenediynes, such as 183 displayed a
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ratio o f 1:15 single- to double-strand breaks, so it was hoped to improve this ratio by 
addition o f either a carboxamide or naphthyl moiety.
The desired carboxamide chain was tethered to the lactenediyne via 2- and 5-carbon 
linkers, 185 and 184, through the nitrogen o f the P-lactam ring. Analogue 185 
showed remarkable cleavage efficiency with a double to single strand cleavage ratio 
o f 1:6 which, it is claimed, ranks them among the most effective simplified artificial 
enediynes synthesised so far.
However, the expected increase in potency o f these hybrids when compared to the 
natural parent compound calicheamicin has not been satisfied. A possible reason for 
this is that the enediyne “warhead” requires a very precise docking position onto 
DNA in order to facilitate efficient cleavage.
In summary, the majority of SAR studies exploring novel Nt and Dst hybrids find 
that an increased number of pyrrole units leads to an increase in efficacy.75 Linker 
length and flexiblility is another variable SAR subject. In the case of uramustine 
hybrids, the longer linker gave increased potency, but this could be attributed to 
increased lipophilicity.81 Through CD experiments and molecular modelling, 
Semmelhack attributed a short acetate linker with poor cleavage and binding, and 
found a longer crotonate tether much more potent.98 A rigid linker was also proposed
* • 97as a key element such as that found in the potent natural product calicheamicin.
4.4 Strategies fo r  Artemisinin-Minor Groove Binding Conjugates 
In the search for potent and selective antitumor agents, the development of an 
artemisinin-polypyrrole hybrid is an interesting route to examine. Artemisinin 
displays a remarkable selectivity for rapidly proliferating cancerous cells, and has
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recently been shown to induce DNA damage. Coupling this selectivity with an agent 
that can deliver artemisinin to the DNA target could afford a compound with unique 
properties. These hybrids also have the potential for excellent antimalarial potency. 
The coincidence of the high affinity of the m inor groove binders for AT rich regions, 
and high AT composition o f P. falciparum  renders these hybrids ideal for specific 
antimalarial activity.
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4.5 Summary
1) As well as antimalarial activity, artemisinin also demonstrates potent activity 
and selectivity toward cancerous cells. Selectivity is conferred by the high 
iron content of cancer cells facilitating activation o f the artemisinin peroxide 
bridge.
2) Netropsin and distamycin, isolated from bacteria, are naturally occurring 
oligopeptidic pyrrole chains that demonstrate: a) reversible binding (H- 
bonding and ionic interactions) at the m inor groove of DNA, specifically at A 
and T rich tracts, and b) an inhibitory effect on microorganisms and DNA- 
viruses.
3) Netropsin and distamycin have a potent and specific antiprotazoal effect 
towards P. falciparum. Specificity is imparted by the AT rich DNA of the 
m alaria parasite (80%) compared to man (59%). Proposed targets are the 
inhibition of DNA helicases.
4) Analogues of netropsin and distamycin, termed lexitropsins, have been 
“programmed” to bind to specific DNA sequences including G and C tracts.
5) Analogues o f netropsin and distamycin have been exploited as DNA delivery 
units and through coupling to other cytotoxic agents (alkylating agents, 
intercalators, free radical generating agents) m inor groove binding hybrids 
have been synthesised.
6) SAR studies of these hybrids identify: a) an increased number o f pyrrole units 
lead to an increase in cytotoxic activity and DNA binding affinity and b) that 
the length and flexibility of the linker joining the hybrid units affects activity 
and DNA binding affinity.
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The specific and potent cytotoxicity of artemisinin towards cancerous cells has been 
docum ented thoroughly.1'5 A literature report by Li and co-workers demonstrates the 
D N A  cleavage profile of artemisinin and implicates DNA cleavage as one potential 
m ode o f cytotoxic action.6 Hybrid compounds with cytotoxic (e.g. alkylators, 
intercalators and free radical generating agents) and DNA binding moieties have 
been synthesised widely.7 O f particular interest are the conjugates of the minor 
groove binders, netropsin and distamycin.8 Netropsin and distamycin are naturally 
occurring antibiotics, consisting o f a chain of amide-linked TV-methyl pyrrole units, 
demonstrating high affinity for the m inor grove o f DN A.9 The hybrid strategy has 
often allowed for compounds with enhanced activity as a result of their efficient 
delivery to the DNA target.
W ith these developments in mind we decided to attempt the synthesis o f conjugates 
o f  artemisinin with synthetic analogues of netropsin and distamycin. W e then 
planned to assess these conjugates for DNA binding affinity: a vital param eter in the 
action of agents causing cleavage o f the DNA duplex.10' 14 Literature reports on the 
SARs of these conjugates have highlighted the influence of the number of A-methyl 
pyrrole units in the minor groove binding portion, and the effect o f the incorporation 
o f  a flexible or rigid linker between the conjugated portions. ’ ’ ’ W ith this in 
m ind, we planned to synthesise a series o f conjugates by varying the length o f the 
pyrrole chain (m), the length of the flexible linker (n) and the carboxylic acid tether 
employed at the C-10 position of artemisinin ( 0  (Figure 5.1).
5.0 Results and Discussion - Synthesis and Biological Activity of Minor Groove
Binding-Artemisinin Conjugates
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Figure 5.1 Proposed points o f  diversification o f minor grove binding- 
artemisinin conjugates.
5.1 Modification o f  Artemisinin at the C-10 Position
The initial part of the synthesis was the modification o f artemisinin at the C-10 
position. Our synthetic route was focused on the amide coupling o f the m inor groove 
binding component to the artemisinin unit, making a carboxylic acid functionality on 
the artemisinin portion imperative.
Scheme 5.1 Reagents 
trimethylsilane, ZnCh,
and conditions: i) BzCl, py, CH2CI2, 0 °C, 16 hr; ii) Allyl 
4Â molecular sieves, DCE, 0 °C, 3 hr; iii) O3, MeOH, -78 °C,
1 hr; iv) PPh3, MeOH, -78 °C -  rt; v) NaC102, 2-methyl-2-butene, NaH2P 0 4, t-
BuOH/H20 ,  r.t., 2 hr.
198
Tw o alternative carboxylic acid linkers were proposed as suitable intermediates, the 
m etabolically stable C-10 carba-linker16 190 (Scheme 5.1) and C-10 phenoxy- 
linker17 199 (Scheme 5.2). These two intermediates should allow for structural 
diversity in the target conjugates. The route to the C-10 carba-carboxylic acid was 
previously developed within the O ’Neill group and is shown in Scheme 5.1.18 
Acylation of dihydroartemisinin 186 with benzoyl chloride provided the a- 
configured benzoate 187 in excellent yield. The stereoselectivity at the C-10 position 
was determined from *H NM R spectra. A doublet at 6.02 ppm with J  = 9.8 Hz is a 
result of coupling of H-10 with H-9 and is typical o f a /rans-diaxial relationship 
between the adjacent protons.
The observed diastereoselectivity is due to the nucleophilic nature o f the pyridine 
catalyst and its formation o f a reactive acyl pyridinium intermediate 191 (Figure 5.2). 
The acyl pyridinium ion undergoes steric interactions with the methyl group at C-9 
and ensures that only the artemisinin conformer with the a-directed hydroxyl group 
undergoes acylation.18
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191
Figure 5.2 Formation o f an acyl pyridinium ion intermediate 191 ensures
diastereoselectivity.
The benzoate 187 was then treated with a solution o f the mild Lewis acid ZnC h and 
allyl trimethylsilane in optimised conditions outlined by O ’Neill et al..16 This
199
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furnished the versatile allyl intermediate 188 in moderate yield and with reversed p- 
diastereoselectivity. The Lewis acid catalyst facilitates the formation of an oxonium 
ion intermediate 192, which in turn ensures axial attack o f the allylic nucleophile 
providing p-selectivity.16 Previous methods outlined in the literature, using BF3.Et20 , 
reported anhydroartemisinin (AHA) 193 as a major by-product formed by 
deprotonation of the oxonium intermediate (Figure 5.3).19 W e presumed some AHA 
was formed as t.l.c o f the crude reaction mixture visualised a red spot when 
developed with p-anisaldehyde. However AHA formation was kept to a m inimum  by 
using reaction conditions that facilitated controlled generation of the oxonium 
intermediate. The good benzoyl leaving group, as shown in 187, together with the 
use of a weaker Lewis acid and a large excess of allyl TMS, ensured that throughout 
the reaction there were large quantities of nucleophile available to react with the 
oxonium intermediate.
200
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Figure 5.3 The oxonium intermediate and potential formation o f anhydroartemisinin
(AHA) 193.
A highly effective oxidation of the allyl intermediate to the carboxylic acid had been 
previously used by our group which we subsequently implemented. Firstly synthesis 
o f the aldehyde 189 proceeded via the ozonolysis of 188 in methanol to give an a- 
hydroperoxy ether intermediate 197 (Figure 5.4). Subsequent addition of triphenyl 
phosphine to 197 facilitated reduction to the desired aldehyde 189. The ozonolysis of 
the allyl functionality initially forms a molozonide 195 followed by reverse 1,3- 
dipolar addition to a dipolar carbonyl oxide 196, which in alcoholic solvents is 
trapped out to the aforementioned ether 197.
201
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Figure 5.4 Ozonolysis o f the allyl group provides an a-hydroperoxy ether.
Finally, oxidation of the aldehyde 189 with sodium chlorite gave the desired 
carboxylic acid 190 (Scheme 5.1) in excellent yield.
Facile synthesis o f the C l0-aryl ether linker was then carried out in two steps 
(Scheme 5.2). DHA 186 was treated with methyl-3-hydroxybenzoate and a 
TM S0Tf/A gC 104 catalyst system to furnish the P-epimer o f the phenoxy ester 198. 
Saponification o f the ester subsequently provided the phenoxy carboxylic acid 199 in 
excellent yield.
H
186 198 80%
Schem e 5.2 Reagents and conditions: i) M ethyl-3-hydroxybenzoate, TMSOTf, 
AgC104, NEt3, CH2C12, -78 °C, 3 hrs; ii) 5% KOH/MeOH, r.t., 4 days.
Earlier approaches to the addition o f phenols to DHA (Scheme 5.2, step (i)) mainly 
involved the use boron trifluoride etherate catalysis; however the m ajor product 
formed from this route was the anhydro derivative AHA 193 (Figure 5.3) and the 
product was formed as a mixture o f a- and p-anomers. In 2001 the O ’Neill group
202
reported the use o f a TMSOTf-AgCICU catalyst system whereby the desired ether
* 1 7was formed in excellent yield and diastereoselectivity, favouring the p-isomer. 
These conditions were originally developed by Toshima20 for the C-arylglycosylation 
o f 1-O-methyl sugars where the phenoxy glycoside intermediate underwent an O- to 
C-aryl glycoside rearrangement as shown in Figure 5.5.
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Figure 5.5 C-aryl glycosidation o f 1-O-methyl sugars using the TMSOTf-AgCl04
catalyst system.
The identification of dihydroartemisinin lactol as related to a pyranose sugar with a 
free anomeric hydroxyl group allowed for the application of the conditions outlined 
by Toshim a et al. for the functionalisation of artemisinin. Only minor quantities of 
AHA 193 (Figure 5.3) were reported by O ’Neill and no such O- to C-glycoside 
rearrangement was noted, possibly as a result of the low temperature reaction 
conditions (-78 °C).17 The productivity and stereoselectivity of this system over other 
Lewis acid catalysts has no obvious explanation: it could be a result of either 
stabilisation o f the oxonium ion or the catalysis of its slow formation thereby 
m inimising AHA formation and optimising the yield. Correspondingly, we obtained 
198 in excellent yield.
Previous methods of saponification o f 198 to 199 (Scheme 5.2) involved the use of 
2.5% KOH/MeOH solution and was reported to give complete transformation to the
203
acid in 21 days.18 W e improved this method by reducing the reaction time to 4 days 
by increasing the concentration of the base with no detriment to the delicate 
artemisinin peroxide bridge. Careful acidification to neutral pH allowed for safe 
workup o f the peroxide product.
5.2 Synthesis o f the Carboxamide Chain: Netropsin Analogue
W ith the artemisinin-carboxylic acid intermediates in hand, we progressed to the
synthesis o f the minor groove binding portion o f the conjugates, the carboxamide
21chain. The first three steps were conditions reported by Zhao and Lown.
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Schem e 5.3 Reagents and conditions i) CI3CCOCI, CH2CI2, r.t. 3 hr: ii) 70% HNO3, 
AC2O, -40 °C 0.5 hr: iii) 3-Dimethylaminopropylamine, THF, 0 °C —»■ r.t. lhr.
The first step involved the substitution o f trichloroacetyl chloride to the inexpensive 
TV-methyl pyrrole starting material 200 (Scheme 5.3). This furnished the pyrrole ring 
with a versatile trichloroacetyl group at the 2-position in 90% yield 201. The 
trichloroacetylated product 201 was then treated with nitric acid at -40 °C, which 
ensured regiospecific substitution at the 4-position.22 Recrystallisation at -20°C with 
isopropyl alcohol gave 202 in 45% yield. In subsequent nitration reactions, 
recrystallisation greatly benefited from seeding with a sample o f 202.
204
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Com pound 202, being the basic pyrrole unit o f which the carboxamide chains are 
comprised, could then undergo a variety o f transformations.
To synthesise the terminal unit o f the carboxamide chain, 202 was treated with 3- 
dimethylaminopropyl amine to give 203 in 86% yield. This terminal group allows for 
a positive charge to be distributed across the dimethylamine group thereby forming 
electrostatic interactions with DNA tracts.
The pyrrole chain could then be built from the terminal unit 203 (Scheme 5.4). 
Reduction o f the nitro group would give a reactive amine 203a and subsequent 
addition o f the pyrrole unit 202 to 203a would give the dipyrrole 204.
Schem e 5.4 Reagents and conditions: i) H2, 1 atm, PtC>2, MeOH, 16 hr: ii) DMF, 0 
°C -► r.t, 1 hr.
The nitro group o f 203 was hydrogenated at atmospheric pressure using catalytic 
platinum  (IV) oxide in MeOH. However, upon removal o f the solvents in vacuo 
decomposition of the product was observed and only very polar degradation products 
were recovered. This problem was overcome by using a technique proposed by 
H otzel.23 The hydrogenation was repeated in MeOH as before, however upon 
completion of reaction, MeOH was removed under vacuum, the vacuum released to 
an inert atmosphere of nitrogen, and the residue immediately dissolved in DMF. The 
D M F was removed under vacuum until half of the original volume had been
205
evaporated, ensuring complete removal o f all MeOH. The vacuum was again 
released to an inert atmosphere and a solution of 202 in DM F was added to the 
solution of 203a at 0 °C. The solution was allowed to warm to room temperature 
with stirring.
Subsequent removal of the solvent and purification by column chromatography gave 
the carboxamide dipyrrole 204, in 60% yield (Scheme 5.4).
Literature methods reported purification o f product 204 could be achieved by 
recrystalisation of the crude residue in isopropyl alcohol.23 However, the residue we 
obtained assumed a gum-like appearance which did not crystallise. W e therefore 
found column chromatography the m ost effective method of purification using a 
M eOH/CH2Cl2 eluent (1:10) containing 0.25% v/v NH3 to aid elution of the polar 
product.
An area of structure activity relationship we wished to explore was the effect o f the 
length of the pyrrole unit on the DNA binding affinity o f the conjugates. W e 
therefore also synthesised a tripyrrole carboxamide unit 205. Reduction of 204 to 
give the reactive amine intermediate 204a and subsequent addition of pyrrole unit 
202 provided the tripyrrole carboxamide unit 205 in 44% yield (Scheme 5.5).
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204a 202 205 44%
Schem e 5.5 Reagents and conditions: i) H2, 1 atm, P t0 2, MeOH, 16 hr: ii) DMF, 0 
°C —► r.t, 1 hr.
206
5.3 Synthesis o f  the Target Conjugates via Amide Coupling
The final step, to synthesise our two m ost simplified conjugates, was the amide 
coupling of the synthetic carboxamide chain to the artemisinin carboxylic acid 
derivatives (Figure 5.6).
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Figure 5.6 Proposed amide coupling method to furnish the minor groove binding
artemisinin conjugates.
From  our previous practical experience, it was realised that the reduction of the nitro 
group to the amine 204a must be performed as described above (Section 5.2) and the 
activated artemisinin carboxylic acid 190a would need to be added in situ. A  number 
o f m ethods and amide coupling reagents were tried. Formation o f the acid chloride of 
artemisinin derivative 190 and subsequent addition to the amine was attempted 
initally. Analysis by t.l.c. showed a large amount o f artemisinin starting material and 
no discernable spot relating to our proposed product 206. Similarly, when the 
reaction was carried out using mixed anhydride conditions24 and then later
207
carbodiimide coupling reagents (EDC)25 27 no impact was made on the starting 
materials. W e attributed these problems to the steric bulk o f both portions we wished 
to couple. Disillusioned by these results, we attempted the coupling reaction using 
the artemisinin C-10 aryl ether derivative 199 (Scheme 5.2), hoping that the extended 
linker of 199 would readily facilitate a coupling reaction more removed from the 
steric bulk of artemisinin.
W e carried out this coupling using the uronium salt coupling reagent 0-(  1H- 
benzotri azol-1 -yl)-/V,N,/V ’,iV’-tetramethyluronium hexafluorophosphate (HBTU) 207 
(Figure 5.7).28 Uronium coupling reagents consist of the aforementioned salt, an O- 
benzotriazole (OBt) portion and a counter ion that has been shown to have no 
practical influence on the reaction course.29,30 Attack on HBTU 207 by the 
carboxylate anion forms an amidinium ion 208 which, driven by the loss o f urea 210, 
initiates attack by the OBt portion 209. The active OBt ester 211 is subsequently 
formed, available for attack from an amine to furnish the amide product 212.
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211 210
i . 2 9Figure 5.7 Activation process using the HBTU coupling reagent.
The artemisinin C-10 aryl ether 199 was thus treated with EDIPA and HBTU, and 
the prepared amine 204a was added in situ at 0 °C (Scheme 5.6).
Analysis by t.l.c. indicated the formation of a very polar product, showing a faint 
purple/brown tone when developed with p-anisaldehyde, typical o f a peroxide 
containing compound. Purification by column chromatography furnished the desired 
hybrid 213 in 40% yield. However, 'H  NMR indicated strong contamination from 
the 1-hydroxy benzotriazole by-product 215 (Figure 5.8) which proved difficult to 
completely remove by conventional chromatography. Additional purification by 
HPLC furnished the pure product in low yields but sufficient amounts were isolated 
for biological testing.
209
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Schem e 5.6 Reagents and conditions: i) HBTU, EDIPA, DMF, 0 °C, 30 min: ii) 
DM F, 0 °C ->  r.t., 3 hr.
Sim ilar conditions gave limited success in the coupling o f the ClO-carba linked 
artemisinin 190 to the dipyrrole 204a, the proposed synthesis shown in Figure 5.6. 
The product 206 was found to be more difficult to visualise by t.l.c., with it 
appearing as a more intense area within a smudge of material moving up the plate. 
Purification by column chromatography only gave a very impure sample o f the 
product. This material was confirmed to contain the product by high resolution mass 
spectrometry (HRMS). A poorly resolved *H NM R spectrum showed doublets 
typical o f methyl groups 6-Me and 9-Me of artemisinin (8 0.94 ppm, J — 6.1 Hz and 
8 0.90 ppm, J  = 7.7 Hz respectively), a singlet corresponding to H-12 of artemisinin 
(8 5.50 ppm), dimethyl amine of the pyrrole terminus (8 2.89 ppm), A-methyl groups 
o f pyrroles (8 3.85 ppm) and pyrrolic protons (approx. 8 7.16 and 6.78 ppm)
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potentially confirming the correct structure (see appendix for full characterisation). 
However, subsequent efforts to purify the products via HPLC were unsuccessful. The 
inconclusive characterisation and questionable purity o f this compound m eant that it 
would not be suitable for biological testing.
A  common side reaction when using uronium salts is the guanidylation o f the free
29  30am ine if  unreacted HBTU is still present in the reaction mixture (Figure 5.8). ’
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Figure 5.8 Guanidinium formation with uronium type coupling reagents.
This transformation could potentially be one side reaction leading to the observed 
m ixture of products if the pathway to the attack o f uronium was more favourable 
than that o f the activated C-10 carba linked carboxylic acid.
This problem could be circumvented in the future by only using a 1:1 stoichiometry 
o f the acid to coupling reagent. Inclusion of additional HOBt has also been reported 
to reduce the guanidylation side reaction. Furthermore, perhaps the use of HATU 
reagents, known to facilitate cleaner coupling reactions, would be more suited to this 
substrate.30
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5.4 Synthesis o f Structurally Modified Conjugates
After some success with the synthesis of the more simplified conjugates, we 
continued with the synthesis o f analogues incorporating tethers o f various lengths. A 
search o f commercially available amino esters with varying chain lengths highlighted 
reagents 216 and 217 (Scheme 5.7). The linkers were Boc protected and 
subsequently hydrolysed to allow efficient amide coupling with the dipyrrole unit 
204a (Scheme 5.7, step iii and iv) using the HBTU coupling conditions outlined in 
Figure 5.7.
kl' ( CH2 W ° ^H CIH 2N If
o
n = 3 216 
n = 5 217
n = 3 218 73% 
n = 5 219 81%
n = 3 220 93% 
n = 5 221 67%
220 221 iN ».
r 1 H?N \ j -
H O
+ ' 1 TK
\
n = 3 220a
n = 5 221a 204a
Scheme 5.7 Reagents and conditions: i) B0C2O, NEt3, MeOH, r.t., 1 hr: ii) 2M 
NaOH/M eOH, r.t., 16 hr: iii) HBTU, EDIPA, DMF, 0 °C, 30min: iv) DMF, 0 °C -+ 
r.t., 3 hr.
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Coupling to the artemisinin carboxylic acid derivatives 190 and 199 was achieved by 
removal o f the Boc group of 222 or 223 using trifluoroacetic acid (TFA) followed by 
in situ addition of the relevant HBTU activated artemisinin carboxylic acid (Scheme 
5.8).
Again, coupling o f the O-aryl linked artemisinin 199 with dipyrroles 222 and 223 
was successful and purification by HPLC provided 224 and 225 for biological testing 
(Scheme 5.8).
Schem e 5.8 Reagents and conditions: i) TFA, r.t., 2 hr: ii) DMF, r.t., 16 hr: ii) DMF, 
0 °C -* r.t., 3 hr.
W e had hoped that the extended primary amine o f 223 would assist in a clean amide 
coupling with artemisinin derivative 190, due to the removal some of the steric 
interference. However, similar results were obtained as before with a large amount of 
polar by-products being formed making purification difficult. The presence o f the
213
desired product 226 was confirmed by HRMS and a poorly resolved 'H  NM R spectra 
indicated the expected structure, nevertheless the data again proved inconclusive.
An additional area o f SAR we wished to examine was the effect o f the number of 
pyrrole units on the DNA binding affinity o f the conjugates. As outlined above 
(Section 5.2), we synthesised a tripyrrole carboxamide unit 205 in moderate yield. 
W e attempted the peptide coupling o f 205 with artemisinin derivative 199 using 
HBTU conditions, however no reaction was observed.
In an effort to facilitate the coupling we synthesised a tripyrrole chain incorporating a 
three carbon linker 227: nonetheless the amide coupling reaction was still 
unsuccessful. This was disappointing as there are numerous literature examples 
where an increase in pyrrole unit length, facilitates an increase in DNA binding 
affinity, and we had hoped to exploit this property.8,15
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5.4.1 Synthesis o f Conjugates via the Modified Curtius Reaction 
In addition to flexible methylene linkers o f varying lengths, we wished to incorporate 
m ore rigid spacers such as aromatic or piperazine linkers. However, we found that 
the choice o f commercially available aminoesters of the type required was limited. In
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an effort to expand our options we looked at a modified Curtius reaction as a means 
o f  coupling that would allow the use of a carboxylic acid-alcohol linker.
The reaction proceeds through the interaction of the carboxylate anion with 
diphenylphosphoryl azide (DPPA) to give a carboxylic acid azide 228, which 
undergoes thermal rearrangement to give an isocyanate 229 which in turn reacts with 
the alcohol to give the required carbamate 230 (Figure 5.9).
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DPPA
NEt3 RUT
228 229
R 'V °'R'o
230
Figure 5.9 Pathway o f the modified Curtius rearrangement using DPPA.
W e were unsure whether an aromatic carboxylic acid, of the type shown in 199, 
would freely undergo the proposed rearrangement to form the carbamate. We 
therefore carried out a model study with a protected alcohol-ester chain 231 shown in 
Scheme 5.9.
Schem e 5.9 Reagents and conditions: i) DPPA, NEt3, MeCN, 55 °C, 24 hr.
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The expected carbamate product 232 was obtained in 54% yield, so we continued 
with the addition o f the alcohol linked dipyrrole 234 to the artemisinin phenoxy 
derivative 199 (Scheme 5.10).
Schem e 5.10 Reagents and conditions: i) DPPA, NEt3, MeCN, 55 °C, 24 hr.
Using the same conditions followed by purification by column chromatography, we 
obtained crude material that gave a weak but promising *H NM R spectrum. Analysis 
by HRMS indicated the presence of a small amount of the desired product 
accompanied by a high proportion of unwanted impurities making further 
purification of the product problematic. Optimisation o f this reaction sequence could 
involve the hydrolysis of compound 232 (Scheme 5.9), followed by activation o f the 
resulting carboxylic acid by HBTU and coupling to the dipyrrole moiety to furnish 
compound 235. Regrettably we decided to discard this synthetic route as time 
pressures dictated that the work should continue to biological evaluation of the 
products we had in hand.
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5.5 Future Routes for the Synthesis of Minor Groove Binding-Artemisinin 
Conjugates
The use o f an alternative O-benzyl linker has been identified as a promising route to 
structural variation of the conjugates we have in hand.
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Figure 5.10 Proposed route to incorporate an extended phenoxy linker at the C-10 
position o f artemisinin. Reagents and conditions: i) TMSOTf AgCl0 4 , NEti; ii) 
KOH/MeOH; iii) HBTU, EDIPA; iv) 204a.
In the proposed synthesis shown in Figure 5.10, alcohol 236 can be used to provide 
an extended phenoxy linker 237 with two additional methylene groups. Ester 
hydrolysis and activation o f the resulting carboxylic acid 238 should enable efficient 
coupling with a dipyrrole carboxamide unit to furnish the novel conjugate 239. The 
extended benzyl linker also provides additional rigidity which may have an effect on 
the DNA binding affinity of 239. It is anticipated that the coupling o f dipyrrole 
chains fitted with methylene tethers, e.g. 222 and 223, to artemisinin derivative 238
217
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will proceed smoothly to furnish a library o f conjugates suitable for biological 
testing.
/
— N
OH
186
Figure 5.11 Proposed route to allow the coupling o f artemisinin to tri- and 
tetrapyrrole units. Reagents and conditions: i) HBTU, EDIPA; ii) TMSOTf AgClC>4,
NEt3.
In an attempt to facilitate the synthesis o f artemisinin conjugates incorporating tri- 
and tetrapyrrole carboxamide chains, we propose a synthesis whereby the O-aryl 
carboxylic acid 240 can be first coupled to the pyrrole portion, 205a, and thereafter 
the free alcohol 241 can be coupled to DHA via an ether linkage to give 242 
(Figure 5.11).
218
5.6 Determination ofDNA Binding Affinity by Thermal Denaturation Studies 
After the successful synthesis of three artemisinin-minor groove binder conjugates 
213, 224 and 225, we then wanted to evaluate their DNA binding affinity. If  the 
conjugates can successfully bind to double-stranded DNA, the duplex should be 
stabilised when exposed to the conjugates, which can be determined by thermal 
m elting studies. The hybrids were compared to the potent m inor groove binder 
netropsin to a) determine the effect of the additional artemisinin portion on the 
binding affinity of the m inor groove binding unit, and b) determine if the linker 
length of the hybrids had an effect on DNA binding.
5.6.1 Hypochromicity and DNA Melting Curves
Double-stranded DNA demonstrates a 30% lower molecular absorbance than 
denatured single-strand DNA due to an effect termed hypochromicity. The close 
proxim ity of the bases in the duplex state, results in the Jt-electrons o f neighbouring 
bases interacting, thereby reducing the transition dipoles of the bases and a reduced 
ability to absorb light and a reduced UV absorbance for the duplex.
This effect can be used to observe the transition of duplex to single-strand DNA. By 
m easuring the UV absorbance whilst increasing the temperature, one can produce a 
thermal melting curve (Figure 5.12). The stability o f the duplex in solution can be 
determined by the mid-point o f the curve and is termed the thermal melting stability 
(Tm).
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Figure 5.12 A typical melting curve fo r  a dodecamer duplex, where Tm is the 
transition from the duplex to single strand DNA.
5.6.2 The d(CGCGAATTCGCG) Dodecamer
The duplex we chose, to study the effects of our conjugates, was a synthetic 
dodecam er d(CGCGAATTCGCG), often called the Dickerson-Drew dodecamer. 
This sequence has been a popular choice to observe the binding of netropsin and 
distamycin to the AT tract using X-ray crystallography and NOE experiments. 
Netropsin has been shown to bind tightly at the centre o f the AATT tract at a 
duplex :drug ratio o f 1:1.32,33 The general use of this sequence as a model for the 
binding of netropsin to DNA, and reported thermal denaturation studies of this 
duplex, indicated its suitability for thermal melting studies with the artemisinin- 
dipyrrole conjugates.34
This system also allowed us to control the stoichiometry of the number o f drug 
m olecules per duplex to a 1:1 ratio as opposed to using natural double-stranded DNA 
where the stoichiometry of binding is more variable. This stoichiometric control 
would give a more meaningful comparison o f the Tm values between the three 
conjugates.
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All drug:duplex solutions were prepared in a 1:1 ratio. The samples were heated 
from 19-90°C and the UV absorption recorded approximately twice per 1°C to 
produce a melting curve.
5.6.3 Thermal Dénaturation o f d(CGCGAATTCGCG)
The curves produced from  thermal dénaturation of the d(CGCGAATTCGCG) 
duplex alone (series 1; control), the duplex with netropsin (series 2), the duplex with 
conjugate 213 (series 3), the duplex with conjugate 224 (series 4) and the duplex 
with conjugate 225 (series 5), are shown in Figure 5.13.
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Figure 5.13 Melting curves produced fo r  the d( CGCGAATTCGCGjduplex alone and 
when exposed to netropsin, conjugate 213, conjugate 224 and conjugate 225.
The curves shown in Figure 5.13 are normalised to 30 °C regarding the duplex 
control. One can clearly see the stabilisation provided to the duplex by netropsin
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(series 2), shown by the shift o f the curve to the right o f the control indicating 
denaturation at a higher temperature.
However, when the duplex is exposed to conjugate 225 (series 5), incorporating a 5- 
carbon tether, the curve matches closely with that of the control, indicating no 
additional stabilisation of the duplex. W hen the duplex is exposed to conjugate 213, 
with no tether (series 3), the duplex actually appears to be destabilised, the curve 
shifting to the left.
An anomalous result was produced from the thermal denaturation of the duplex in 
the presence o f conjugate 224 (series 4), incorporating a 3-carbon tether. Repetition 
o f the experiment produced the same result giving what could be described as a 
biphasic melting curve.
The m ost accurate method of comparing the stability of the duplex in the various 
conditions described, is in terms of the Tm which is calculated from the maximum 
point of the first derivative o f the melting curve produced (Figure 5.12). However the 
curves produced from our experiments, including the control, did not show typical 
m elting behaviour i.e. none of the curves formed a plateau at higher temperatures to 
give a classic sigmoidal shape. As a result no maximum point could be determined 
form  the first derivative o f the curves. The curves were also quite shallow, not 
showing a sharp transition from the duplex to the denatured single-strand. 
Disappointingly, the outcome of this poor melt behaviour is that we cannot, at this 
point, draw definite conclusions from this preliminary testing. However, it does 
appear that none of the drug conjugates show comparable binding to that of 
netropsin.
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The Dickerson sequence (d(CGCGAATTCGCG)) was chosen because o f previously 
reported studies (mainly NM R) with minor groove binders and the predictable 
stoichiometry o f binding. However, self-complementary sequences o f this type do 
have the potential to form hairpin structures 243 (Figure 5.14) that can complicate 
the T ra studies and could explain the biphasic melting o f the duplex when exposed to 
conjugate 224. A better approach for future work may be to use a non-self­
complementary sequence e.g. 245, which is likely to have better behaved melting 
properties.
2
t t c g c g
a a g c g 6
CGCGAATTCGCG
GCGCTTAAGCGC
CCGGTTAAGGCC
GGCCAATTCCGG
243 244 245
Figure 5.14 Potential hairpin structures formed by the self-complementary 
d(CGCGATATCGCG) oligomer.
5.7 Conclusion
In conclusion, we have highlighted a successful route to the coupling of artemisinin 
to a synthetic dipyrrole. Use of an O-aryl linked carboxylic acid at the C-10 position 
o f artemisinin, allows for facile coupling to amine-functionalised dipyrrole chains 
using HBTU/EDIPA amide coupling conditions.
The coupling o f a C-10 carba linked carboxylic acid to the dipyrrole portion, 
however, proved problematic, with side reactions evident, making purification 
difficult. The coupling o f artemisinin to a synthetic tripyrrole was also unproductive 
both with and without an extended linker.
Diversification of the C-10 O-aryl conjugates was successfully achieved by the 
incorporation of a flexible tether linking the two portions. It was proposed that the
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flexibility and length of said linker would allow more freedom of movement for both 
portions o f the conjugate thereby optimising interactions with the DNA duplex.
The use o f alternative O-benzyl linkers has been proposed as a route to a series of 
m ore structurally rigid hybrids that m ay demonstrate an altered affinity for the m inor 
groove of DNA.
Thermal denaturation studies o f the d(CGCGAATTCGCG) duplex in the presence of 
netropsin and conjugates 213, 224 and 225 have been carried out. However the 
selected duplex did not produce the classic sigmoidal denaturation curve, even under 
control conditions. Early comparisons of the curves obtained, indicate that the 
conjugates tested may not demonstrate DNA binding affinity comparable with 
netropsin. W ork is ongoing to improve the curves produced so as to define a value 
for Tm, and to allow accurate evaluation of the artemisinin-dipyrrole conjugates.
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6.0 Experimental Procedure - Synthesis and Biological Activity of Minor 
Groove Binding-Artemisinin Conjugates
6.1 Chemical Procedures
Reaction procedure: Air- and moisture-sensitive reactions were carried out in oven- 
dried glassware sealed with rubber septa under a positive pressure o f dry nitrogen 
from  a balloon, unless otherwise indicated. Similarly, sensitive liquids and solutions 
were transferred via syringe or stainless steel cannula. Reactions were stirred using 
Teflon coated magnetic stir bars. Organic solutions were concentrated using a Buchi 
rotary evaporator with a diaphragm vacuum pump.
Purification o f reagents and solvents: Anhydrous solvents were either obtained from 
comm ercial sources or dried and distilled immediately prior to use under a constant 
flow of dry nitrogen. THF, diethyl ether were distilled from Na/Ph2CO, and 
dichloromethane from CaH2. All other reagents were used as received from 
comm ercial sources unless otherwise indicated.
Purification o f products: Analytical thin layer chromatography was performed with 
0.25 mm silica gel plates (Merck 60 F254). Plates were visualised by ultraviolet light 
or by treatment with iodine, p-anisaldehyde, ninhydrin or potassium permanganate 
followed by gentle heating. Chromatographic purification of products was 
accom plished by flash chromatography performed on silica gel (BDH 60 230-400 
mesh). High pressure liquid chromatography (HPLC) was performed using a Gilson 
321-pump coupled to a Gilson UV/Vis-151 spectrophotometer on a reverse phase, 
semi-preparative column. Preparative traces were plotted using Clarity - 
Chrom atography software.
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Analysis: M elting points were determined on a Gallenkamp apparatus and are 
uncorrected. NM R spectra were measured on a Bruker AM X 400 ( 'H , 400 MHz and 
13C, 100 M Hz) nuclear magnetic resonance spectrometer. Solvents are indicated in 
the text. Solids and liquids were used directly without any further treatment to record 
IR spectra using a JASCO FT/IR-4100 spectrometer. Mass spectra (MS) and high 
resolution mass spectra (HRMS) were recorded on a VG analytical 7070E machine 
and a Fisons Trio 1000 quadrupole GC mass spectrometer using electron ionisation 
(E l) or chemical ionisation (Cl) respectively. M icroanalyses were determined by the 
University of Liverpool Microanalysis Laboratory.
*H NM R signals corresponding to artemisinin have been assigned using the 
following numbering system:
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Dihydroartemisinin lOa-benzoate1 187
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Benzoyl chloride (3.2 mL, 27.6 mmol) was added to a stirring solution of DHA 186 
(5.00 g, 17.6 mmol) in anhydrous CH2C12 (60 mL) and anhydrous pyridine (9 mL) at 
0  °C. After stirring at room  temperature for 16 hours, the solvents and pyridine were 
rem oved in vacuo and the residue dissolved in EtOAc. This was then washed 
successively with 7% aq. citric acid solution (2 x 50 mL), sat. NaHCCh (50 mL) and 
water (50 mL). The organic extracts were dried over MgSCU and the solvents 
rem oved under reduced pressure to give a yellow oil. Purification by flash column 
chromatography (10:90 EtOAc: Hexane) gave 187 (6.25 g, 92%) as a white 
crystalline solid.
187: m.p. 110-112 °C Lit. 111-112 °C; IR vmax 2929 (vc.H), 1736 (vc=0), 1452 (vc=c), 
877, 831 (v0-o) c m 1; NMR (400 MHz, CDCI3) 8 8.14 (2H, m, Ar-H), 7.64-7.55 
(1H, m, Ar-H), 7.50-7.26 (2H, m, Ar-H), 6.03 (1H, d, 7=9.9 Hz, H-10p), 5.53 (1H, s, 
H-12), 2.81 (1H, ddq, 7 =9.8, 7.1, 4.5 Hz, H-9), 2.43 (1H, td, 7=13.5, 4.0 Hz, H-4a), 
2.08-0.94 (19H, m) (including 1.43 (3H, s, 3-Me), 0.99 (3H, d, 7=5.9 Hz, 9-Me), 
0.94 (3H, d, 7=7.2 Hz, 6-Me)) ppm; 13C NMR (100 MHz, CDCI3) 5 165.7, 133.7,
130.5, 130.0, 128.7, 104.9, 92.9, 92.0, 80.6, 52.1, 45.8, 37.7, 36.7, 34.5, 32.4, 26.3,
25.0, 22.5, 20.7 and 12.7; m/z (El) 411.1766 ([M + Na]+) requires 411.1784; Anal. 
C 22H2g06 requires C 68.02%, H 7.27%, found C 67.70%, H 7.11%.
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lOp-AlIyldeoxoartemisinin1188
A solution of 187 (0.40 g, 1.03 mmol) in anhydrous 1,2-dichloroethane (4 mL) was 
added dropwise via cannula to a stirring mixture of allyltrimethylsilane (0.76 mL, 
4.80 mmol), anhydrous ZnCl2 (0.16 g, 1.20 mmol) and powdered 4 A molecular 
sieves in anhydrous 1,2-dichloroethane (5 mL) at 0 °C. After stirring at 0 °C for 3 
hours, the reaction mixture was diluted with EtOAc (150 mL) and washed with 5% 
aq. citric acid (50 mL), saturated aq. N aH C 03 (50 mL), and brine (50 mL). The 
organic extracts were dried over MgSCL and the solvents removed in vacuo. 
Purification by flash column chromatography (10:90 EtOAc:Hexane) afforded 188 
(0.19 g, 60%) as a white crystalline solid.
188: m.p. 73-75 °C Lit. 76-78 °C; IR vmax 2991, 2958, 2918, 2873 (v C -h ), 1643 
(vc=c), 879, 840, 823 (v0-o) cm '1; ‘H NM R (400 MHz, CDC13) 5.98 (1H, m, - 
CH=CH2), 5.32 (1H, s, H-12), 5.15 (2H, m, -CH=CH2), 4.32 (1H, m, H-10), 2.73 
(1H, m, H-9), 2.45-2.18 (3H, m), 2.06-1.58 (5H, m), 1.53-0.90 (14H, m) (including 
1.42 (3H, s, 3-Me), 0.97 (3H, d, 7=6.1 Hz, 6-Me), 0.90 (3H, d, 7=7.6 Hz, 9-Me)) 
ppm; 13C NM R (100 MHz, CDCI3) 8 136.9, 116.5, 103.5, 89.5, 81.1, 75.1, 52.8, 
44.7, 37.9, 37.0, 34.9, 34.6, 30.6, 26.5, 25.3, 25.1, 20.6 and 13.4; m/z (ES) 331.1878 
([M + Na]+) requires 331.1385; Anal. CisH^CL requires C 70.10%, H 9.15%, found 
C 70.29%, H 9.19%.
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10p-(2-Oxoethyl)deoxoartemisinin2 189
Ozone was bubbled through a solution o f 188 (0.80 g, 2.60 mmol), in anhydrous 
M eOH (45 mL) at -78 °C for 60 minutes until the solution became saturated with 
ozone and appeared blue. Nitrogen was then bubbled through the solution to purge 
excess ozone. PPh3 (2.04 g, 7.79 mmol) was added to the stirring solution at -78 °C. 
The mixture was allowed to warm to room temperature and stirred overnight. The 
solvent was removed in vacuo and the residue purified by flash column 
chromatography (15:85 EtOAc:Hexane) to give 189 (0.74 g, 92%) as a white solid. 
189: m.p. 95-96 °C; IR vmax 2933 (vC-H), 1718 (vc=o), 877, 825 (v0.0) cm '1; 'H  NMR 
(400 MHz, CDCI3) 9.80 (1H, dd, 7=3.1, 1.5 Hz, -CHO), 5.32 (1H, s, H-12), 4.98 
(1H, m, H-10), 2.79-2.61 (2H, m, -CH2CHO), 2.47-2.41 (1H, m), 2.37 (1H, td, 
7=14.6, 4.0 Hz, H-4a), 2.07 -2.01 (1H, m), 1.97-1.91 (1H, m), 1.82-1.76 (1H, m), 
1.71-1.66 (2H, m), 1.55-0.88 (14H, m) (including 1.41 (3H, s, 3-Me), 0.98 (3H, d, 
7=6.0 Hz, 6-Me), 0.88 (3H, d, 7=7.6 Hz, 9-Me)) ppm; 13C NM R (100 MHz, CDC13) 
6 202.2, 103.6, 89.7, 81.3, 69.8, 52.5, 44.8, 44.4, 37.9, 36.9, 34.7, 30.1, 26.4, 25.1,
25.0, 20.5 and 13.4; tn/z (Cl) 328.21328 ([M + N H 4D  requires 328.21240; Anal. 
C17H26O5 requires C 65.78%, H 8.44 %, found C 65.69 %, H 8.47 %.
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10p-(2-Carboxyethyl)deoxoartemisinin2 190
Nat^PCU (0.40 g, 3.38 mmol) was added to a stirring solution o f 189 (0.70 g, 2.26 
mmol) in i-BuOH (31 mL) and water (6 mL). 2-Methyl-2-butene (13.0 mL, 26.00 
mmol) was then added, followed by NaC102 (0.61 g, 6.80 mmol). The resulting pale 
yellow solution was stirred at room  temperature for 2 hours and then concentrated in 
vacuo. 1.0 M aq. NaOH (50 mL) was added and the resulting solution washed with 
CH2CI2 (3 x 50 mL). The aqueous phase was acidified with 1.0 M aq. HC1 and 
extracted with CH2CI2 (3 x 50 mL). The combined organic extracts were dried over 
MgSCL, filtered and concentrated under reduced pressure to give 190 (0.66 g, 90%) 
as a white brittle foam.
190: m.p. 150-152 °C; IR vmax 3423 (v 0 -h ), 2939 (v C -h ), 1590 (vc=o), 877, 845 (v0.0) 
c m 1; !H NM R (400 MHz, CDC13) 5.36 (1H, s, H-12), 4.88 (1H, ddd, 7=9.9, 6.1, 3.4 
Hz, H-10), 2.75-2.62 (2H, m, H-9 and -CH2C 0 2H), 2.52 (1H, dd, 7=15.7, 3.6 Hz, - 
CH2CO2H), 2.37 (1H, td, 7=13.4, 4.1 Hz, H-4a), 2.06 (1H, m), 1.96 (1H, m), 1.83 
(1H, m), 1.71 (2H, m), 1.59-0.89 (15H, m) (including 1.42 (3H, s, 3-Me), 0.98 (3H, 
d, 7=6.0 Hz, 6-Me), 0.89 (3H, d, 7=7.6 Hz, 9-Me)) ppm; 13C NMR (100 MHz, 
CDCI3) 8 176.2, 103.7, 100.0, 89.8, 81.2, 71.3, 52.5, 44.2, 37.9, 36.8, 36.2, 34.7,
30.2, 26.2, 25.1, 20.5 and 13.1; m/z (ES) 349.1615 ([M + Na]+) requires 349.1627.
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EDIPA (0.27 g, 2.13 mmol) and HBTU (0.51 g, 1.36 mmol) were added sequentially 
to a stirring solution of 190 (0.35 g, 1.06 mmol) in DM F (10 mL) at 0 °C under 
nitrogen. This was allowed to stir for up to an hour before addition o f the desired 
amine at 0 °C.
O-Methyl-3-benzoate dihydroartemisinin3 198
TM SO Tf (1.5 mL, 8.32 mmol) was added to a stirring solution of DHA 186 (1.69 g, 
5.94 mmol), methyl 3-hydroxybenzoate (2.71 g, 17.82 mmol) and AgCICL (0.25 g, 
1.19 mmol) in anhydrous CH2CI2 (50 mL) at -78 °C. After 3 hours NEt3 (7.5 mL) 
was added. The reaction mixture was allowed to warm to room temperature and the 
solvent removed in vacuo to give a brown oil. Purification by flash chromatography 
(15:85 EtOAc:Hexane) gave 198 (2.00 g, 80%) as a white solid.
198: m.p. 60-62 °C; IR vmax 3359 (vc.H> Ester), 2933 (vC-H), 1712 (vc=0), 874, 819 (va  
O) cm '1; *H NM R (400 MHz, CDC13) 7.69 (2H, m, Ar-H), 7.38 (2H, m, Ar-H), 5.57
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(1H, d, J=2.7 Hz, H-10), 5.48 (1H, s, H-12), 3.91 (3H, s, -OMe), 2.85 (1H, m, H-9), 
2.42 (1H, td, 7=14.2, 3.8 Hz, H-4a), 2.09-0.97 (19H, m) (including 1.44 (3H, s, 3- 
M e), 1.04 (3H, d, 7=7.3, 6-Me), 0.97 (3H, d, 7=6.1, 9-Me)) ppm; 13C NMR (100 
M Hz, CDCI3) 5 167.2, 158.0, 131.9, 130.0, 123.6, 121.4, 118.3, 104.7, 100.8, 88.7, 
81.4, 52.9, 52.6, 44.7, 37.8, 36.7, 35.0, 31.3, 26.5, 25.0, 24.9, 20.7 and 13.4; m/z (ES) 
441.1905 ([M + Na]+) requires 441.1889.
O-carboxy-3-phenyl dihydroartemisinin3 199
A  solution of 198 (1.65 g, 3.95 mmol) in 5% w/v KOH/MeOH (50 mL) was stirred at 
room  temperature for 4 days at which point complete consumption of the starting 
material was observed. The solution was acidified to neutral pH with 3.0 M aq. HC1 
and the solvent removed in vacuo. The resulting aqueous solution was extracted with 
EtOAc (4 x 50 mL), the organic extracts dried over MgSCU and concentrated in 
vacuo to give 199 (1.21 g, 76%) as a white solid.
199: m.p. 128-130 °C; IR vmax 3535 (v0.H), 2924 (vc.H), 1687 (vc=o), 874, 825 (v0-o) 
c m 1; *H NM R (400 MHz, CDCI3) 7.80 (2H, m, Ar-H), 7.42 (2H, m, Ar-H), 5.59 
(1H, d, 7=2.8 Hz, H-10), 5.50 (1H, s, H-12), 2.89 (1H, m, H-9), 2.43 (1H, td, 7=14.2,
3.8 Hz, H-4a), 2.10-0.97 (19H, m) (including 1.45 (3H, s, 3-Me), 1.05 (3H, d, 7=7.3 
Hz, 6-Me), 0.97 (3H, d, 7=6.1 Hz, 9-Me)) ppm; 13C NMR (100 MHz, CDC13) 8
172.2, 157.8, 131.1, 130.1, 124.1, 122.2, 118.9, 104.7, 100.8, 88.7, 81.4, 52.9, 44.8,
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37.8, 36.8, 35.0, 31.3, 26.5, 25.1, 24.9, 20.7 and 13.4; m/z (ES) 427.1740 ([M + 
N a]+) requires 427.1733.
HBTU activated O-carboxy-3-phenyl dihydroartemisinin 199a
F.DTPA (0.27 g, 2.07 mmol) and HBTU (0.59 g, 1.56 mmol) were added sequentially 
to a stirring solution of 199 (0.42 g, 1.04 mmol) in DM F (10 mL) at 0 °C under 
nitrogen. This was allowed to stir for up to an hour before addition of the desired 
amine at 0 °C.
l-MethyI-2-trichioroacetylpyrrole4 201
A solution o f jV-methyl-pyrrole 200 (1.62 g, 20.00 mmol) in CH2CI2 (8 mL) was 
added dropwise to a solution o f trichloroacetyl chloride (3.65 g, 20.10 mmol) in 
CH2CI2 (12 mL) over 3 hours. During this time, the reaction mixture was stirred 
vigorously and a stream of N2 was passed over the reaction mixture into a Drechsel 
flask containing 1 M NaOH to remove HC1 as it was formed. Once all the 
trichloroacetyl chloride was added, the system was sealed under nitrogen and the 
solution stirred overnight. The solvent was removed in vacuo and resultant dark red 
residue was dissolved in chloroform and filtered through a short column of silica gel.
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Removal of chloroform under reduced pressure gave analytically pure pale yellow 
needles o f 201 (4.50 g, 100%).
201: m.p. 62-63 °C, Lit. 64-65 °C;4 IR vmax 3126 (vPy.H), 2954 (vc.H), 2811 (vc.N), 
1653 (vc=o), 806, 741, 685, 609 (vC-ci) cm’1; !H NM R (400 MHz, CDC13) 7.51 (1H, 
dd, 7=4.4, 1.6 Hz, Py-H5), 6.98 (1H, t, 7=2.2 Hz, Py-H3), 6.23 (1H, dd, 7=4.5, 2.5 
Hz, Py-H4), 3.97 (3H, s, Py-CH3) ppm; 13C NM R (100 MHz, CDC13) 8 173.3, 134.0, 
124.4, 122.2, 109.3, 96.7 and 39.0; m/z (Cl) 225.96014 ([M + H]+) requires 
225.95932; Anal. C7H6C13N 0  requires C 37.12%, H 2.67%, N 6.18; found C 
37.13%, H 2.62%, N 6.09%.
l-Methyl-2-trichloroacetyl-4-nitropyrrole4 202
02N
A suspension o f 201 (2.00 g, 8.81 mmol) in acetic anhydride (20 mL) was cooled to - 
40 °C and to it was added 70% H N 0 3 (1.0 mL, 1.8 eq) over a period of five minutes. 
The reaction vessel was allowed to warm to room  temperature over a period of 3 
hours and stirred at ambient temperature overnight. The mixture was cooled to 
-20 °C and a few drops o f cold isopropyl alcohol added until a precipitate formed. 
The precipitate was collected by filtration, washed with cold isopropyl alcohol and 
dried under reduced pressure to give 202 (0.98 g, 41%) as a white solid.
202: m.p. 133-135 °C, Lit. 135-140 °C;4 IR vmax 3145 (vPy.H), 2968 (vc .H), 1691 
(vc=o), 1514, 1311 (v C-n ) , 812, 798, 748, 684, 609 (vC-ci) cm '1; ]H NM R (400 MHz, 
CDC13) 7.96 (1H, d, 7=1.7 Hz, Py-H5), 7.77 (1H, d, 7=1.8 Hz, Py-H3), 4.06 (3H, s, 
Py-CH3) ppm; 13C NMR (100 MHz, CDC13) 8 174.1, 135.2, 130.6, 122.6, 118.0,
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100.0 and 40.2; rrJz (ES) 324.9510 ([M + Na]+) requires 324.9526; Anal. 
C7H5CI3N2O3 requires C 30.97%, H 1.86%, N  10.32%, found C 30.89%, H 1.85%, N 
10.35%.
A-(3-(Dimethylamino)propyl)-l-methyl-4-nitro-lH-pyrrole-2-carboxamide4 203
A solution of 3-dimethylaminopropylamine (0.41 g, 4.00 mmol) in TH F (10 mL) was 
stirred at 0 °C. A solution of compound 202 (0.90 g, 3.33 mmol) in THF (10 mL) 
was added dropwise and stirred at 0 °C for a further 5 minutes. After removal of 
solvent in vacuo, the residue was purified by flash column chromatography (10:90 
M eOH:CH2Cl2) to give 203 as a yellow crystalline solid (0.73 g, 86%).
203: m.p. 106-108 °C; IR vmax 3248 (vN.H, Amide), 3126 (vPy.H) , 2947, 2860, 2819, 
2769 (v C-h ) , 1649 (vc=o), 1545, 1340 (vN=o) cm '1; *H NMR (400 MHz, CDCI3) 7.55 
(1H, d, 7=1.9 Hz, Py-H5), 7.04 (1H, d, 7=2.0 Hz, Py-H3), 4.00 (3H, s, Py-CH3), 3.49 
(2H, m, -NCH2-), 2.54 (2H, t, 7=6.0 Hz, -NCH2-), 2.34 (6H, s, -N(CH3)2), 1.80 (2H, 
quin, 7=6.2 Hz, -CH2CH2CH2-) ppm; 13C NM R (100 MHz, CDC13) 5 160.8, 135.3,
127.3, 126.8, 107.1, 59.1, 51.0, 45.5, 40.1, 38.3 and 25.3; m/z (Cl) 255.14607 ([M + 
H ]+) requires 255.14572.
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A solution of 203 (1.00 g, 4.16 mmol) in MeOH (40 mL) was hydrogenated at 
atmospheric pressure over PtC>2 overnight. The catalyst was removed by filtration 
through celite and the solvent removed in vacuo. The residual oil was dissolved in 
D M F (20 mL) and concentrated to half its original volume under reduced pressure to 
completely remove MeOH. A solution o f 202 (1.12 g, 4.16 mmol) in DM F (8 mL) 
was added with stirring at 0 °C. The reaction mixture was then allowed to return to 
ambient temperature and stirred overnight. The solvent was removed in vacuo and 
the residue purified by flash column chromatography (10:90 MeOH:CH2Cl2 + NH3 
0.25% v/v) to give 204 as an orange crystalline solid (0.90g, 60%).
204: m.p. 189-191 °C, Lit. 190-191 °C;4 IR vmax 3587, 3297 (vN-H, A m id e ) , 3124 (vPy_H), 
2945, 2861, 2822, 2779 (vc.H), 1647 (vc=o), 1500, 1308 (vN=o) c m 1; *H NMR (400 
M Hz, MeOD) 7.89 (1H, d, 7=1.9 Hz, Py-H5), 7.41 (1H, d, 7=2.0 Hz, Py-H5), 7.22 
(1H, d, 7=1.9 Hz, Py-H3), 6.90 (1H, d, 7=2.0 Hz, Py-H3), 4.00 (3H, s, Py-CHs), 3.89 
(3H, s, Py-CHa), 3.42 (2H, t, 7=6.4 Hz, -NCH2 ), 3.19 (2H, m, -NCH2-), 2.92 (6H, s, 
-N(CH3)2), 2.03 (2H, quin, 7=6.5 Hz, -CH2CH2CH2-) ppm; 13C NMR (100MHz, 
CDCI3) 5 164.5, 160.0, 136.6, 129.1, 128.2, 125.2, 123.3, 120.8, 109.1, 106.2, 58.8,
45.8, 39.0, 38.4, 37.2 and 28.6; m/z (ES) 377.1931 ([M + H]+) requires 377.1937.
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A solution of 204 (0.90 g, 2.40 mmol) in M eOH (40 mL) was hydrogenated at 
atmospheric pressure over PtC>2 overnight. The catalyst was removed by filtration 
through celite and the solvent removed in vacuo. The residual oil was dissolved in 
D M F (20 mL) and concentrated to half its original volume under reduced pressure to 
completely remove MeOH. A solution o f 202 (0.63 g, 2.40 mmol) in DM F (8 mL) 
was added with stirring at 0 °C. The reaction mixture was then allowed to return to 
ambient temperature and stirred overnight. The solvent was removed in vacuo and 
the residue purified by flash column chromatography (10:90 MeOH/CH2Cl2 + NH3 
0.25% v/v) to give 205 (0.53 g, 44%) as an orange crystalline solid.
205: m.p. 188-190 °C; IR vmax 3275 (vN.H, A m id e ) > 3128 ( v p y - H) ,  2947 ( v C -h ) ,  1641 
(vc=o), 1500, 1308 (vN=o) cm '1; 'H  NM R (400 MHz, MeOD) 7.71 (1H, d, 7=1.8 Hz, 
Py-H5), 7.57 (1H, d, 7=1.6 Hz, Py-H5), 7.31 (1H, d, 7=1.7 Hz, Py-H5), 7.06 (1H, d, 
7=1.7 Hz, Py-H3), 6.51 (1H, d, 7=1.9 Hz, Py-H3), 6.29 (1H, d, 7=1.7 Hz, Py-H3),
4.03 (3H, s, Py-CH3), 3.89 (3H, s, Py-CH3), 3.80 (3H, s, Py-CH3), 3.54 (2H, q, 7=5.8 
Hz, -NCH2-), 2.47 (2H, t, 7=6.2 Hz, -NCH2-), 2.28 (6H, s, -N(CH3)2), 1.78 (2H, quin, 
7=6.1 Hz, -CH2CH2CH2-) ppm; 13C NM R (100 MHz, MeOD) 8 162.5, 159.6, 158.2,
135.4, 127.4, 126.6, 124.9, 123.2, 121.8, 121.5, 120.1, 119.8, 108.5, 104.3, 103.4,
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59.2, 45.8, 40.2, 38.6, 37.1, 36.8 and 26.0; m/z (ES) 499.2426 ([M + H]+) requires 
499.2417.
General Procedure 1
Carboxamide-Artemisinin Coupling Conditions
A solution of 204 (ca. 0.50 mmol) in M eOH (20 mL) was hydrogenated at 
atmospheric pressure over PtC>2 until complete consumption o f the starting material 
was observed. The catalyst was removed by filtration through celite and the solvent 
rem oved in vacuo. The residual oil was dissolved in DM F (20 mL) and concentrated 
to half its original volume under reduced pressure to completely remove MeOH. The 
remaining solution was then transferred to a flask containing a stirring solution o f the 
pre-activated artemisinin with carboxylic acid linker 199a (ca. 1.00 mmol). This was 
allowed to stir overnight and the solvent then removed in vacuo. The residue was 
dissolved in EtOAc and washed with water (3 x 50 mL). The combined aqueous 
washings were then reduced in vacuo and the crude m ixture purified by flash column 
chromatography (5:95 M eOHrCHiCL) to give the desired conjugate. Further 
purification by reverse phase HPLC (M eOH:H20, 50:50 to 100:0 over 1 hr) was 
performed.
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Synthesis and Biological Activity of Minor Groove Binding-Artemisinin Conjugates
240
6.0 - Experimental Procedure
Synthesis and Biological Activity o f Minor Groove Binding-Artemisinin Conjugates
Artemisinin-Dipyrrole Conjugate with a Phenoxy-Linker 213
A solution o f 204 (0.26 g, 0.69 mmol) in M eOH (20 mL) was hydrogenated and 
added to a prepared solution of 199a (0.42 g, 1.03 mmol) as outlined in General 
Procedure 1. This was allowed to stir overnight and the solvent then removed in 
vacuo. The residue was dissolved in EtOAc and washed with water (3 x  50 mL). The 
combined aqueous washings were then reduced in vacuo and the crude mixture 
purified by flash column chromatography (5:95 M eOH:CH2Cl2) to give 213 (0.10 g, 
20%) as an orange crystalline solid.
213: IR vmax 3408 ( v n -h , A m id e ) . 2939 ( v c -h ) ,  1639 (vc=o, A m id e ) . 921, 835 (vo-o), 746 
(vc=c) cm '1; !H NM R (400 MHz, MeOD) 7.70-7.20 (5H, m, Ar-H and Py-H5), 7.18 
(1H, d, 7=1.7 Hz, Py-H5), 7.04 (1H, d, 7=2.0 Hz, Py-H3), 6.89 (1H, d, 7=1.9 Hz, Py- 
H3), 5.60 (1H, d, 7=3.3 Hz, H-10), 5.51 (1H, s, H-12), 3.95 (3H, s, Py-CH3), 3.89 
(3H, s, Py-CHs), 3.42 (2H, t, 7=6.5 Hz, -NCH2-), 3.13 (2H, t, 7=7.2 Hz, -NCH2-), 
2.86 (6H, s, -N(CH3)2), 2.85 (1H, m, H-9), 2.37 (1H, td, 7=14.3, 3.8 Hz, H-4a), 2.08­
0.99 (21H, m) (including 1.36 (3H, s, 3-Me), 1.08 (3H, d, 7=7.3 Hz, 6-Me), 0.99 
(3H, d, 7=6.3 Hz, 9-Me)) ppm; 13C NM R (100 MHz, MeOD) 5167.4, 165.3, 161.8,
159.3, 131.3, 129.9, 125.1, 124.3, 123.8, 123.7, 122.8, 122.6, 121.9, 121.6, 121.5,
121.4, 117.1, 107.1, 90.2, 82.4, 57.0, 50.3, 46.1, 43.9, 39.0, 37.7, 37.4, 37.3, 37.0,
36.2, 32.7, 31.5, 26.8, 26.5, 21.1, 19.7 and 13.7; mJz (ES) 733.3915 ([M + H]+)
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requires 733.3925.
Methyl 4-(tert-butoxycarbonylamino)butanoate5 218
O
To a stirred solution of methyl 4-aminobutanoate 216 (1.00 g, 6.51 mmol) in MeOH 
(60 mL), triethylamine (6.3 mL, 45.6 mmol) and subsequently di-tert- 
butyldicarbonate (2.13 g, 9.75 mmol) were added. The reaction was stirred for 1 hour 
at ambient temperature. MeOH was removed in vacuo and the residue purified by 
colum n chromatography to give 218 (1.03 g, 73%) as a clear oil.
218: IR Vmax 3592, 3356 (V n -H, A m id e ) , 2976 (V C -h ) ,  1730 (Vc=0, E ste r) , 1691 (vc=0, A m id e ) 
cm '1; !H NM R (400 MHz, CDC13) 4.96 (1H, brs, NH), 3.68 (3H, s, -OCifc), 3.20 
(2H, q, 7=6.5 Hz, -HNCHa-), 2.38 (2H, t, 7=7.3 Hz, -CH2CO-), 1.85 (2H, quin, 7=7.1 
Hz, -CH2CH2CH2-), 1.44 (9H, s, t-Bu) ppm; 13C NM R (100 MHz, CDC13) 8 174.2,
156.4, 79.6, 52.1, 40.3, 31.7, 28.8 and 25.7; m/z (Cl) 218.13938 ([M + H]+) requires 
218.13923.
4-(teri-Butoxycarbonylamino)butanoic acid6 220
H S
A methanolic solution o f NaOH (2 M, 70 mL) was added to a stirring solution of 
m ethyl 4-(tm-butoxycarbonylam ino)butanoate 218 (1.00 g, 4.61 mmol) in 
CH2Cl2/M eOH (9:1 v/v, 20 mL). The solution was stirred until complete 
consumption of the starting material was observed. The solvents were then removed
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in vacuo and the residue diluted with water. The aqueous solution was cooled and 
acidified to pH 2-3 with HC1 (2 M, 10 mL). The acidified mixture was then extracted 
with diethyl ether (2 x 50 mL) and dried over NaiSCU. The ether was removed in 
vacuo to yield 220 (0.88 g, 93%) as a clear oil with no need for further purification. 
220: m  vmax 3590, 3347 (vN.H> A m id e ) , 2978 (vC-H), 1691 (vc=0) cm ’1; *H NMR (400 
M Hz, CDC13) 4.75 (1H, brs, NH), 3.20 (2H, t, 7=6.2 Hz, -HNCH2-), 2.41 (2H, t, 
7=7.3 Hz, -CH2CO-), 1.86 (2H, quin, 7=7.1 Hz, -CH2CH2CH2-), 1.44 (9H, s, r-Bu) 
ppm ; 13C NMR (100 MHz, CDC13) 8 178.7, 156.6, 79.9, 40.2, 31.7, 28.8 and 25.6; 
mJz (Cl) 204.12325 ([M + H]+) requires 204.12358.
HBTU Activated 4-(terf-Butoxycarbonylamino)butanoic acid 220a
6.0 - Experimental Procedure
Synthesis and Biological Activity o f Minor Groove Binding-Artemisinin Conjugates
EDIPA (0.45 g, 3.51 mmol) and HBTU (1.00 g, 2.63 mmol) were added sequentially 
to a stirring solution of 220 (0.36 g, 1.76 mmol) in DM F (10 mL) at 0 °C under 
nitrogen. This was allowed to stir for up to an hour before addition o f the desired 
amine at 0 °C.
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terT-butyl 4-(5-(5-(3-(dimethylamino)propylcarbamoyl)-l-methyl-lH-pyrrol-3-yl 
carbamoyl)-l-methyl-lH-pyrrol-3-ylamino)-4-oxobutylcarbamate 222
A solution o f 204 (0.33 g, 0.88 mmol) in M eOH (20 mL) was hydrogenated and 
added to a prepared solution o f 220a (0.36 g, 1.76 mmol) as outlined in General 
Procedure 1. This was allowed to stir overnight and the solvent then removed in 
vacuo. The residue was dissolved in EtOAc and washed with water (3 x  50 mL). The 
combined aqueous washings were then reduced in vacuo and the crude mixture 
purified by flash column chromatography (20:80 M eOH:CH2Cl2 + NH3 0.25% v/v) to 
give 222 (0.35 g, 75%) as an orange crystalline solid.
222: IR vmax 3291 (vN-H, A m id e ) , 2977, 2937 (vC-h), 1646 (vc=o) cm 1; !H NMR (400 
M Hz, MeOD) 7.24 (1H, d, 7=1.7 Hz, Py-H5), 7.21 (1H, d, 7=1.4 Hz, Py-H5), 6.91 
(1H, d, 7=1.8 Hz, Py-H3), 6.84 (1H, m, Py-H3), 3.87 (3H, m, Py-CH3), 3.84 (3H, m, 
Py-CHs), 3.38 (2H, t, 7=6.2 Hz, -NCH2-), 3.13-3.08 (4H, m, -NCH2-), 2.82 (6H, s, - 
N(CH3)2), 2.42 (2H, m, -CH2C = 0), 1.99 (2H, m, -CH2CH2CH2-), 1.86 (2H, m, - 
CH 2CH2CH2-), 1.42 (9H, s, i-Bu) ppm; 13C NM R (100 MHz, M eOD) 8 173.1,
165.0, 161.7, 159.0, 129.3, 124.9, 124.5, 123.8, 123.7, 121.3, 117.6, 111.1, 80.5,
57.2, 44.1, 37.4, 35.0, 34.7, 31.6, 29.4 and 26.9; m/z (ES) 532.3266 ([M + H]+) 
requires 532.3247.
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Artemisinin-dipyrrole conjugate with a 3C-extended phenoxy linker 224
The Boc-protected linker 222 (0.33 g, 0.61 mmol) was stirred in TFA (10 mL) for 2 
hours or until complete consumption o f the starting material was observed. The TFA 
was removed in vacuo and the residue dissolved in DM F (10 mL) which was then 
added to a prepared solution o f 199a (0.25 g, 0.61 mmol) as outlined in General 
Procedure 1. This was allowed to stir overnight and the solvent then removed in 
vacuo. The residue was dissolved in EtOAc and washed with water (3 x 50 mL). The 
combined aqueous washings were then reduced in vacuo and the crude mixture 
purified by flash column chromatography (10:90 M eOH:CH2Cl2) to give 224 (0.20 g, 
40% ) as an orange crystalline solid.
224: IR vmax 3302 ( v n . h . A m id e ) , 2929 (vc .H), 1639 (vc=o, A m id e ) , 867, 815 (v0-o), 746 
(vc=c) cm '1; 'H  NMR (400 MHz, MeOD) 7.48-7.17 (4H, m, Ar-H) ,7.09 (1H, d, 
7=1.9 Hz, Py-H5), 7.05 (1H, d, 7=1.9 Hz, Py-H5), 6.73 (1H, d, 7=1.8 Hz, Py-H3), 
6.72 (1H, d, 7=1.9 Hz, Py-H3), 5.50 (1H, d, 7=3.3 Hz, H-10), 5.43 (1H, s, H-12), 
3.79 (6H, s, Py-CH3), 3.39 (2H, m, -NHCH2-), 3.30-3.26 (4H, m, -NHCH2-), 2.74 
(1H, m, H-9), 2.38-2.25 (3H, m, -N H C H r and H-4a), 2.22 (6H, s, -N(CH3)2), 1.99­
0.90 (23H, m) (including 1.26 (3H, s, 3-Me) and 0.99 (3H, d, 7=7.3 Hz, 6-Me), 0.90 
(3H, d, 7= 6.4 Hz, 9-Me)) ppm; 13C NM R (100 MHz, M eOD) 8 173.0, 170.3, 164.6, 
161.7, 159.2, 137.5, 131.2, 125.0, 123.7, 123.6, 122.5, 121.4, 121.0, 120.8, 117.1,
113.0, 106.3, 106.0, 90.1, 82.4, 58.7, 54.3, 46.1, 45.8, 41.0, 39.0, 37.8, 37.2, 37.3,
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36.2, 36.2, 35.2, 32.7, 28.7, 27.2, 26.5, 26.2, 26.1, 21.2 and 13.7; m/z (ES) 818.4485 
([M  + H]+) requires 818.4453.
Methyl 6-(te/7-butoxycarbonylamino)hexanoate 219
To a stirred solution of methyl 6-aminohexanoate.HCl 217 (2.50 g, 13.76 mmol) in 
M eOH (150 mL), triethylamine (13.4 mL, 96.32 mmol) and subsequently d i-rm - 
butyldicarbonate (4.50 g, 20.64 mmol) were added. The reaction was stirred for 1 
hour at ambient temperature. M eOH was removed in vacuo and the residue purified 
by column chromatography to give 219 (2.73 g, 81%) as a clear oil.
219: IR Vmax 3369 (VN-H, Amide). 2933 (Vc -h ) .  1732 (Vc=0, Ester), 1693 (vc=0, Amide); 'H 
NM R (400 MHz, CDCI3) 4.53 (1H, brs, NH), 3.64 (3H, s, -OCH3), 3.14 (2H, q, 
7=6.3 Hz, -HNCH2-), 2.33 (2H, t, 7=7.4 Hz, -CH2CO-), 1.68 (2H, quin, 7=7.6 Hz, - 
HNCH2CH2-), 1.53 (2H, q, 7=7.2, -CH2CH2CO-), 1.44 (9H, s, r-Bu), 1.38 (2H, m, - 
(CH2)2C£l2(CH2)2-) Ppm; 13C NM R (100 MHz, CDCI3) 8 174.5, 156.4, 79.5, 51.9,
40.8, 34.3, 30.2, 28.8, 26.7 and 25.0; m/z nominal mass (Cl) 246 ([M + H]+) requires 
246.
6-(ter<-Butoxycarbonylamino)hexanoic acid 221
A methanolic solution o f NaOH (2 M, 122 mL) was added to a stirring solution of 
methyl 6-(rm-butoxycarbonylam ino)hexanoate 219 (2.00 g, 8.16 mmol) in
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CH2Cl2/MeOH (9:1 v/v, 40 mL). The solution was stirred until complete 
consumption o f the starting material was observed. The solvents were then removed 
in vacuo and the residue diluted with water. The aqueous solution was cooled and 
acidified to pH 2-3 with HC1 (2 M, 10 mL). The acidified mixture was then extracted 
with diethyl ether (2 x 50 mL) and dried over Na2SC>4. The ether was removed in 
vacuo to yield 221 (1.26 g, 67%) as a clear oil with no need for further purification. 
221: IR vmax 3364 (vN.H, Amide), 2948, 2872 (vc.H), 1687 (vc=0) c m 1; *H NMR (400 
M Hz, CDC13) 9.80 (1H, brs, -OH) 4.64 (1H, brs, -NH), 3.13 (2H, m, -HNCH2-), 
2.37 (2H, t, 7=7.4 Hz, -CH2CO-), 1.69 (2H, quin, 7=7.4 Hz, -HNCH2CH2-), 1.54 
(2H, quin, 7=7.3 Hz, -CH2CH2CO-), 1.44 (9H, s, t-Bu), 1.40 (2H, m, - 
(CH2)2CH2(CH2)2-) ppm; 13C NMR (100 MHz, CDCI3) 5 179.5, 156.5, 79.6, 40.7,
34.3, 30.1, 28.8, 26.6 and 24.7; m/z (Cl) 232.15475 ([M + H]+) requires 232.15488.
HBTU activated 6-(tert-butoxycarbonylamino)hexanoic acid 221a
6.0 - Experimental Procedure
Synthesis and Biological Activity o f Minor Groove Binding-Artemisinin Conjugates
EDIPA (1.03 g, 7.97 mmol) and HBTU (2.25 g, 5.98 mmol) were added sequentially 
to a stirring solution of 221 (0.92 g, 3.99 mmol) in DM F (10 mL) at 0 °C under 
nitrogen. This was allowed to stir for up to an hour before addition of the desired 
amine at 0 °C.
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tert-Butyl 6-(5-(5-(3-(dimethylamino)propylcarbamoyl)-l-methyl-lH-pyrrol-3- 
ylcarbamoyl)-l-methyl-lH-pyrrol-3-ylamino)-6-oxohexyIcarbamate 223
A solution of 204 (0.75 g, 1.99 mmol) in MeOH (20 mL) was hydrogenated and 
added to a prepared solution o f 221a (0.36 g, 1.76 mmol) as outlined in General 
Procedure 1. This was allowed to stir overnight and the solvent then removed in 
vacuo. The residue was dissolved in EtOAc and washed with water (3 x 50 mL). The 
combined aqueous washings were then reduced in vacuo and the crude mixture 
purified by flash column chromatography (20:80 M eOH:CH2Cl2 + NH3 0.25% v/v) to 
give 223 (0.14 g, 12%) as an orange crystalline solid.
223: 'H NM R (400 MHz, MeOD) 7.21 (1H, m, Py-H5), 7.18 (1H, d, 7=1.6 Hz, Py- 
H5), 6.91 (1H, s, Py-H3), 6.87 (1H, s, Py-H3), 3.90 (3H, s, Py-CH3), 3.89 (3H, s, Py- 
CH3), 3.43 (2H, t, 7=6.4 Hz, -OCNHCH2-), 3.18 (2H, t, 7=7.0 Hz, -OCNHCH2- ),
3.08 (2H, m, -CH2N(CH3)2), 2.90 (6H, s, -N(Cijb)2), 2.40 (2H, quin, 7=7.4 Hz, 
-ClfcCONH-), 2.02 (2H, m, -CH2CH2CH2-) 1.76 (2H, m, -NCH2CJi>(CH2)3-), 1.55­
1.36 (4H, m, -OCCH2CH2CH2(CH2)2-), 1.44 (9H, s, f-Bu) ppm; 13C NM R (100 MHz, 
M eOD) 8 176.3, 165.2, 161.7, 159.0, 129.7, 125.8, 125.7, 123.8, 121.3, 121.2, 119.3,
113.0, 80.5, 57.2, 44.1, 37.4, 35.0, 34.7, 31.6, 29.4 and 26.9; m/z (ES) 560.3548 ([M 
+ H ]+) requires 560.3560.
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Artemisinin-dipyrrole conjugate with a 5C-extended phenoxy linker 225
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The Boc-protected linker 223 (0.13 g, 0.24 mmol) was stirred in TFA (10 mL) for 2 
hours or until complete consumption o f the starting material was observed. The TFA 
was removed in vacuo and the residue dissolved in DM F (10 mL) which was then 
added to a prepared solution o f 199a (0.20 g, 0.48 mmol) as outlined in General 
Procedure 1. This was allowed to stir overnight and the solvent then removed in 
vacuo. The residue was dissolved in EtOAc and washed with water (3 x 50 mL). The 
combined aqueous washings were then reduced in vacuo and the crude mixture 
purified by flash column chromatography (10:90 M eOH:CH2Cl2) to give 225 (0.02 g, 
14%) as an orange crystalline solid.
225: IR Vmax 3301 (V n -H , A m id e ) . 2939 (V c -h ) ,  1639 (vc=0, A m id e ) , 867, 809 (V o -o ), 746 
(vc=c) cm '1; 'H  NMR (400 MHz, M eOD) 7.69-7.25 (4H, m, Ar-H), 7.18 (1H, d, 
7=1.7 Hz, Py-H5), 7.12 (1H, d, 7=2.0 Hz, Py-H5), 6.90 (1H, d, 7=1.7 Hz, Py-H3), 
6.85 (1H, d, 7=2.0 Hz, Py-H3), 6.45 (1H, s, H-12), 5.43 (1H, m, H-10), 3.92 (3H, s, 
Py-CH3), 3.89 (3H, s, Py-CH3), 3.42 (2H, m, -NHCH2-), 3.17 (2H, m, -NHCH2-), 
2.97-2.80 (9H, m) (including 2.89 (6H, s, -N(CH3)2), 2.86 (1H, m, H-9)), 2.55 (2H, 
m, -CifcQCONH-), 2.38 (1H, m, H-4a), 2.04-0.99 (27H, m) (including 1.30 (3H, s, 
3-Me) and 1.09 (3H, d, 7=7.2 Hz, 6-Me), 0.99 (3H, d, 7= 6.0 Hz, 9-Me)) ppm; 13C 
NM R (100 MHz, M eOD) 8 171.1, 169.1, 165.1, 161.7, 159.3, 137.5, 131.1, 130.0,
128.9, 124.7, 124.4, 123.4, 123.0, 122.0, 121.8, 119.8, 117.5, 113.3, 110.6, 109.3,
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29.0, 28.1, 27.2, 26.7, 26.4, 21.2 and 13.3 ppm; m/z (ES) 846.4786 ([M + H]+) 
requires 846.4766.
6.2 Appendix
tert-Butyl 4-(5-(5-(5-(3-(dimethyIamino)propylcarbamoyl)-l-methyl-lH-pyrrol- 
3-ylcarbamoyl)-l-methyl-lH-pyrrol-3-ylcarbamoyl)-l-methyl-lH-pyrrol-3- 
ylamino)-4-oxobutylcarbamate 227
A solution o f 205 (0.65 g, 1.30 mmol) in M eOH (20 mL) was hydrogenated and 
added to a prepared solution o f 220a (0.40 g, 1.95 mmol) as outlined in General 
Procedure 1. This was allowed to stir overnight and the solvent then removed in 
vacuo. The residue was dissolved in EtOAc and washed with water (3 x 50 mL). The 
combined aqueous washings were then reduced in vacuo and the crude mixture 
purified by flash column chromatography (20:80 M eO lL C lL C h + NH3 0.25% v/v) to 
give 227 (0.40 g, 47%) as an orange crystalline solid.
227: NM R (400 MHz, MeOD) 7.24-7.19 (3H, m, Py-H), 6.97-6.87 (3H, m, Py-
/
N
\
H), 3.90 (3H, s, Py-CH3), 3.89 (3H, s, Py-CH3), 3.87 (3H, s, Py-CH3), 3.46 (2H, m, -
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OCNHCH2-), 3.18-3.10 (4H, m, -NHCH2- ), 2.89 (6H, s, -N(CH3)2), 2.42 (2H, quin, 
7=7.6 Hz.-C& CO NH-), 2.00 (2H, quin, 7=6.9 Hz, -CH2CH2CH2-) 1.87 (2H, quin, 
7=7.2 Hz, -CH2CH2CH2-), 1.43 (9H, s, i-Bu) ppm; 13C NM R (100 MHz, M eOD) 6
173.2, 170.6, 165.2, 161.8, 144.7, 129.4 124.9, 124.4, 123.8, 123.7, 121.3, 121.1,
109.2, 107.1, 106.4, 80.5, 57.1, 43.9, 41.3, 38.5, 37.3, 31.4, 29.2, 27.8 and 26.8; m/z 
(ES) 461.2874 ([M + H]+); requires 461.2876.
Artemisinin-Dipyrrole Conjugate with a Carba-Linker 206
A solution of 204 (0.20 g, 0.53 mmol) in MeOH (20 mL) was hydrogenated and 
added to a prepared solution of 190a (0.35 g, 1.06 mmol) as outlined in General 
Procedure 1. This was allowed to stir overnight and the solvent then removed in 
vacuo. The residue was dissolved in EtOAc and washed with water (3 x  50 mL). The 
combined aqueous washings were then reduced in vacuo and the crude mixture 
purified by flash column chromatography (5:95 M eOH:CH2Cl2) to give 206 (0.12 g, 
33%) as an orange crystalline solid.
206: !H NM R (400 MHz, CDCI3) 7.43 (1H, s, Py-H5), 7.31 (1H, d, 7=1.8 Hz, Py- 
H5), 6.97 (1H, d, 7=1.8 Hz, Py-H3), 6.64 (1H, s, Py-H3), 6.01 (1H, s, H-12), 3.99 
(6H, s, Py-CH3), 2.98 (6H, s, -N(CH3)2), 2.57-2.33 (3H, m, H-9 and -CH2C(0)NH-), 
2.10-1.25 poorly resolved, 1.31 (3H, s, 3-Me), 0.99 (3H, m, 6-Me), 0.87 (3H, m, 9-
251
6.0 - Experimental Procedure
Synthesis and Biological Activity o f Minor Groove Binding-Artemisinin Conjugates
M e) ppm; 13C NMR (100 MHz, CDCI3) 8 172.7, 165.4, 161.8, 130.0, 124.3, 123.5,
107.0, 106.5, 106.4, 105.5, 101.5, 93.3, 90.6, 82.9, 56.8, 54.3, 47.2, 46.3, 37.4, 37.0, 
28.6, 19.7 and 12.3; mJz (ES) 655.3834 [M + H]+) requires 655.3819.
Artemisinin-dipyrrole Conjugate with a 5C-extended carba-Iinker 226
The Boc-protected linker 223 (0.35 g, 0.62 mmol) was stirred in TFA (10 mL) for 2 
hours or until complete consumption o f the starting material was observed. The TFA 
was removed in vacuo and the residue dissolved in DM F (10 mL) which was then 
added to a prepared solution o f 190a (0.20 g, 0.61 mmol) as outlined in General 
Procedure 1. This was allowed to stir overnight and the solvent then removed in 
vacuo. The residue was dissolved in EtOAc and washed with water (3 x  50 mL). The 
combined aqueous washings were then reduced in vacuo and the crude mixture 
purified by flash column chromatography (10:90 M eOH:CH2Cl2) to give 226 as an 
orange crystalline solid.
226: 'H  NMR (400 MHz, CDC13) 8 7.18 (1H, d, 7=1.6 Hz, Py-H5), 7.15 (1H, d, 
7=2.0 Hz, Py-H5), 6.89 (1H, d, 7=1.6 Hz, Py-H3), 6.86 (1H, d, 7=1.3 Hz, Py-H3),
6.01 (1H, s, H-12), 3.91 (3H, s, Py-CH3), 3.90 (3H, s, Py-CH3), 3.45 (2H, m, -NCH2- 
), 3.25 (2H, m, -N Q fe-), 3.07 (2H, m, -NCfih-), 2.82 (6H, s, -N(CH3)2), 2.46-2.20
252
6.0 - Experimental Procedure
Synthesis and Biological Activity o f Minor Groove Binding-Artemisinin Conjugates
(3H, m, H-9 and -CH2C (0)N H -), 2.10-1.25 poorly resolved, 0.99 (3H, m, 6-Me), 
0.87 (3H, m, 9-Me) ppm; 13C NM R (100 MHz, CDCI3) 8 173.7, 163.7, 163.4, 163.0,
128.6, 127.7, 120.1, 118.9, 117.2, 112.1, 98.1, 57.0, 43.9, 40.7, 19.4 and 13.4; m/z 
(ES) 768.4614 ([M + H]+) requires 768.4660.
Artemisinin phenoxy linker with extended 5C-linker via modified Curtius 
rearrangement 232
A solution of 190 (0.20 g, 0.49 mmol), ethyl 6-hydroxyhexanoate 231 (0.04 g, 0.25 
mmol), DPPA (0.14 mg, 0.49 mmol) and triethylamine (0.05 g, 0.49 mmol) in 
anhydrous MeCN (10 mL) was stirred at 55 °C for 24 hours. The solvent was then 
rem oved in vacuo and the residue taken up in EtOAc (50 mL). The solution was 
washed successively with 5% citric acid, H20 ,  NaHCC>3 and brine and the combined 
organic extracts dried over Na2SC>4. Purification by column chromatography (10:90 
M eOH:CH2Cl2) afforded 232 (0.08 g, 54%) as a white crystalline solid.
232: IR vmax 3343 ( v n -h , A m id e ) . 2941, 2869 ( v c -h ) ,  1735 (vc=o), 873, 826 (vo-o) cm '; 
*H NM R (400 MHz, M eOD) 5 7.21 (2H, m, Ar-H), 7.01 (1H, m, Ar-H), 6.86 (1H, m, 
Ar-H), 5.74 (1H, d, 7=5.7 Hz, H-10a), 5.49 (1H, s, H-12), 4.16 (2H, t, 7=6.6 Hz, - 
H N C (0)O C H 2-), 4.15 (2H, q, 7=7.2 Hz, -C (0 )0 C H 2CH3), 2.83 (1H, m, H-9), 2.42 
(1H, td, 7=14.3, 3.9 Hz, H-4a), 2.34 (2H, t, 7=7.4 Hz, -CH2C (0)O Et), 2.07-1.84 (5H,
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m), 1.79-1.47 (8H, m) (including (4H, m, -CH2CH2CH2CH2CH2-)), 1.46-0.97 (15H, 
m ) (including 1.43 (3H, s, 3-Me), 1.31 (2H, m, -EtCIJ?Et-) and 1.27 (3H, t, 7=7.2 Hz, 
-C (0 )0 C H 2CH3), 1-02 (3H, d, 7=7.3 Hz, 6-Me), 0.97 (3H, d, 7=6.1 Hz, 9-Me)) ppm; 
13C NM R (100 MHz, MeOD) 5 174.1, 158.5, 154.0, 139.5, 130.2, 120.4, 112.6,
111.6, 107.9, 104.6, 100.8, 88.7, 65.4, 60.7, 52.9, 44.8, 37.8, 36.7, 35.0, 34.6, 31.4,
29.0, 26.4, 25.8, 25.0, 24.8, 20.7, 14.7 and 13.4; m/z (ES) 584.2834 ([M + Na]+) 
requires 584.2836.
6-Hydroxyhexanoic acid 233
O
A methanolic solution of NaOH (2 M, 187 mL) was added to a stirring solution of 
ethyl 6-hydroxyhexanoate 231 (2.00 g, 12.48 mmol) in CH2Cl2/MeOH (9:1 v/v, 20 
mL). The solution was stirred until complete consumption of the starting material 
was observed. The solvents were then removed in vacuo and the residue diluted with 
water. The aqueous solution was cooled and acidified to pH 2-3 with HC1 (2 M, 10 
mL). The acidified mixture was then extracted with diethyl ether (2 x 50 mL) and 
dried over Na2S 0 4. The ether was removed in vacuo to yield 233 (1.57 g, 95%) as a 
clear oil with no need for further purification.
233: IR vmax 3332 (v0.H), 2937, 2866 (v C -h ), 1706 (vc=o) cm '1; NM R (400 MHz, 
CDC13) 6 5.00 (1H, br, -OH), 3.68 (2H, t, 7=6.5 Hz, -CH2OH), 2.39 (2H, t, 7=7.4 Hz, 
- 0 ( 0 ) 0 ^ - ) ,  1.70 (2H, quin, 7=7.4 Hz, -CH2CH2(C3H6)-), 1.63 (2H, quin, 7=7.0 Hz, 
-CH2C a2(C 3H6)-), 1.46 (2H, m, -(CH2)2CH2(CH2)2-) ppm; 13C NM R (100 MHz, 
CDC13) 8 179.3, 62.9, 34.3, 32.5, 25.6 and 24.8 ppm; m/z (Cl) 150.11334 ([M + 
NH4]+); requires 150.11302.
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HBTU-activated 6-Hydroxyhexanoic acid 233a
EDIPA (0.26 g, 2.00 mmol) and HBTU (0.57 g, 1.50 mmol) were added sequentially 
to a stirring solution of 233 (0.13 g, 1.0 mmol) in DM F (10 mL) at 0 °C under 
nitrogen. This was allowed to stir for up to an hour before addition o f the desired 
amine at 0 °C.
Ar-(3-(Dimethylamino)propyl)-4-(4-(6-hydroxyhexanamido)-l-methyl-lH- 
pyrrole-2-carboxamido)-l-methyl-lH-pyrrole-2-carboxamide 234
A solution o f 204 (0.26 g, 0.68 mmol) in MeOH (20 mL) was hydrogenated and 
added to a prepared solution of 233a (0.13 g, 1.00 mmol) as outlined in General 
Procedure 1. This was allowed to stir overnight and the solvent then removed in 
vacuo. The residue was dissolved in EtOAc and washed with water (3 x  50 mL). The 
combined aqueous washings were then reduced in vacuo and the crude mixture 
purified by flash column chromatography (20:80 MeOH/CH2Cl2) to give 234 (0.14 g, 
45% ) as an orange crystalline solid.
234: IR vmax 3128 ( v 0-h ) ,  2935 ( v C -h ) ,  1639 (vc=o) cm’1; *H NMR (400 MHz, CDC13) 
5 7.20 (1H, d, 7=1.8 Hz, Py-H), 7.18 (1H, d, 7=1.8 Hz, Py-H), 6.89 (1H, d, 7=1.8,
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Py-H), 6.88 (1H, d, 7=1.8 Hz, Py-H), 3.92 (3H, s, Py-CHs), 3.86 (3H, s, Py-Cfcb), 
3.59 (2H, t, 7=6.6 Hz, -CH2OH), 3.39 (2H, t, 7=6.5 Hz, -NCH2 ), 3.08 (2H, t, 7=7.2 
Hz, -NCH2-), 2.81 (6H, s, -N(CH3)2), 2.35 (2H, t, 7=7.7 Hz, -C (0)C H 2-), 1.98 (2H, 
m , -NCH2CH2-), 1.73 (2H, quin, 7=7.2 Hz, -CH2CH2(C3H6)-), 1.60 (2H, quin, 7=7.1 
Hz, -CH2CH2(C3H6)-), 1.45 (2H, m, -(CH2)2CH2(CH2)2-) ppm; 13C NMR (100 MHz, 
CDC13) 8 173.7, 165.1, 161.8, 125.0, 124.5, 123.8, 123.7, 121.3, 121.1, 107.0, 106.4,
63.2, 57.2, 44.1, 37.7, 37.4, 37.3, 33.8, 27.3 and 27.1.
6.2 Biological Testing
M elting curves were measured using a Hewlett Packard HP8452a spectrophotometer 
coupled to a Peltier thermostat. The measurements were performed in buffer, pH 7 
(10 mM NaH2PC>4, 100 mM NaCl), with a drug-D NA ratio of 1:1. The DNA- 
dodecam er used, d(CGCGAATTCGCG), was kindly provided by Dr J. Gaynor and 
D r R. Cosstick o f the Department o f Chemistry, University of Liverpool. Solutions 
o f conjugates 213, 224 and 225 were made up in RNAase free H20  with 
approximately 1% v/v DMSO.
The temperature inside the cuvette was increased over the range 19-90 °C with a 
heating rate o f 1.0 °C min-1 for 19-25 °C, 0.5 °C min-1 for 25-80 °C and returning to
1.0 °C min-1 for 80-90 °C. The absorption data were registered and plotted against 
the temperature. The melting curve was analysed using Microsoft Excel for data 
analysis and technical graphics.
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